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ABSTRACT 
ROLE OF THE FACIAL TRIAD IN FACTOR INHIBITING HIF (FIH): 
LIGAND BINDING, SUBSTRATE SELECTIVITY, AND COUPLING 
 
SEPTEMBER 2018 
 
VANESSA D. CHAPLIN 
 
 B.S., BAY PATH COLLEGE 
 
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
 
Directed by: Professor Michael J. Knapp 
 
Alpha-ketoglutarate (αKG) dependent oxygenases comprise a large superfamily of 
enzymes that activate O2 for varied reactions. While most of these enzymes contain a non-
heme Fe bound by a His2Asp facial triad, a small number of αKG-dependent halogenases 
require only the two His ligands to bind Fe and activate O2. The enzyme “factor inhibiting 
HIF” (FIH) contains a His2Asp facial triad and selectively hydroxylates polypeptides, however 
removal of the Asp ligand in the D201G variant leads to a highly active enzyme, seemingly 
without a complete facial triad.  Herein, we report on the formation of an Fe-Cl cofactor 
structure for the D201G variant using x-ray absorption spectroscopy (XAS), which provides 
insight into the structure of the His2Cl facial triad found in halogenases.  D201G variant 
supports anion dependent peptide hydroxylation, demonstrating the requirement for a complete 
His2X facial triad to support O2 reactivity. Our results indicate that exogenous ligand binding 
to form a complete His2X facial triad was essential for O2 activation, and provides a structural 
model for the His2Cl-bound nonheme Fe found in halogenases.  
viii 
 
 
We also propose that the facial triad ligands couple O2 activation with hydroxylation in 
FIH, providing insight into the coupling mechanism for this broad class of enzymes. Mutating 
the Asp201 ligand resulted in uncoupled product formation. For the D201X variants, O2 was 
consumed much faster than primary substrate was hydroxylated, which suggested branching 
in the chemical mechanism. EPR studies established that this branching occurs following the 
formation of the Fe(IV)=O intermediate as the metal centers of WT FIH and D201G were 
triggered by substrate whereas the metal centers of D201E and D201A were unaffected. 
Investigation into the fate of O2 in the absence of primary substrate identified two products: 
hydrogen peroxide (H2O2) and autohydroxylated Trp (TrpOH). This study provides insight into 
significance of the facial triad in substrate triggering within the αKG oxygenase family of 
enzymes and describes the products of uncoupling. 
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PREFACE 
 
This dissertation centers around understanding the mechanistic role of the facial triad 
carboxylate in the Fe(II)/αKG dependent hydroxylase Factor Inhibiting HIF (FIH). Chapter 1 
reviews mammalian oxygen sensing mechanisms, with a focus on the regulation of HIF by 
the HIF hydroxylases. Section 1.5 of this chapter was written by Prof. Michael Knapp. A 
former Knapp lab undergraduate student, Alexandra Barbato (B.S. UMass Amherst 2017), 
wrote section 1.6. This chapter has been published by the Royal Society of Chemistry as part 
of the book Gas Sensing in Cells (2018). 
Chapter 2 explores the unique observation of chloride-enhanced substrate hydroxylation 
activity of the D201G variant of FIH. This chapter is the result of a cumulative effort over the 
course of several years. A former graduate student in the Knapp lab, Dr. John Hangasky 
(PhD UMass Amherst 2014), made the D201A/E/G variants of FIH and evaluated the initial 
rate of enzyme activity in the presence of various anions. He also conducted the UV-Vis 
assays to check for anion binding to the (Fe+ αKG)FIH enzyme form. The XAS sample was 
run and analyzed by Hsin-Ting Huang (Maroney lab). Prof. Michael Maroney and Hsin-Ting 
Huang wrote the XAS results and discussion section and prepared the XAS figure. Ran Duan 
conducted Kd binding assays for D201E and WT FIH. This chapter is currently being 
reviewed by Inorganic Chemistry. 
Chapter 3 stems from the finding that the D201G variant of FIH binds chloride. In this 
chapter, we sought to engineer alternate rebound chemistry (such as chlorination) through 
site-directed mutagenesis of the second coordination sphere of D201G FIH. However, it was 
discovered that second coordination sphere mutations were not sufficient to position the 
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halide ligand to outcompete the hydroxide ligand for rebound chemistry. As this project did 
not yield the desired result, this chapter is not being considered for publication.  
Chapter 4 investigates the role of the facial triad carboxylate ligand in coupling O2 reactivity 
and substrate binding using a variety of kinetic and spectroscopic techniques. This chapter is 
currently being prepared for publication.  
Appendix A details a collaboration with the Rotello lab at UMass Amherst to deliver FIH 
into mammalian cells in order to control the hypoxic response. Ryan Landis developed the 
polymer-nanoparticle emulsion delivery system (Rotello lab) and Yiwei Lee (Rotello lab) 
collected the confocal images.  
Appendix B describes the methodology used for screening compound libraries to identify 
selective inhibitors of the HIF hydroxylases and provides an example screening study.  
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CHAPTER 1 
 
MAMMALIAN O2 SENSING AND SIGNALLING 
This chapter has been published as: Chaplin, V.D., Barbato, A.N., Knapp, M.J. Gas 
Sensing in Cells. Chapter 7. Royal Society of Chemistry (2018) 219-252. 
1.1  Introduction 
Mammals sense low pO2 (hypoxia) by processes over multiple length scales, 
ranging from cellular-based pathways up through tissue-based pathways.  The most 
prominent O2 sensing pathway centers on the hypoxia inducible factor (HIF), which 
induces gene expression under hypoxic conditions. HIF is regulated primarily by the HIF 
hydroxylases, the Factor Inhibiting HIF (FIH) and Prolyl Hydroxylase Domain (PHD) 
enzymes, which are nonheme Fe, alpha-ketoglutarate dependent dioxygenases.  FIH and 
PHD recognize selective sequences on HIFα, but they also hydroxylate alternative 
substrates, such as protein containing ankyrin repeat domains (ARDs) and a variety of 
proteins involved in cellular stress responses, making the search for new substrates of FIH 
and PHD a rich area of research.  Proposals for additional O2 sensors, such as H2S and the 
F-box and leucine-rich repeat protein 5 (FBXL5), are introduced.   The tissue-level 
responses of vasopermeation and vasoconstriction are discussed, and are put in context 
with cellular events such as changes in potassium channels.   
1.2  Cellular O2 Sensing 
Maintaining the delicate balance of oxygen homeostasis and ensuring adequate O2 
delivery throughout the body is crucial to cell survival. In addition to acting as the terminal 
electron acceptor for mitochondrial respiration, O2 is an essential co-substrate for many 
2 
 
enzymatic processes.1,2 Consequently, cells and tissues sense and respond to changes in O2 
levels.3 Cellular O2 homeostasis is necessary for normal growth and development, 
including cellular functions such as metabolism and biosynthesis, as well as tissue or 
organismal-level adaptations such as angiogenesis and erythropoiesis. Unsurprisingly, 
misregulation of O2 homeostasis is associated with a variety of pathophysiologies 
including anemia, ischemia, inflammation and cancer.3-5  
The scientific literature typically refers to O2 sensing in terms of cell responses to 
conditions of hypoxia, or low pO2, as the hypoxic response is tied to energy balance, iron 
mobilization, and proliferation.1 Sensing and responding to changes in O2 levels is a 
requirement for survival in aerobic organisms. In addition to balancing metabolic flux 
between aerobic and anaerobic metabolism, many cellular processes are connected to O2 
levels. Distinct hypoxia sensing mechanisms maintain this delicate balance.6 In mammals 
and most eukaryotes, the master response is mediated by the Hypoxia Inducible Factor 
(HIF), which leads to a pronounced transcriptional activity that is directly correlated to O2 
levels.5 
The primary method for sensing hypoxia within cells is through post-translational 
hydroxylation of the Hypoxia Inducible Factor-1 (HIF-1) which leads to a variety of 
transcriptional responses that will be discussed below.7 In addition to the hydroxylation of 
the HIF-1 transcription factor, growing evidence suggests that other protein hydroxylations 
may connect to O2-dependent pathways. Protein hydroxylation changes protein-protein 
binding affinities, altering protein stability and downstream enzyme activities.7 For 
example, under normoxia, prolyl hydroxylation of the eukaryotic elongation factor kinase 
(eEF2K) interferes with the kinase binding to calmodulin, inhibiting eEF2K activity. 
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eEF2K activity is upregulated in hypoxia, increasing the rate of translation elongation and 
protein synthesis.7,8 This regulation suggests a cytoprotective role for eEF2K and 
highlights that interaction between hypoxia sensing and broader metabolic response to 
stress.  
As protein hydroxylation is such a simple post-translational modification, there 
may be additional pathways regulated by hydroxylation, whether or not they are due to the 
hypoxia response.7 While there are a number of protein hydroxylase enzymes that have 
been identified, there is a need to identify new substrates of these enzymes. Similarly, 
identifying new hydroxylating enzymes is crucial to pushing this area of research forward. 
This knowledge could uncover additional O2 sensing pathways and provide novel 
therapeutic targets and regulation mechanisms to improve human health. 
1.2.1 HIF Transcriptional Regulator  
The primary pathway for O2 sensing in human cells is the HIF pathway, in which 
changes in [O2] lead to transcriptional responses of over 1,000 genes.5,9-11 This pathway is 
essential for normal growth and differentiation of tissues. The products of those genes 
controlled by HIF are powerful therapeutic targets, both because of their protective roles 
in responding to varied pO2 levels as well as their antagonistic impacts on tumor growth. 
Genes upregulated by HIF are thought to play protective roles in human responses to 
myocardial ischemia, wound healing, and chronic rejection of organ transplants; 
conversely, genes upregulated by HIF may play antagonistic roles in hypertension, ocular 
neovascularization, erythrocytosis, and a variety of cancers.2 
The function of many proteins under HIF transcriptional control can be sorted into 
two categories: those that increase O2 delivery and those that decrease O2 consumption.12 
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Erythropoietin (EPO) and vascular endothelial growth factor (VEGF), for example, are 
proteins that increase O2 delivery throughout the body by increasing blood O2 carrying 
capacity and vascular permeability respectively.13 Proteins that decrease O2 consumption 
include lactate dehydrogenase A (LDHA) and pyruvate dehydrogenase kinase 1 (PDK1) 
which are crucial in shifting the cell from oxidative to glycolytic metabolism in response 
to decrease pO2.14 These proteins and resulting biological effects will be discussed in 
greater detail later in this chapter.  
HIF was discovered following the observation that the level of EPO was increased 
by hypoxia.5,15 HIF is a heterodimeric transcription factor that is a member of the PER, 
ARNT, SIM (PAS) superfamily and is composed of two basic helix-loop-helix proteins, 
HIFα and HIFβ. This HIFα/β dimer binds to hypoxia response elements (HREs) in DNA 
that are known to be associated with transcription.11 HIFβ, also known as ARNT, is a 
constitutively expressed nuclear protein known to play many roles in biology. HIFα is the 
more significant protein in relation to oxygen sensing as the abundance of HIFα is 
decreased when pO2 is increased.  
1.2.2 HIFα 
HIFα is found as three isoforms in humans and most higher organisms: HIF-1α, 
HIF-2α, and HIF-3α.9 All three forms of HIFα are tightly regulated by post-translational 
modification and alternative splicing. HIF-1α activity is also controlled by its 
nuclear/cytoplasmic distribution. Both HIF-1α and HIF-2α are regulated by post-
translational protein modifications including hydroxylation, acetylation, sumoylation, and 
phosphorylation in their NODD and CODD domains as well as their catalytically active 
NTAD and CTAD domains as described in Figure 1.11,16 HIF-3α is unique in that its CODD 
5 
 
domain is regulated by alternative splicing. One spliced variant of HIF-3α contains the 
bHLH and PAS domains, but lacks the CODD and other C-terminal sequences.9  This 
spliced version of the protein is referred to as inhibitory PAS protein (IPAS). The extensive 
nature of HIFα regulation highlights the significance of this protein in oxygen homeostasis.  
 
Figure 1.1 Post-translational modifications of HIF-1α in homo sapiens.17 
1.2.3 HIF Hydroxylases  
The direct link between HIF-1α activity and O2 levels is formed by the action of a 
small family of non-heme Fe(II) dependent enzymes, which are known as the HIF 
hydroxylases. This family is composed of FIH and three PHD enzymes. Discovered in 
2001 through a combination of sequence analysis and biochemical experiments, these 
enzymes hydroxylate specific amino acid residues within the sequence of HIF-1α, leading 
to a decrease in the transcriptional levels of HRE controlled genes.18,19  
The HIF hydroxylases are thought to follow the consensus chemical mechanism for 
the alpha-ketoglutarate (αKG) oxygenase superfamily. Enzymes in this superfamily couple 
the splitting of O2 to the hydroxylation of primary substrate and oxidative decarboxylation 
of αKG. Their net chemistry for a simple hydroxylation is: 
O2 + RH+ αKG → CO2 + ROH + succinate 
where R is the primary substrate.2  
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Applying the consensus mechanism to the HIF hydroxylases provides an example 
of the fundamental steps involved in turnover. The enzyme initially forms a six coordinate 
Fe(II) complex bound to a two-His one-carboxylate facial triad. As shown in Figure 1.2, 
binding of primary substrate displaces the H2O ligand coordinated to Fe, leading to the 
reaction with O2. Oxidative decarboxylation of αKG produces succinate and CO2, and an 
Fe(IV)=O intermediate. This ferryl intermediate can then oxidize an unactivated C-H bond 
in the primary substrate (R) allowing for hydrogen atom transfer and rebound chemistry to 
produce the hydroxylated product (R-OH). 
 
Figure 1.2 Consensus mechanism for the HIF hydroxylases. 
 
A prominent feature of this catalytic cycle is the multiple changes in geometry 
about the Fe cofactor, as reported for FIH and several other αKG oxygenases.20-22 The 
cause of this coordination change is not clear, however altered local contacts to the second 
coordination sphere are thought to induce aquo release.20,23 Crystallographic data indicates 
that the backbone of the hydroxylated residue of HIF-1α is positioned to hydrogen bond to 
the distal O of the active site Asp residue, which is thought to weaken the hydrogen bond 
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between Asp and the aquo ligand. In addition, steric clashes within the active site appear 
to impact the binding of the aquo ligand in the E(Fe+αKG) enzyme form, suggesting that 
a more constrained active site upon HIF-1α binding may destabilize the aquo ligand.24 
Although all of the αKG dependent oxygenases require O2 as a substrate, both FIH 
and PHD are O2 sensors due to their role in regulating HIF-1α. The abundance of all 
reagents impacts the activity of the HIF hydroxylases, including primary substrate, O2, 
Fe(II), and αKG, resulting in a response that is proportional to substrate and cofactor 
availablity.25 A unique feature of FIH and PHD isozymes is the very high Michaelis 
constant relative to physiological O2 levels (KM(O2) >> [O2]), leading their activity to be 
directly proportional to [O2] over physiologically relevant values. Interestingly, FIH has a 
lower KM(O2) than PHD, meaning it has a more pronounced activity response at lower 
oxygen tensions than PHD. This difference in the kinetic constants between the HIF 
hydroxylases suggests that they may fulfill distinct cellular functions over a wide range of 
[O2].26 
The common protein fold for the catalytic domain of the αKG-dependent 
oxygenases is the cupin fold, in which 8 β-strands wrap around to form a barrel that binds 
the Fe cofactor. FIH is a relatively simple example of the cupin fold, however FIH is a 
homodimer with two catalytic subunits per biological unit. The PHD isoforms exhibit a 
more complicated structure, as they are composed of a MYND domain as well as a cupin 
fold.27 
PHD2 is thought to be the main prolyl hydroxylase isozyme mediating HIF-1α 
stability in vivo as inactivation of PHD2 alone has been shown to upregulate HIF1α protein 
levels and HIF target gene expression in several cell lines.6,28  PHD1 and PHD3 are active 
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in the testis and heart respectively whereas PHD2 is ubiquitously expressed.9,29,30 The PHD 
isozymes also exhibit differential cellular distributions, with PHD1 found as a nuclear 
protein, PHD2 predominately found in the cytoplasm, and PHD3 present in both the 
nucleus and cytoplasm. Although the reasons for the different localizations of the PHD 
enzymes is unknown, it is speculated that cytoplasmic HIF hydroxylases control the HIF 
transcriptional system under normoxia while the nuclear hydroxylases serve as a backstop 
to downregulate HIFα following sudden reoxygenation.25  
PHDs catalyze hydroxylation of conserved prolyl residues within the N- and C- 
oxygen degradation domains (N/CODDD) of HIFα (Figure 1.3). Once hydroxylated at one 
or both ODDDs, HIFα is then recognized by pVHL, which targets HIFα for proteasomal 
degradation. The action of PHD causes the HIFα protein levels to decrease in response to 
elevated [O2], leading to a primary control over the transcriptional activity of HIF.31,32 As 
the activity of the PHDs is directly proportional to [O2] over the physiological range, simple 
chemical kinetics provide the main control over the transcriptional activity of HIF, 
although levels of PHD2 and PHD3 are themselves also upregulated in response to 
hypoxia.25 
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Figure 1.3 Regulation of HIF-1α by the HIF hydroxylases. 
 
FIH hydroxylates the β-carbon of a specific asparagine residue in the CTAD of 
HIF-1α and HIF-2α.  This hydroxylation blocks the binding of co-activator p300, 
preventing HIFα from assembling an active transcriptional complex. p300 and its paralog 
CBP interact with several transcription factors, regulating their activity. The p300/CBP 
proteins are composed of several protein-binding domains, including two homologous 
transcriptional adaptor zinc-binding (TAZ) domains.33 These TAZ domains are responsible 
for protein-protein interaction and transcriptional regulation of several cellular pathways; 
despite sharing sequence homology TAZ1 and TAZ2 are known to bind different groups 
of transcription factors. Studies of the free TAZ1 domain revealed that the TAZ1 domain 
is able to form a stable fold without being complexed to a transcription factor, indicating 
that this domain acts as a preformed scaffold with unique surfaces and grooves to mediate 
protein-protein recognition. These slight structural differences allow the activation domain 
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of HIF-1α to distinguish between TAZ1 and TAZ2 and form an active transcriptional 
complex.  
In addition to the HIF hydroxylases, several other enzymes are involved in cellular 
responses to hypoxia. As hypoxia responses are so closely tied to cellular energetics and 
proliferation, and a variety of post-translation modifications alter HIFα activity, 
distinguishing O2-specific responses from other metabolic responses is challenging.34,35 
Similarly, there are a growing number of oxygenases linked to gene expression through 
histone demethylation or DNA repair, which demonstrates that O2-initiating enzymes may 
regulate genes without being hypoxia sensors.36-39  
 
Figure 1.4 Model for the regulation of VHL and HIF-1α by JMJD6 in trophoblast cells. 
In normoxia, JMJD6 stabilizes VHL through lysyl hydroxylation, resulting in 
translocation of VHL into the nucleus where it undergoes SUMOylation by SUMO1. 
SUMOylated VHL then targets HIF-1α for degradation.40 
1.2.4 Other O2 Sensing Enzymes  
There is very strong evidence supporting an O2-sensing role for the enzyme Jumonji 
domain-containing 6 protein (JMJD6). This oxygen sensing role is illustrated in early 
placental development as JMJD6 expression levels correlate with changes in oxygen 
11 
 
tension.40 In normoxia, JMJD6 hydroxylates lysine residues on pVHL, allowing pVHL to 
translocate into the nucleus where it undergoes SUMOylation and targets HIF-1α for 
degradation (Fig. 4).40 Under hypoxic conditions, HIF-1α upregulates JMJD6 expression. 
However, the dioxygenase activity of JMJD6 is reduced in low oxygen environments, 
resulting in VHL degradation and accumulation of HIF-1α.  The discovery of more oxygen 
sensing enzymes is anticipated as the regulation of oxygen sensing in mammalian cells is 
investigated further.  
1.3 Discovering new targets for the HIF hydroxylases  
HIF hydroxylases react selectively with a target residue within a peptide sequence 
context; however, there is some variability in these sequences. Both FIH and PHD have 
been shown to react with proteins other than HIFα suggesting that there are additional 
substrates remaining to be discovered for these enzymes.  
1.3.1 HIF-1α 
HIF-1α is the established physiological substrate for FIH and the PHD isozymes 
with the specific reactions being asparaginyl hydroxylation within the C-terminal 
transactivation domain (CTAD) for FIH, and prolyl hydroxylation in the C/N terminal 
oxygen-dependent degradation domain (ODDD) for PHD.10,16,25  The protein sequence of 
HIF-1α is highly conserved in these domains highlighting the specific nature of these 
modifications. As shown in Figure 1.5 there is little diversity in the CTAD region of HIF-
1α across numerous species. The CTAD sequence of DXEVNAP, with Asn803 being the 
residue hydroxylated by FIH, is highly conserved indicating that these residues are crucial 
for regulation of HIF-1α by FIH.  
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Figure 1.5 Logo representation of the CTAD consensus sequence of HIF-1α across 
several species. 9 eukaryotic HIF-1α protein sequences of various phylums and classes 
were aligned using Clustal Omega, then modelled using the web logo program developed 
at the University of California, Berkeley. The N803 is the site of hydroxylation. Aligned 
species (accession number): Homo sapiens (NP_001521.1), Rattus norvegicus 
(NP_077335.1), Myotis davidii (ELK27249.1), Canis lupus familiaris 
(NP_001274092.1), Bos grunniens (AAT39520.1), Branchiostoma floridae 
(AGX25238.1), Tribolium castaneum (EFA04586.2), Expaiptasia pallida (KXJ20783.1), 
and Saccoglossus kowalevskii (ADB22425.1). 
 
The conserved recognition site in CTAD correlates with the area of CTAD that 
binds in the active site pocket of FIH as seen in Figure 1.6 The alpha helical and loop 
residues which reside outside of the FIH active site are not responsible for substrate 
recognition and subsequent hydroxylation; therefore, there is a higher tolerance of 
variability at these sites.  
 
Figure 1.6 Crystal structure of CTAD (magenta) in the active-site pocket of FIH (wheat). 
Residues that are conserved in the CTAD consensus sequence are displayed and labeled 
(cyan). CTAD residues 807-811 are not resolved in the crystal structure. PDB Code: 
1H2K.41 
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The PHD recognition sequence within the ODDD displays a greater tolerance for 
residue variability. Both Pro402 and Pro564 are targeted for hydroxylation and subsequent 
regulation of HIF-1α by the PHD isozymes. This variability in recognition sequence may 
explain why the PHD isozymes hydroxylate two different proline residues with the ODDD. 
As seen in Figure 1.7 using the same HIF-1α sequences as the CTAD HIF-1α alignment, 
the NODDD PHD binding site has a consensus sequence of LTXXAPAAGD whereas the 
CODDD consensus sequence is even more variable: LXXXAPYIXX.  
 
Figure 1.7 Logo representation of the NODDD (top) and CODDD (bottom) consensus 
sequence of HIF-1α across several species. The same eukaryotic HIF-1α protein 
sequences of various phylums and classes as used in Figure 1.5 were aligned using 
Clustal Omega, then modelled using the web logo program developed at the University of 
California, Berkeley. The hydroxylated residues are P402 (NODDD)and P564 
(CODDD). Aligned species (accession number): Homo sapiens (NP_001521.1), Rattus 
norvegicus (NP_077335.1), Myotis davidii (ELK27249.1), Canis lupus familiaris 
(NP_001274092.1), Bos grunniens (AAT39520.1), Branchiostoma floridae 
(AGX25238.1), Tribolium castaneum (EFA04586.2), Expaiptasia pallida (KXJ20783.1), 
and Saccoglossus kowalevskii (ADB22425.1). 
  
As seen with the FIH/CTAD adduct, the CODDD residues that bind in the active 
site of PHD are conserved (Fig. 1.7 & 1.8). Fewer residues of CODDD fit in the PHD 
active site pocket, which leads to a greater tolerance for variability in the rest of the 
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CODDD chain (Fig. 1.8). Close inspection of the HIF hydroxylase recognition sites in HIF-
1α suggests the FIH/CTAD binding is more selective than PHD2/CODDD as there are 
more conserved residues in the CTAD consensus sequence. 
 
Figure 1.8 Crystal structure of CODD (magenta) in the active-site pocket of PHD2 
(wheat). CODD residues that are conserved in the consensus sequence are displayed and 
labeled (cyan). PDB Code: 5L9B.42 
1.3.2 Ankryin Repeat Domains 
FIH also hydroxylates a limited set of target residues within proteins containing 
ankyrin repeat domains (ARDs). ARDs are composed of repeating ~33 amino acid 
segments in a helix-loop-helix conformation with a β-hairpin loop connecting adjacent 
repeats. These ARDs are found in numerous biologically significant proteins and can exist 
on their own as a single domain or in tandem with other domains to compose a larger 
protein.43 ARD-containing proteins mediate a wide variety of protein-protein interactions 
in the areas of cell-cell signaling, transcription and cell cycle regulation, inflammatory 
response, and development.43 
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FIH displays a broad tolerance for several target residues within the ARD sequence 
context, in contrast to the specificity for Asn within the CTAD context.44  FIH will 
hydroxylate Asn, His, Leu, Ile, Ser, and Asp target residues within a consensus ARD 
peptide sequence in vitro, indicating that polar and hydrophobic target residues are 
accepted.26 In addition to the in vitro peptide substrates, biological assays revealed 
hydroxylation at Asn, Asp, and His target residues.45, 46 The ARD substrates are the only 
known example of non-asparaginyl substrate hydroxylation by FIH.  
 
Scheme 1.1 Substrate hydroxylation by FIH. 
 
Hydroxylation of ARD substrates by FIH likely follows the same consensus 
mechanism as CTAD hydroxylation (Scheme 1.1). The added hydroxyl group forms a 
hydrogen bond to nearby aspartyl residues stabilizing the ARD fold in solution.47 
Hydroxylation of His is less efficient than the other residues, which may reflect the 
positioning of the target residue within the active site of FIH. 
 
Figure 1.9 Logo representation of known ARD-containing substrates for asparaginyl 
hydroxylation by FIH. Protein sequences were aligned using Clustal Omega. The 
hydroxylated residue is N16. Aligned human proteins (hydroxylated residue): ASPP2 
(N986), IκBα (N210), IκBα (N244), p105 (N678), p19-INK4d (N101), ILK-1 (N94), 
FEM1β (N526), FGIF (N168), GABP-β1 (N98), Gankyrin (N100), Myotrophin (N62), 
RNaseL (N233), MYPT1 (N67), Notch1 (N1956), Rabankyrin-5 (N316), AnkyrinR 
(N105), Tankyrase-1 (N864), Tankyrase-2 (N203). 
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As exemplified in Figure 1.9, the 33 amino acid structure of the ARDs is well 
conserved. Despite the high degree of sequence conservation of the ARDs, insertions in 
the loop regions of the ARDs are not uncommon.43 Structure alignments of the p105 and 
IκBα proteins, which were the first ARD-containing proteins confirmed as FIH substrates, 
revealed that the hydroxylated residue resides at the apex of the hairpin loop which 
connects the ARD repeating units.47 As the loop region containing the target residue is 
semi-conserved throughout the ARD family, it was hypothesized that more ARD 
containing proteins would also be suitable FIH substrates. This hypothesis was confirmed 
through biochemical assays and modeling, resulting in ARDs becoming the largest class 
of hydroxylation substrate to date.47 All of the current known ARD and HIF substrates of 
FIH are listed in the table below.   
Table 1.1 Known FIH substrates for asparaginyl hydroxylation.  
Substrate Peptide 
Sequence 
Function Substrate 
Class 
Reference 
HIF-1α YDCEVNAPIQ HIF transcriptional regulation HIF Wilkins 2009 
HIF-2α YDCEVNAPVL HIF transcriptional regulation HIF Wilkins 2009 
ASB4 NNAEVNARDD Ubiquitin-mediated proteolysis ARD Ferguson 2007, 
Cockman 2009 
ASPP2 FGVNVNAADS Regulates cell-cell contacts and 
maintenance of tight junctions 
ARD Janke 2013 
FEM1β CGAEVNAVDN Unknown ARD Cockman, 2006  
GABP-β HGADVNAKDM Unknown ARD Cockman, 2006 
Gankyrin KGAQVNAVNQ Unknown ARD Cockman, 2006, 
Wilkins 2012 
1κBα LGADVNAQEP NF-κB signaling ARD Cockman 2006, 
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CGADVNRVTY Webb Anyi 2009 
ILK-1 YKADINAVNE Unknown ARD Cockman, 2006 
Myotrophin KGADINAPDK Unknown ARD Cockman, 2006 
MYPT-1 AGYDVNIKDV Actin-myosin contractility ARD Cockman 2009, 
Webb Anyi 2009 
Notch-1 ASADANIQDN 
SHADVNAVDD 
Proliferation, differentiation, 
apoptosis 
ARD Cockman 2009, 
Coleman 2007, 
Wilkins 2009 
Notch-2 AGADANAQDN 
CQADVNAVDD 
Proliferation, differentiation, 
apoptosis 
ARD Cockman 2009, 
Coleman 2007, 
Wilkins 2009 
Notch-3 AGADTNAQDH 
SHADVNAVDE 
Proliferation, apoptosis ARD Cockman 2009, 
Coleman 2007, 
Wilkins 2009 
P19-INK4d GADVNVPDG Unknown ARD Cockman, 2006 
p105 
(NFKB1) 
AGADVNAQEQ NF-κB signaling ARD Cockman 2006, 
Webb Anyi 2009 
Rabankryin-5 HQADINVRTQ 
SGCDVNSPRQ 
DGANVNAQDA 
NGAFVNAATL 
Endocytosis, macropinocytosis ARD Cockman, 2009 
RIPK-4 PGVSVNAQTL Influences RIPK4 stability and 
downstream signaling 
ARD Rodriguez, 2016 
RNaseL HGADVNVRGE Endoribonuclease ARD Cockman 2009, 
Webb Anyi 2009 
Tankyrase-1 HGADVNAQDK Telomere, vesicle regulation ARD Cockman 2006, 
Webb Anyi 2009 
Tankyrase-2 TPLNVNCHAS Telomere, vesicle regulation ARD Cockman, 2009 
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HGACVNAMDL 
TVQSVNCRDI 
HEAKVNALDN 
HGAVVNVADL 
SPDNVNCRDT 
HGADVNAQDK 
YNACVNATDK 
OTUB1 DSEGVNCLAY Cellular metabolism DUB Scholz, 2016 
 
Hydroxylation of the ARDs does not induce a conformational change in the ARD 
structure as show by crystallography of the Notch-1 substrate.47 The proposed function of 
ARD hydroxylation is to induce localized changes in the ankyrin repeat stability in order 
to regulate its function. This hypothesis is based on studies of IκBα which indicated that 
changes in ARD stability influence NF-κB association and effect the half-life of the 
uncomplexed protein.54 
While the biological significance of FIH hydroxylation of ARDs is unknown, there 
is some speculation that ARD proteins are competitive inhibitors of the CTAD FIH 
substrate.25,47 Evidence to support this theory includes the tighter binding of FIH to ARD 
than to CTAD (resulting in a lower KM(ARD) than KM(CTAD)).27 Interestingly, FIH has been 
shown to bind some ARDs without hydroxylating them, suggesting that ARDs may serve 
to buffer the availability of FIH to sense O2.  Further, when co-expressed in transfected 
cells, ARD proteins compete with CTAD for hydroxylation.27 In addition, the FIH-ARD 
complex reacts slower with O2 than FIH-HIFα.26 Exploring the scope of ARD 
hydroxylation by FIH will provide further insight into the protein-protein interactions these 
ARDs mediate and may identify other pathways regulated by FIH. 
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1.3.3 Alternate Substrates of PHD 
Several non-HIF substrates have been identified for the PHD isozymes, many of 
which play a significant role in the biological pathways activated during hypoxia. For 
example, IKKβ activates the NF-κB pathway which is critical to the inflammatory 
response.55 Hydroxylation of Rpb1 by PHD1 and PHD2 promotes tumor growth, which is 
known to be unregulated during certain cancers.56 A complete list of the known 
hydroxylation substrates of the PHD isozymes is presented in Table 1.2 The wide range of 
substrate hydroxylation by the PHD isozymes implies that there are a host of HIF-
independent responses to changes in oxygen tension within the cell.  
Table 1.2 Known substrates hydroxylated by the PHD isozymes. 
Substrate Peptide 
Sequence 
PHD 
Isoform 
Function Reference 
Akt FRSGSPSDNSG 
TFCGTPEYLAP 
PHD2 Decrease in Akt-
mediated cell 
proliferation and 
tumorigenesis 
Guo 2016 
Β(2)AR CEDLPGTEDFV
GHQGTV-
PSDNI 
PHD3 Regulation of 
receptor 
degradation 
Wong 2013, 
Xie 2009 
Β and γ 
actin 
ITALAPSTMK 
GTTMYPGIAD 
PHD3 Impaired actin 
polymerization 
Luo 2014 
CEP192 LSSLAPPYVK PHD1 Control of cell 
cycle 
progression 
Moser 2013 
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CERKL Unknown PHD1,3 Regulation of 
CERKL protein 
stability 
Chen 2015 
DYRKI
A/B 
Unknown PHD1 HIF-2α 
destabilization 
Lee 2016 
EPOR LLRPWTLCPE 
LPPTPPHLK 
PHD3 Decrease in 
erythropoiesis 
and EPO induced 
JAK-STAT 
signaling 
Heir 2016 
FLNA Multiple Pro 
residues 
PHD2 Inhibition of p53 
transcriptional 
activity 
Segura 2016 
FOXO3 SGLGSPTSSF 
STVFGPSSLN 
PHD1,3 Prevents binding 
of USP9x 
Zheng 2014 
HCLK2 LAQLGEPELR PHD3 Promotes DNA 
damage response 
Wong 2013, 
Xie 2012 
HIF-1α LEMLAPYIPM 
LTLLAPAAGD 
PHD1,2,3 HIF 
transcriptional 
regulation 
Tarhonskaya 
2015 
HIF-2α LETLAPYIPM 
LAQLAPTPGD 
PHD1,2,3 HIF 
transcriptional 
regulation 
Tarhonskaya 
2015 
IKKβ LQYLAPELLE PHD1 Activation of 
NF-κB 
Cummins 
2006 
MAPK6 MDLKPLGCGG PHD3 Stabilization of 
MAPK6 protein 
Rodriguez 
2016 
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Myogeni
n 
Unknown PHD3 Stabilization of 
myogenin 
protein 
Wong 2013, 
Fu 2007 
NDRG3 CGGLPQVVQP PHD2 Decrease in 
RAF-ERK1/2 
kinase signaling 
Lee 2015 
 
p53 Unknown PHD1 Phosphorylation 
of Ser15 on p53, 
binding with p38 
Deschoemae
-ker 2015 
PDE4D SSLTNSSIPR PHD2 Regulation of 
intracellular 
cAMP levels 
Wong 2013, 
Huo 2012 
PKM2 PITSDPTEAT 
(OR not both) 
PHD3 HIF activation Wong 2013, 
Luo 2011 
Rbp1 P1465 PHD1,2 Activation of 
Rbp1 and tumor 
growth 
promotion 
Wong 2013, 
Mikhaylova 
2007, 
Kuznetsova 
2003 
Spry2 GSQPLLQTPR 
FSSGPVADGI 
SELKPGELKP 
PHD1,2,3 Negative 
regulation 
Wong 2013, 
Anderson 
2011 
TR-α  PHD2,3 Increased 
transcription of 
PLN 
Xie 2015 
TRPA1 LKNLRPEFMQ PHD1,2,3 Negative 
regulation of ion 
channel activity 
Takahashi 
2011, 
Wong 2013 
22 
 
1.4 New Target Identification  
Despite the physiological role for FIH and PHDs as HIF hydroxylases, there is 
still much to be learned about new hydroxylation targets of these enzymes. Identifying 
new targets may include pathways involved in O2 sensing independent of HIF, or 
complementary to HIF. Alternative targets have been discovered for both FIH and the 
PHD isozymes, as described in the previous section; additional substrates are likely to 
be discovered. 
 Identifying new substrates for this group of enzymes will provide insight into 
other roles of the HIF hydroxylases, such as the potential for HIF-independent O2 
sensing. Substrate discovery is challenging due to limited methods for naïve screening 
to identify substrate hydroxylation. Unlike many other post-translational modifications, 
hydroxylation does not significantly alter the molecular weight of the target, as occurs 
in ubiquitination; nor does it alter the pI of a peptide, as is the case for acetylation or 
phosphorylation.52,71 This means that bulky methods, such as column enrichment used 
for phosphopeptides, do not work to selectively enrich hydroxylated peptides. 
Consequently, there is a reliance on lower throughput methods, such as biological 
binding assays or high-resolution mass spectrometry (MS).  
 The general approach for detecting hydroxylation is summarized as follows: 
identify the hydroxylated peptide, quantify hydroxylation prevalence with and without 
hydroxylase present, then evaluate the molecular and biological function of the 
hydroxylation.7,52 In addition to sequencing analysis to identify putative substrates 
based on sequence similarity, there are a variety of chemical and biochemical 
approaches to assay for hydroxylation which will be discussed in detail in this section.  
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An unbiased method to identify hydroxylation is based on a radio-tracer 
decarboxylation assay.65 It is well known that hydroxylation by the αKG oxygenases 
results in the decarboxylation of αKG and release of CO2. This technique takes 
advantage of the decarboxylation chemistry as the alpha carbon of αKG is labeled with 
radioactive 14C resulting in the release of radioactive 14CO2 in the presence of a 
substrate as described in Figure 1.10. 14CO2 release can then be quantified as a measure 
of enzyme activity, which is typically stimulated by binding primary substrate. A 
strength of this assay is that it is very widely applicable, independent of substrate 
identity; weaknesses include the low-throughput nature and complications of 
uncoupled decarboxylation that is prominent in some αKG oxygenases. 
 
Figure 1.10 αKG decarboxylation assay design. *=14C labelled. 
 
 
This approached yielded multiple hits from a library of proteins expressed from 
1,000 cDNAs.65 One target in particular, FOXO3a, was thoroughly characterized for 
its role in oxygen sensing. Hydroxylation of FOXO3a by PHD2 inhibits binding of the 
deubiquitinase USP9x which results in proteasomal degradation of FOXO3a. In 
hypoxia, FOXO3a is not hydroxylated leading to its accumulation in cells and 
subsequent suppression of the mammary proliferation protein Cyclin D1.65 
 Biophysical binding assays for new substrates can be quite powerful, provided 
that the enzyme/substrate binding affinity is high enough to be directly probed. One 
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type of binding assay used to successfully identify new substrates for PHD is the yeast 
2-hybrid assay, which probes the interactions between a fusion protein (ie. Gal4) and a 
reporter gene. The binding domain of the fusion protein recognizes the unique upstream 
activator sequence (UAS) in the reporter gene and targets the enzyme-BD fusion 
protein. Interaction between the enzyme and substrate bring the BD and activation 
domains (AD) together spurring expression of the reporter gene.72-74 A specific 
example of a yeast 2-hybrid assay design is described in Figure 1.11.  
 This technique is powerful as it is amenable to high throughput screening of 
substrate libraries in order to identify substrates which bind to a protein of interest. 
However, one glaring limitation of the yeast 2-hybrid method is that the assay tests for 
target binding to the enzyme, but does not test for the ability of enzyme to hydroxylate 
the substrate. In addition, low affinity binding is challenging to observe, meaning that 
many substrates may be overlooked. Several HIF hydroxylase binding partners, such 
as ATF-4, have been identified via MBP pull-down assays; hydroxylation could not be 
confirmed by MS suggesting that protein-protein binding may involve the non-catalytic 
domains of the HIF hydroxylase.57,72  
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Figure 1.11 Example yeast 2-hybrid assay design used to study protein–protein 
interactions. Interactions between the enzyme and substrate bring the BD and AD of 
the Gal4 fusion protein in proximity to initiate expression of the reporter gene.73 
 
 
 Heir and colleagues took a more specific approach to identifying potential 
substrates of the PHD isozymes using FLAG-tagged coimmunoprecipitation.63 The 
EPO receptor (EPOR) was known to interact with VHL during polyubiquitination, 
suggesting that EPOR may play a role in oxygen homeostasis by an unknown 
mechanism.63 Heir hypothesized that one of the PHD isozymes bound to EPOR, 
leading to an oxygen-dependent modification of EPOR. Flag-tagged gene products 
which precipitated with a PHD isozyme were pooled as potential substrates for 
subsequent screening by MS. PHD3, but not PHD1 or PHD2, preferentially 
precipitated with EPOR-FLAG, suggesting that only the PHD3 isozyme reacted with 
EPOR. Subsequent MS-detected activity assays confirmed prolyl hydroxylation at two 
sites in EPOR. While this method would not work for screening pools of potential 
substrates, it does work well for identifying interaction partners for a specific target.  
 A very precise method to identify new substrates is through the use of targeted 
MS based proteomics to detect the increased mass from hydroxylation on a target 
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analyte. To use this tactic, a specific substrate library of interest must be identified. For 
the HIF hydroxylases, screening FIH or PHD against consensus sequence or peptides 
containing ARDs are common approaches. Several groups have screened PHDs against 
the –LXXLAP- binding motif2,10 of the PHD substrates.59,60,68 Several new substrates 
have been identified using targeted libraries. It was shown that subunit 1 of RNA 
polymerase II (Rbp1) was modified by prolyl hydroxylation. Hydroxylation of Rbp1 
led to pVHL binding and subsequent ubiquitination of Rbp1, which regulated the 
elongation of TH gene mRNA.68  
 Luo and coworkers applied this technique to the pyruvate kinases isoforms 
PKM1 and PKM2 and discovered that PKM2 was a substrate for the PHD3 isozyme. 
PKM2 plays a prominent role in cancer cells contributing to tumorigenesis and altering 
glucose metabolism; hydroxylated PKM2 exhibited enhanced binding affinity towards 
HIF-1α suggesting PKM2 may play a role in oxygen sensing by promoting HIF-1 
transactivation.59 Moser and coworkers identified the centrosome protein Cep 192 as a 
substrate of PHD1 by screening for the –LXXLAP- motif. Here, cell cycle progression 
is halted based on changes in PHD activity, which can result from oxygen deprivation 
or metabolic alterations. Hydroxylation of Cep 192 by PHD1 identified a new target 
which linked cell cycle progression to environmental changes.60  
 Since FIH is known to hydroxylate ARDs,44-47 screening for the ARD motif has 
been a successful method for identifying new FIH substrates, however this is biased 
towards substrates which contain an ARD. In what can be viewed as a generalizable 
approach (Figure 1.12), a substrate library based on the ARD sequence was screened 
for binding to FIH in the presence of enzyme inhibitor. Proteins that could bind to FIH 
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were trapped, immunoprecipitated (IP), and subsequently identified by MS.47,50 
Numerous FIH substrates have been identified using this method including Tankyrase-
247 and the deubiquitinase ovarian tumor domain containing ubiquitin aldehyde binding 
protein (OTUB1).53 Possible roles of Tankyrase-2 hydroxylation include vesicle 
trafficking and telomere regulation.47 Hydroxylation of OTUB1 promotes its 
interaction with metabolic proteins; removal of the hydroxylation site alters these 
interactions suggesting a link between metabolic regulation and oxygen sensing.  
 
Figure 1.12 A generalized workflow for identification of novel FIH-ARD interactors 
by means of substrate trapping with DMOG.47 
 
Combining two methods can increase the scope while searching for new 
substrates.  Quantitative interaction proteomics combines Cockman’s substrate 
trapping approach with an unbiased search for new substrates, not reliant on screening 
for a particular consensus sequence or motif.52 As before, DMOG “traps” inactive 
hydroxylase-substrate complexes enriching the pool of hydroxylated proteins from 
which to screen and increasing the number of bound hydroxylases-substrate 
complexes. Substrate screening begins by overexpressing the hydroxylase of interest 
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in cells, then precipitating the hydroxylase along with any proteins bound to it (Figure 
1.13). MS followed by label-free quantitation algorithms, such as MaxQuant 
(MaxLFQ), is then implemented to identify and quantify IP proteins.75 The intensity of 
the MaxLFQ readout correlates to relative protein abundance and changes in protein 
interaction. Ingenuity pathway analysis is then used to propose the biological 
significance of new hydroxylase-substrate interactions through mapping precipitated 
proteins onto various signaling pathways.52  
 
Figure 1.13 Schematic illustration of the mass spectrometry-based hydroxylase 
screen. Cells are transfected with hydroxylase enzyme and treated with the inhibitor 
DMOG. Hydroxylases (E) were immunoprecipitated (IP) along with any bound 
protein targets (S), digested, and analysed via liquid chromatography mass 
spectrometry (LC-MS).52 
 
Rodriguez and coworkers identified two new hydroxylase substrates using this 
method. The PHD3 isozyme hydroxylates Pro25 of MAPK6, stabilizing hydroxylated 
MAPK6 and protecting this protein from proteasomal degradation. FIH hydroxylates 
the signaling protein RIPK4, which was shown to regulate RIPK4 kinase-dependent 
phosphorylation.52  
These experiments highlight the successes in identifying new hydroxylase 
targets to further understand the extent of HIF hydroxylase oxygen sensing activity 
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within the cell. The development of high resolution mass spectrometry and improved 
mass accuracy has greatly improved peptide fragment analysis and hydroxylation site 
assignment, however there is still a need for a more efficient substrate enrichment and 
screening method for hydroxylation.  
1.5 Selected Hypoxia Sensitive Pathways  
One of the greatest impacts of oxygen availability on biological pathways is 
seen in cellular metabolism. As the amount of oxygen in the cell determines the balance 
between oxidative and glycolytic metabolism, metabolic O2 consumption must be 
equilibrated to O2 supply. Cellular hypoxia induces a cascade of reactions which affect 
the metabolic pathway: (1) The accumulation of HIF-1α leads to increased transcription 
of genes that encode glucose transporters and glycolytic enzymes, (2) HIF-1α induces 
PDK1 which has the effect of suppressing the Krebs cycle and oxidative 
phosphorylation within the mitochondria. (3) Suppression of the Krebs cycle leads to a 
shift in mitochondrial glutamine metabolism from oxidative to reductive 
carboxylation.14,59  
HIF-1α mediated alterations of cellular metabolism during hypoxia result in a 
reduction of mitochondrial O2 consumption and an increase in O2 independent ATP 
production.14  Key genes induced by HIF-1α during this process include the glucose 
transporters GLUT1 and GLUT3, LDHA which converts pyruvate to lacate 
regenerating NAD+ for glycolysis, and monocarboxylate transporter 4 (MCT4) which 
then transports lactate out of the cell. In cancer cells, pyruvate kinase M2 (PKM2) plays 
a role in reprogramming glucose metabolism. Located in the nucleus, PKM2 stabilizes 
HIF-1 binding to DNA and helps recruit p300 to form an active transcriptional 
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complex.59 Through this interaction, PKM2 aids in upregulating the genes controlled 
by HIF-1. There is speculation that PKM2’s interaction with HIF-1α and cofactor p300 
may aid HIF-1α in avoiding negative regulation by the HIF hydroxylases.59 
The impact of HIF-mediated gene regulation on the glycolytic pathway is 
extensive. In normoxia, pyruvate is converted to acetyl CoA by pyruvate 
dehydrogenase (PDH) linking glycolysis to the Krebs cycle; however, under hypoxia 
conditions, pyruvate is converted to lactate.76 PDH activity is regulated by two 
enzymes, the phosphorylating kinase PDK which inactivates PDH and pyruvate 
dehydrogenase phosphatase which dephosphorylates PDH into its active form. These 
transcriptional changes result in pyruvate being exported from the mitochondria, 
instead of being directed to the Krebs cycle, decreasing the efficiency of the electron 
transport chain. Overall, it is important to recognize that the metabolism of pyruvate 
drastically changes under hypoxia.   
Substantial cross-talk occurs between the oxygen sensing and inflammatory 
pathways. Both pathways are activated in response to environmental stress and can spur 
disease states when deregulated. As in the oxygen sensing pathway, the inflammatory 
pathway is highly regulated through small peptides, glycoproteins, and transcription 
factors.77 The transcription factor NF-κB is a main player in the inflammatory response. 
Disregulated NF-κB is apparent in several disease states including inflammatory bowel 
disease, asthma, cancer, and HIV.77 
Parallel to HIF in the hypoxic response, NF-κB is one of the main regulators of 
the inflammatory pathway. HIF and NF-κB are linked at both the molecular level and 
in their resulting physiological responses.77 Unactivated NF-κB resides in the cytosol 
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bound to an inhibitory protein IκB. Stimuli (such as the pro-inflammatory cytokine 
tumor necrosis factor α) activates the IκB kinase resulting in phosphorylation and 
degradation of IκB, and allowing NF-κB to translocate to the nucleus where it binds to 
specific DNA sequences, forming an active transcriptional complex as described in 
Figure 1.14.78 At the molecular level, NF-κB works in concert with HIF1β to stabilize 
HIF1α levels in hypoxia.79,80 Furthermore, HIF1α has been shown to suppress NF-κB 
both in vivo and in vitro during inflammation.81-83  
 
Figure 1.14 Overview of the canonical NF-κB pathway. Activated in response to 
stimuli, IKK mediates phosphorylation of IκB, targeting it for degradation. Once IκB 
is released from NF-κB, NF-κB translocates into the nucleus where it binds DNA to 
form an active transcriptional complex.77 
 
 
Crosstalk between HIF and NF-κB is evident in the systemic autoimmune 
disorder rheumatoid arthritis (RA), among other disease states.77,84 Hallmarks of RA 
include chronic inflammation of synovial membranes in joint tissues at multiple sites 
in the body which results in localized joint destruction and deformity. In the context of 
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RA, NF-κB, along with several other transcription factors, is deregulated. NF-κB is 
over-activated in the RA synovium85 leading to the formation of a positive feedback 
loop due to NF-κB’s activation of pro-inflammatory cytokines, chemokines, 
metalloproteins, and metabolic proteins. This enhanced activation of pro-inflammatory 
signals manifests as chronic and persistent inflammation.54,86  
HIF is a known potential therapeutic target for RA as it is responsible for 
tackling the severe hypoxic state of the synovial tissue.87 Hypoxia activates HIF1α and 
HIF2α stimulating angiogenesis and activating pro-inflammatory cytokines 
respectively. A misregulated hypoxic response to RA gives rise to cellular dysfunction, 
eventually resulting in cell death.88 It is important to note that HIF1α is known to 
repress the NF-κB pathway playing an anti-inflammatory role whereas HIF2α 
stimulates inflammation.78,81 Taking into consideration that NF-κB is an activator of 
the HIF transcription factors, one might infer that NF-κB may play a role in 
differentiating the responses of HIF1α and HIF2α in the presence of hypoxia or 
inflammation, or a combination thereof.77 
In order to fully decipher the intricate link between the hypoxia and 
inflammatory pathways, an improved inflammatory model in which both pathways and 
their respective stimuli can be controlled is necessary. Insight into the regulation of the 
hypoxia and inflammatory pathways will allow for the development of more successful 
therapeutic strategies against disease states where hypoxia and inflammation are 
prominent, such as RA.77 
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1.5.1 Hydrogen Sulfide and Hypoxia 
A controversial proposal for hypoxia sensing is that speciation of S between 
oxidized and reduced pools, most notably, hydrogen sulfide (H2S), directly senses acute 
hypoxia in many tissues of higher organisms.89,90 There are a number of correlations 
between pO2 and H2S biochemistry, and responses to increased [H2S] resemble those 
caused by hypoxia.89  It has been proposed that the increased speciation of sulfur into 
reduced pools serves as a signal for decreased pO2, with an unknown signal 
transduction mechanism leading to a cellular response.91 
Sulfur speciation between reduced and oxidized pools depends on the 
availability of O2, correlating hypoxia and elevated [H2S].91  Cytosolic metabolism of 
S-containing compounds produces H2S whereas mitochondrial oxidation of H2S to 
SSO32- and SO42- provides a dynamic system responsive to pO2.  However, there are 
other sources of H2S, such as H2S production from glutathione,92 and sinks of H2S, 
such as the consumption of H2S by ROS,93-95 that are additional drivers of H2S levels.  
This interplay between ROS, glutathione, pO2, and [H2S] makes a clear link between 
hypoxia and H2S elusive. 
The transsulfuration pathway is a major source of cellular H2S.93,94,96,97  H2S is 
produced from cysteine, homocysteine, and cystathionine by the cytosolic enzymes 
cystathione β-synthase (CBS) and cystathione γ-lyase (CSE).98 An additional source of 
H2S from Cys is the path from cysteine aminotransferase (CAT) and mercaptopyruvate 
sulfotransferase (MST).99  Sulfur excretion occurs via the oxidation of H2S to SO42- in 
the mitochondria.  The fate of cytosolic H2S is unclear, however correlations between 
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H2S and glutathione levels imply that the cytosolic pool of H2S is fed into the 
mitochondria for oxidation.  
As H2S is oxidized by enzymes in the mitochondrial matrix, H2S connects to 
respiration via the inner membrane quinone pool.96 This has led to the proposal that 
that H2S oxidation rather than H2S production is the key step in hypoxia sensing.100 
The enzyme sulfide quino-oxidoreductase (SQR) oxidizes S2- to S0 forming a persulfide 
with glutathione (GSSH).96  Subsequent oxidation to sulfite by persulfide dioxygenase 
(ETHE1)96,97,101 is a key step, with the terminal oxidation to sulfate or thiosulfate 
(SSO32-).  
 
Figure 1.15 Oxidation reactions of sulfur species in the mitochondria. Key species 
include glutathione (GSSH), hydrogen sulfide, sulfite, thiosulfate, and sulfate. 
 
The dynamic metabolism of thiols leads to connections between pO2, H2S, and 
SO42- with GSH, thiosulfate, and sulfite as enzymatically produced intermediates.  As 
H2S consumption decreases in bovine tissues when [O2] drops below ~ 20 μM,91 acute 
hypoxia appears to lead to elevated [H2S].  Notably, the non-enzymatic reduction of 
thiosulfate by GSH rapidly produces H2S under hypoxic conditions, suggesting that 
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this non-enzymatic reaction may play a major role in determining the levels of several 
sulfur species under acute hypoxia.89  Another potential checkpoint which may lead to 
elevated H2S levels under hypoxia is the enzyme ETHE1, as this enzyme consumes 
stoichiometric O2 while oxidizing H2S to sulfite.101  Although the proposal that H2S 
levels report on acute hypoxia is plausible through the above correlations, the molecular 
basis for transducing the signal of elevated [H2S] remains the largest unanswered 
question for this model of hypoxia sensing.   
Exogenously administered H2S stimulates a hypoxic response in tissues,91 
suggesting that the responses to elevated [H2S] and hypoxia may be complementary.94  
However, as mentioned above, the molecular pathways linking H2S levels to tissue 
hypoxia responses have not yet been identified.  Although the transcriptional effects of 
chronic H2S in C. elegans requires HIF-1, the genes regulated by chronic H2S are 
distinct from those regulated by hypoxia.102 It is possible that better discrimination of 
responses to acute hypoxia from those due to chronic hypoxia would help to clarify the 
specific effector pathways induced by H2S.  
1.5.2 FBXL5  
F-box and leucine-rich repeat protein 5 (FBXL5) has been proposed as an O2 
sensor, due to its O2-dependent role in cellular responses to iron ions.  A hemerythrin 
(Hr)-like domain in FBXL5 makes the stability of FBXL5 dependent upon [O2], 
although it is unclear whether or not this protein responds directly to O2 or to Fe2+. The 
molecular connection between O2 and Fe2+ arises because FBXL5 binds IRP2 to a 
ubiquitin ligase, leading to proteasomal degradation of IRP2 in the presence of both 
Fe2+ and O2.103,104  
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FBXL5 contains a Hr-like domain which reversibly binds a diferrous cofactor, 
similar to that found in typical Hr.105,106  Unfolded FBXL5 is in equilibrium with the 
[Fe2+Fe2+] form of FBXL5, which allows for this form of the protein to be degraded by 
the cell, causing IRP2 to increase in abundance.  The FBXL5 cofactor is oxidized in 
the presence of O2 to the tightly-bound [Fe3+Fe3+] cofactor, irreversibly stabilizing the 
folded structure of FBXL5.  This oxidized FBXL5 is the form that binds both IRP2 and 
an ubiquitin ligase, causing ubiquitinylation of IRP2 and subsequent degradation. 
Although it is not clear whether FBXL5 responds to physiologically-relevant changes 
in [O2], it is clear that this protein connects Fe and O2 homeostasis.   
1.6 Tissue Signaling 
1.6.1 Acute Hypoxia Sensing by Mammalian Tissue 
Mammals utilize very distinct sensing strategies for acute hypoxia (on the time 
scale of minutes) versus chronic hypoxia (on the time scale of hours to days).  Acute 
hypoxia sensing begins at the tissue level with specialized cells, including 
neuroephithelial bodies (NEBs) and type 1 glomus cells, responding to changes in pO2 
by opening and closing ion channels to alter the membrane potential of the cells.107-109  
Cellular hypoxia sensing leads to the fundamental physiological responses of 
vasodilation and vasoconstriction, which serve to regulate oxygen delivery to tissues 
by changing vascular tension to modify blood flow.  Vasodilation is the dilation of 
blood vessels and results in increased perfusion of blood to the affected tissue.110  
Vasoconstriction, which ultimately results in the opposite response as vasodilation, is 
a regulatory mechanism that constricts blood vessels in the pulmonary vasculature 
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allowing the redistribution of blood flow to better ventilated portions of the lung.111 
Although these acute responses are crucial for tissues experiencing hypoxia and are 
thought to be mediated within the cell by ion channel signaling pathways, the specific 
molecular mechanisms linking changes in pO2 to ion channel activity are not 
completely understood.   
The ability of tissues to sense and respond to changes in oxygen availability has 
countless biological impacts, such as the protection against ischemic brain injury 
through hypoxic preconditioning.112  Hypoxic preconditioning occurs upon the 
repetitive short-term exposure of an organism to mild hypoxia, leading to ischemic 
tolerance and stroke protection in both mice and in a neonatal rat model.113,114  It is 
thought that this preconditioning signals to the organism to prepare for more intense 
hypoxia.  It has been shown that the initial preconditioning occurs through the acute 
oxygen sensing pathways.112  There are three phases of responses to acute hypoxia.  
The first consists of the immediate chemical responses to hypoxia, which change 
intracellular ion concentrations,115 stabilize HIF-1 due to increased succinate 
concentration, and remodel the mitochondrial electron-transport chain to favor 
complex II.116 The second phase consists of early biochemical responses to hypoxia 
which regulate signal transduction, such as the activation of glutamatergic, calcium, 
phosphoinositide, and cyclic AMP regulatory systems115 and modification of ion 
channels which lead to secondary messengers.117  The third phase responses to hypoxia 
are the regulation of gene expression by transcription factors activated by the secondary 
messengers.112  Many of these pro-adaptive gene products are involved in intracellular 
plasticity and aid in vital neuronal function and structural integrity.112 
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Long-term hypoxic tolerance results from chronic hypoxia responses, such as 
the desensitization of HIF, which serve to protect cells from necrosis,118 and changes 
in metabolic homeostasis (Fig. 1.15).119  In contrast to hypoxic preconditioning, 
research into hypoxic postconditioning, the exposure of an organism to mild hypoxia 
after injury, is more disputed due to controversial results and variation in experimental 
parameters between different groups.120 
 
Figure 1.16 Cellular responses to acute versus chronic hypoxia. 
1.6.2  Neuroepithelial Bodies (NEBs) and Type 1 Glomus Cells 
The acute hypoxia response is facilitated by specific chemosensory cells termed 
neuroepithelial bodies (NEBs) and type 1 glomus cells of the carotid body.109  NEBs 
line the mucosa of mammalian airways,121 working to sense O2 and transduce signals 
to the central nervous system (CNS) in response to different stressors.  In addition to 
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sensing changes in pO2, NEBs also sense hypercarbia (elevated pCO2), mechanical 
stretch, and certain stimulants, while type 1 glomus cells also sense pCO2, pH, 
temperature, and osmolality.121  The enzyme NADPH oxidase (Nox) mediates the 
hypoxic response in both NEBs and type 1 glomus cells through a path linking ROS 
generation to the CNS.122 
There are seven isoforms of Nox, including Nox1-5 and Duox1-2, which are 
expressed in different tissues and cell types with varying expression, localization, and 
regulation.123  This distribution suggests a broad and varied response to changes in pO2.  
All Nox isoforms produce ROSs, however they do so in different manners; Nox1-3 and 
Nox5 reduce oxygen to superoxide (O2-) and Nox4 and Duox1-2 directly produce 
H2O2.124  Most of the isoforms of Nox are regulated post-translationally with certain 
activators, such as Protein Kinase C (PKC), or inhibitors of Nox turned on or off in 
response to various stimuli.58,123  One isoform that is thought to be mainly 
transcriptionally regulated, Nox4, was recently found to be negatively regulated via 
phosphorylation by the tyrosine kinase FYN under conditions of oxidative stress.125,126  
In various cell types, Nox has been shown to be regulated by changes in transcriptional 
levels of Protein Kinase C, which activates Nox.58 
In NEBs under normal pO2, Nox rapidly converts superoxide to H2O2, which 
signals O2-sensitive K+ channels to remain open.  There is evidence that certain Nox 
isoforms activate specific types of O2-sensitive K+ channels, such as Nox2 activating 
the Kv class of K+ channels and Nox4 activating TASK channels.127  Whether the 
chemical signal to K+ channels is O2– or H2O2 is ambiguous as O2– can dismutate to 
H2O2.  When NEBs experience hypoxia, however, the reduced availability of oxygen 
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results in decreased generation of ROS by Nox and closure of these K+ channels.  This 
channel inhibition causes depolarization of the membrane, activating voltage-gated 
Ca2+ channels to increase Ca2+ influx and neurotransmitter release (Fig. 1.16).128  These 
neurotransmitters relay information to the CNS to elicit a physiological response to 
hypoxia.121 Although activation of Nox by PKC led to hypoxia sensitive K+ channel 
closure in the immortalized model NEB H146 cell line, Nox inhibitors failed to fully 
suppress this response, suggesting that multiple mechanisms may be utilized by these 
cells to sense O2.129  
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Figure 1.17 Comparison of oxygen response in normoxic and hypoxic NEBs. In 
normoxic cells, high ROS generation by Nox keeps K+ channels open. In hypoxic 
cells, low ROS generation by Nox inhibits K+ channels, leading to their closure, 
membrane depolarization, and Ca2+ influx, which triggers neurotransmitter release. 
  
Oxygen sensing by type 1 glomus cells differs subtly from that in NEBs.  When 
type 1 glomus cells experience normal pO2, oxygen-sensitive K+ channels remain open 
as in NEBs, however the exact molecular mechanism of what activates and inhibits 
these channels in type 1 glomus cells is not well understood130  In type 1 glomus cells 
experiencing hypoxia, oxygen-sensitive K+ channels, such as TASK and maxi-K+ 
channels, close.130,131  Neurotransmitters relay information to the carotid-sinus nerve, 
which then conveys the information to the CNS.130  In the glomus cells of mice both 
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deficient of TASK channels and with blocked maxi-K+channels, hypoxia 
depolarization occurs just as it does in cells with those channels, suggesting that there 
are multiple subtypes of potassium channels involved in Ca2+ entry and 
neurotransmitter release in the hypoxic response.131 There is a great dispute as to the 
role of Nox in oxygen sensing in type 1 glomus cells.  Some propose that Nox 
suppresses K+ channel closure, in contrast to its role in NEBs,132 while others propose 
that Nox is not directly involved in type 1 glomus cell oxygen sensing.130  The lack of 
clarity surrounding Nox’s role in type 1 glomus cells suggests that the signaling 
transduction pathway for oxygen sensing may be complex and tissue specific.  In 
addition to the complexity of this signaling pathway, it has also been hypothesized that 
instead of the ROSs being the signal for NEBs and type 1 glomus cells, the reduced 
pyridine nucleotides NADH and NADPH are in fact the signal that triggers K+ channel 
closure and eventual neurotransmitter release,133 however this hypothesis has not been 
rigorously tested in cells.  This follows the broader theme of interrelatedness between 
metabolic status and O2 abundance. 
1.6.3 Smooth Muscle Cells (SMCs) 
Smooth muscle cells (SMCs) work in concert with NEBs and type 1 glomus 
cells to facilitate tissue-specific responses to acute hypoxia.  In pulmonary artery 
SMCs, acute hypoxia closes K+ channels, causing membrane depolarization and Ca2+ 
influx.111,134  This causes muscle cell contraction and results in vasoconstriction, which 
results in the redistribution of blood flow to better ventilated portions of the lung.111 In 
systemic SMCs, acute hypoxia causes ATP-sensitive K+ (KATP) channels to open and 
hyperpolarize the membrane, inhibiting Ca2+ influx.13,135 This causes muscle cell 
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relaxation and vasodilation to increase perfusion of blood to the affected tissue.110  
Recent findings implicate transient NO as a regulator of both vasodilation and 
vasocontraction, however the exact mechanism is not well understood.110,111 The most 
convincing argument links the regulation of vasodilation by NO to S-
nitrosohemoglobin-dependent bioactivity in red blood cells.136 
Both vasoconstriction and vasodilation work together to regulate oxygen 
delivery to tissues by changing vascular tension to modify blood flow depending on 
the affected tissue.137  Although they have opposite effects, both result from changes in 
membrane channels that cause myocyte contraction or relaxation.111,138 In this manner, 
adaptation to acute hypoxia relies on a carefully orchestrated response that involves 
neuroepithelial bodies, type 1 glomus cells, and smooth muscle cells.  The cellular 
machinery that compose the acute hypoxic response are just now emerging and 
understanding of the molecular details awaits further research.  
1.7 Conclusions 
Oxygen sensing in mammals occurs over multiple scales, ranging from the 
molecular-level sensing proposed for reduced sulfur species to the well-established 
chemical sensing by the HIF hydroxylases, leading to well-established tissue-level 
responses.  The most exciting areas involve discovery of new targets for the established 
O2-sensing enzymes, and new enzymes that may sense O2.  Identifying new targets for 
FIH and the PHD isozymes would uncover pathways that can lead to cellular changes 
independent of the HIF transcriptional response. New enzymes would similarly add 
richness to the O2-dependent responses of cells and tissues.  A further complexity is 
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the interplay between O2 levels, metabolism, and stress responses, which simply 
underscores the richness of the field.  
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CHAPTER 2 
 
LIGAND SUBSTITUTION SUPPORTS O2 ACTIVATION IN THE FACIAL 
TRIAD VARIANTS OF FIH, AN αKG DEPENDENT OXYGENASE 
This chapter has been submitted for publication as: Chaplin, V.D., Hangasky, J.A., 
Huang, H.-T., Duan, R., Maroney, M.J. and Knapp, M.J. Inorganic Chemistry. In review. 
 
2.1 Introduction 
The αKG dependent oxygenases functionalize a wide variety of substrates using a 
non-heme Fe(II) coordinated by a His2(Asp/Glu) facial triad.1 The consensus mechanism 
of αKG dependent oxygenases is proposed to follow the HAG mechanism2 involving H-
atom transfer to form a substrate radical, with rebound of an Fe-bound ligand (Scheme 
2.1). Typical enzymes in this superfamily hydroxylate substrates by the transfer of an O-
atom from O2, whereas a subset of αKG oxygenases perform halogenation chemistry 
(Scheme 2.1).3 As seen with both the hydroxylases and halogenases, the presence of the 
organic substrate (R-H) is necessary to trigger O2 activation4-7 leading to the formation of 
an Fe(IV)=O intermediate, giving rise to subsequent rebound chemistry.8-9  Gaining insight 
into the structural factors needed to trigger O2 activation are of paramount interest to the 
field.   
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Scheme 2.1 Mechanism of Fe(II)/αKG hydroxylases and Fe(II)/αKG halogenases. R = 
substrate; for hydroxylases X = Asp/Glu; for halogenases X = halide. 
 
The resting enzyme form for hydroxylases contains a ferrous ion coordinated by a 
His2(Asp/Glu) facial triad, a bidentate αKG, and an aquo ligand.  In contrast to the 
hydroxylases, halogenases naturally have a His2(Ala/Gly) motif, but bind a halide ion to 
support halogenase chemistry.10  The crystal structure of chloride-bound SyrB2 provided 
the first evidence of a halide directly coordinated to the metal in this family of enzymes,10 
supporting earlier studies with model complexes which indicated that metal-bound ligands 
were transferred in non-heme Fe mediated halogenation.11  While XAS studies of CytC3 
and SyrB2 further confirmed the presence of a Fe-bound halide in these halogenases, bound 
chloride was not observed crystallographically, suggesting that a protein conformational 
change was needed to create the chloride binding site.12-13  
Several lines of inquiry have shown that a Cl– ligand is essential for the rebound 
step in halogenases to form halogenated product, but it remains unclear whether a complete 
His2X facial triad is essential for the initial step of O2 activation. Electronic structure 
calculations of a model halogenase cofactor predicted a modest kinetic barrier for OH 
rebound, whereas Cl rebound would be barrier-less, suggesting a kinetic advantage for 
halogenation.14 Reports demonstrate the potential to interconvert hydroxylases and 
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halogenases through changing the disposition of substrate relative to the hydroxide and 
halide ligands.15-17  While the above demonstrate that the Cl– ligand is essential for rebound 
chemistry, it is not clear whether or not a complete facial triad would be necessary for the 
preceding step of O2 activation.  As hydroxylation does not involve the facial triad ligands 
in an obvious manner, hydroxylating enzymes with incomplete His2X facial triads are of 
interest,18-21 as these examples suggest that a complete facial triad is not necessary for O2 
activation chemistry. 
FIH is an αKG dependent oxygenase which hydroxylates the sidechain of Asn803 
within the C-terminal transactivation domain (CTAD) of the hypoxia inducible factor 
(HIF-1α). While the Fe cofactor of WT FIH has the His2Asp facial triad, prior reports 
indicated that D201A/E/G variants of FIH supported intriguing O2 activation and 
hydroxylation chemistry making these variants excellent starting points to test the link 
between His2X facial triads and O2 activation. Here, we demonstrate that exogenous anion 
binding to form a complete His2Cl facial triad is both selective and essential for the D201G 
variant of FIH to support O2 activation chemistry.  We also provide metrical details of the 
Fe-Cl cofactor in the D201G variant, revealing an excellent mimic of the halogenase 
geometry found in SyrB2. These results indicate that a complete His2X facial triad is 
essential for O2 activation, and suggest that an elaborate halide binding pocket is not needed 
to replicate the chloroferrous cofactor found in halogenases.  
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2.2 Methods 
2.2.1 Materials 
All materials, except for the synthetic peptide CTAD and the FIH variants, were 
purchased from commercial vendors and used without further purification. CTAD was 
purchased from EZBiolab (Carmel, IN, USA) as desalted peptide and purified using RP-
HPLC to >95% purity. The CTAD peptide sequence, 
DESGLPQLTSYDAEVNAPIQGSRNLLQGEELLRALDQVN, corresponded to that of 
the C-terminal activation domain of human HIF-1α(788-826) with the Asn803 residue 
targeted by FIH in bold, and a Cys800Ala to prevent unwanted oxidation reactions. 
2.2.2 Protein expression and purification 
WT-FIH and the D201A/E/G variants were overexpressed in Escherichia coli with 
an N-terminal His6 tag. Following lysis of the cell pellet using sonication, WT-FIH and 
each variant were found in the soluble fraction. Centrifugation of the cell lysate (14,000 x 
g, 30 minutes) pelleted the cellular debris and the supernatant was buffer exchanged into 
10 mM Tris pH 8.00 to remove the EDTA from the lysis buffer. The supernatant was 
centrifuged before being loaded onto a Ni-NTA column. The column was washed with 5 
column volumes each of 100% A buffer (50 mM Tris pH 8.0, 300 mM NaCl, 15 mM 
Imidazole) and 15% B buffer (50 mM Tris pH 8.0, 300 mM NaCl, 250 mM Imidazole) to 
remove contaminating proteins before eluting the His6-FIH protein with 100% B buffer. 
The subsequent thrombin cleavage of the His6 tag was performed in thrombin cleavage 
buffer for 36 hrs at 4 °C and resulted in >80% cleavage.  The Ni-NTA column was used to 
remove the His6 tag as well as any remaining uncleaved His6-FIH. Overnight incubation 
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with EDTA (50mM) removed exogenous metals. The FIH dimer was obtained following 
size exclusion chromatography and the purity (>95%) was assessed by SDS-PAGE. 
2.2.3 Activity Assays 
Activity assays used to screen for the halide dependent hydroxylation of CTAD 
contained αKG (100 µM), FeSO4 (25 µM), CTAD (100 µM), ascorbic acid (2 mM), WT 
FIH or an D201 variant (0.5–2.5 µM) and NaX (X = F, Cl, Br or I; 100 mM) in 50 mM 
HEPES pH 7.00. Similarly, the reaction buffer for activity assays that screened for the 
pseudo halide dependent hydroxylation of CTAD contained αKG (100 µM), FeSO4 (25 
µM), CTAD (100 µM) ascorbic acid (2 mM), FIH (0.5–2.5 µM) and the sodium salt of the 
pseudo halide (2 mM) in 50 mM HEPES pH 7.00. All reactions were initiated by the 
addition of enzyme and were performed at 37.0 °C. 
To determine the enzyme activity, reaction mixture aliquots (5 µL) were quenched 
in 75% acetonitrile/0.2% TFA saturated with 3,5-dimethoxy-4-hydroxycinnamic acid (20 
µL) over a predefined time course spanning several minutes.  Each quenched aliquot was 
analyzed for formation of both peptide hydroxylation and (pseudo)-halogenation products 
using a Bruker MicroFlexII MALDI-TOF-MS (Supplemental Figs. 2.5 and 2.6). Initial 
rates were calculated based on the rate of product formation (Supplemental Fig. 2.7).  
2.2.4 O2 Consumption Assays  
The rate of oxygen consumption was monitored using a Clark-type electrochemical 
O2 sensor.  Each day, a new membrane was prepared and the electrode was calibrated using 
air saturated water and dithionite. Ascorbate (50 µM), αKG (100 µM), FeSO4 (25 µM), 
and CTAD (80 µM) in 50 mM HEPES pH 7.00 were equilibrated in the reaction vessel at 
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37.0 ºC until a stable baseline was achieved. The reaction was then initiated with cold 
enzyme (1–10 µM) using a gas-tight Hamilton syringe. O2 consumption over time was 
recorded until the rate of O2 consumption approached the baseline slope.  
2.2.5 UV-Vis absorption spectroscopy   
All reagents were prepared anaerobically using multiple cycles of evacuation and 
N2 flush. Samples consisting of FIH (400 µM), FeSO4 (375 µM) and αKG (400 µM) in 50 
mM HEPES pH 7.00 at 23 °C containing either a sodium salt halide (100 mM) or pseudo-
halide (2mM) were prepared in an anaerobic glove box.  UV-Vis spectra of each sample 
were recorded anaerobically using an Avantes UV-Vis spectrometer with an integration 
time of 25 ms and averaging of 25 spectra.  The spectrum of (Fe)FIH was subtracted from 
the spectrum of (Fe+αKG)FIH to produce the reported spectra. 
2.2.6 X-ray Absorption Spectroscopy   
A sample of 1 mM FeSO4 was prepared in 50 mM HEPES, pH 7.00, 100 mM NaCl 
nand metal concentration was determined using a Perkin Elmer Optima DV4300 ICP-OES 
instrument. This metal sample was used to reconstitute the D201G variant of FIH 
anaerobically with FeSO4 (0.9 eq.), N-oxalylglycine (NOG) (1.0 eq.), and excess NaCl 
(100 eq.) in 50 mM HEPES, pH 7.00. 
Data were collected at the Stanford Synchrotron Radiation Laboratory (SSRL) on 
beam line 9-3 using a 20 element Ge x-ray fluorescence detector on samples containing 1 
mM protein held at liquid He temperature. Beamline set-up and ring conditions are as 
previously described22 and are further detailed in the Supplemental Information (section 
2.5). Internal energy calibration was performed by collecting spectra simultaneously in 
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transmission mode on Fe foil to determine the first inflection point on the edge, which was 
set to 7111.2 eV.   
XANES analysis was performed using OriginPro 2015 to fit the edge background 
and pre-edge features as pseudo-Voigt peaks, as previously described.23  These features 
were analyzed assuming Oh local symmetry for the Fe site. Data processing and analysis 
using the SixPack,23 Artemis, and FEFF624-25 software packages has been previously 
described and further information regarding it is available in the Supplemental Information 
(section 2.5).  Assessment of the goodness of fit was performed as previously described.22 
Reported data sets were fit with separate sets of Δreff (r – reff) or the change in metal-
ligand bond distance with respect to the input path distance, and σ2 for the Cl and nitrogen-
donors including imidazole rings with initial values of 0.0 Å2 and 0.003 Å2, respectively. 
Each fit was initiated with a universal E0 (7125 eV for Fe) and ΔE0 = 0 eV, which was 
allowed to vary for each fit. Histidine ligands were fit as geometrically rigid imidazole 
rings.26-28 Multiple-scattering parameters for imidazole ligands bound to Fe were generated 
using the FEFF6 software package with the imidazole input obtained from average bond 
lengths and angles gathered from crystallographic data, as previously described.29-30 All 
multiple scattering paths with path lengths outside the fitting window (r = 1 – 4 Å) were 
discarded. Histidine ‘counting’ was performed by adding integer numbers of histidine 
imidazole ligands to fits and assessing the effect on the R-factor and reduced χ2. NOG was 
modeled as a geometrically rigid molecule in an identical manner to the histidines.  
2.2.7 Metal Titrations 
The Kd of metal binding to FIH was measured by intrinsic tryptophan fluorescence 
quenching using a PTI fluorimeter.31 Samples containing 20 µM FIH, 500 µM αKG, and 1 
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mM sodium citrate in 50 mM HEPES pH 7.00 were prepared in a fluorescence cuvette. 
Sodium citrate was used to buffer the free metal in solution. The titrating solution contained 
1 mM CoSO4 and 1 mM sodium citrate in 50 mM HEPES pH 7.00. Co(II) was used as an 
Fe(II) mimic to avoid auto-oxidation. Increasing amounts of metal were added to the 
cuvette solution and incubated for 7 minutes at room temperature while stirring. Following 
incubation, samples were excited at 285 nm with emission monitored from 300-400 nm. 
The intensity of the fluorescence peak at 330 nm after each metal addition was used to 
determine the relative fluorescence intensity, which was fit to the following equation to 
determine the Kd(Co) binding for each protein variant.32 
 
𝑦𝑦 = 𝑦𝑦𝑚𝑚𝑚𝑚𝑚𝑚 + 𝑦𝑦𝑚𝑚𝑚𝑚𝑚𝑚 − 𝑦𝑦𝑚𝑚𝑚𝑚𝑚𝑚1 + 10(𝑚𝑚−𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙𝑙)𝐵𝐵 
 
The stability constant of the free Co2+ ion, [Co(H2O)6]2+ in citrate was used to 
calculate the buffered concentration of free Co2+ in solution.33 
2.3 Results and Discussion 
The reactivity of WT FIH and D201A/E/G variants were previously compared to 
test the impact of altering the His2Asp facial triad carboxylate on FIH, however those 
experiments used Tris/HCl buffer20 or HEPES with 100 mM NaCl to control ionic 
strength.21 When preparing protein samples for structural analysis by XAS, we observed 
that initial activity screens of the D201G variant in HEPES buffer showed batch-to-batch 
variation in the rate for hydroxylating the CTAD peptide. We subsequently found that 
prolonged dialysis into chloride-free HEPES buffer led to a protein that had a low rate for 
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CTADOH formation, suggesting that chloride was essential for O2 activation by this variant.  
This raised the potential for Cl– as an essential exogenous anion to complete a His2Cl facial 
triad in this variant, and for anion-selective rescue of activity for the other enzyme variants. 
This was intriguing as anion rescue failed in two αKG-dependent peptidyl hydroxylases,18, 
20 and limited rescue of activity was observed in αKG-dependent hydroxylases utilizing 
smaller substrates.16, 19, 34 
2.3.1 Anion dependent oxygen activation  
FIH variants were screened for anion selective hydroxylation of the CTAD peptide, 
which was used in place of the full-length HIF-1α protein as a substrate for FIH.31, 35 Each 
FIH variant was exhaustively dialyzed into 50 mM HEPES/NaOH, pH 7.00 to remove 
loosely associated anions from the apo-protein sample, then tested for activity at 37.0 °C. 
Reactions were monitored over several minutes by MALDI-TOF-MS in order to detect the 
+16 mass gain due to peptide hydroxylation.   
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Figure 2.1 Activity screens of WT FIH, D201E, D201G and D201A in the presence of 
sodium halides (100 mM). (A) The initial rate for CTADOH formation as measured by 
MALDI-TOF. (B) O2 consumption of D201G in the presence of NaX salts. 
 
MALDI analysis revealed that all variants produced the hydroxylated CTAD 
peptide (CTADOH) albeit with widely different rates for product formation (Fig. 2.1A). As 
we used MALDI for product analysis, we could observe whether products contained an 
additional O-atom (+16) or halogen atom (eg: replacing an H with a Cl would increase 
mass by +34.5 and +36.5); the only product observed was the +16 product corresponding 
to peptide hydroxylation (Supplemental Figure 2.5). WT-FIH exhibited robust 
hydroxylation activity under all tested conditions (Fig. 2.1A); notably, NaX was not 
required for activity; the diminution of activity in the presence of NaI was attributed to 
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partial quenching of the ferryl intermediate by iodide. Notably, the conservative D201E 
variant, which bound the Fe by a His2Glu facial triad, exhibited anion independent 
hydroxylation (Fig. 2.1A) albeit at roughly 10% the rate of WT-FIH.21 
Both of the variants containing a nonpolar sidechain at position 201, D201A/G, 
exhibited anion selective hydroxylation activity with contrasting anion requirements (Fig. 
2.1A).  The D201G variant was nearly as active as WT-FIH toward hydroxylating CTAD, 
provided that NaCl was present. The D201A variant was prepared to mimic the ligands 
found in αKG-dependent halogenases such as SyrB2, however this variant hydroxylated 
CTAD only in the presence of F−. The anion-selectivity indicated that an exogenous anion 
was essential for substrate hydroxylation, implying that a complete His2X facial triad 
formed in these enzyme variants.  This further suggested a complementarity between the 
size of the anion and the bulk of the non-coordinating D201A/G sidechain.   
As forming CTADOH requires successful completion of both half reactions, it was 
possible that the exogenous anion was needed for either the initial O2 activation, or for the 
subsequent peptide hydroxylation.  To gain insight into which step in the consensus 
mechanism was influenced by the anion, O2 consumption by the D201G variant was 
assessed using a Clark-type O2 sensor. The O2 sensor is an electrochemical cell, requiring 
KCl electrolyte under an O2-permeable membrane, which separates the enzyme reaction 
from the electrode. The rate of O2 consumption by D201G was significantly enhanced by 
the addition of chloride to the assay buffer (Fig. 1B) which showed that the chloride anion 
stimulated the O2 consumption step. Relative rates of O2 consumption in the presence of 
other NaX salts were consistent with the relative rates of CTAD hydroxylation, indicating 
anion binding was essential for the initial O2 activation half-reaction.  
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The αKG dependent halogenase, SyrB2, supported incorporation of alternate 
anions into the product, including Cl−, N3−, and NO2−,34 suggesting that richer chemistry 
may be possible with varied exogenous ligands in enzymes with a His2X facial triad.  The 
anion-selective FIH variants D201A/G were screened for anion incorporation using the 
sodium salts of several mono-anions including pseudo-halides, using MALDI-TOF 
analysis to identify the product masses.  Only two of the tested anions supported 
hydroxylation activity above a basal level to form CTADOH, but none of the tested anions 
were incorporated into the product (Fig. 2.2A).  The D201G variant had significant 
hydroxylation activity for X− = N3− and interestingly, both the D201G and D201A variant 
showed near WT activity when X− = OCN−. The higher activity with OCN− may reflect 
the increased charge asymmetry of OCN− relative to N3−.   
There have been very few examples of exogenous ligands binding to and rescuing 
activity in αKG-dependent oxygenases. The most prominent example of exogenous anion 
binding to the Fe cofactor is from the αKG-dependent halogenase SyrB2, which showed 
tolerance for a variety of anions to bind in place of the natural Cl– anion.34 However, SyrB2 
naturally binds Cl– to form a His2Cl facial triad, and is therefore likely to tolerate other 
ligands.  On the other hand, rescuing activity of a natural hydroxylase following mutation 
of the Asp/Glu facial triad ligand is rare.  The D201A variant of taurine dioxygenase 
(TauD) exhibited a trace level of turnover as isolated, which was increased by binding 
formate implying that formate bound to the Fe.  However, the overall rate of turnover 
remained low (<< 1%) relative to WT-TauD.19 Facial triad variants of Prolyl-4-
hydroxlyase were inactive and could not be rescued by addition of exogenous ligands.18  
The single success was the N-substituted l-amino acid dioxygenase (SadA), which 
67 
 
normally forms hydroxylated products. The D157G variant of SadA was able to both bind 
Cl–/Br– as well as perform alternate rebound chemistry, forming a mixture of products 
containing an R-OH and R-X bonds.15 Although structural data for this SadA variant was 
not presented, the chemical competence and requirement of X– clearly implicated 
formation of a complete His2X facial triad.  
2.3.2 Anion binding to the D201G variant 
Anion binding to the facial-triad variants was monitored by UV-Vis absorption 
spectroscopy in an anaerobic glovebox using a diode-array spectrophotometer. D201A/E/G 
variants reconstituted with Fe(II) and αKG exhibited modest shifts in the MLCT band from 
that of WT-FIH (λmax = 500 nm),31, 36 with the largest shift observed for the D201G variant 
(λmax = 485 nm) (Supplemental Fig. 2.8). These electronic transitions indicated that there 
were modest changes in the orbital energies of the Fe(II) + αKG chromophore due to 
removal of the facial triad D201 ligand. The MLCT transitions shifted by less than 5 nm 
upon addition of 100 mM NaCl to the FIH variants presumably due to displacement of an 
aquo ligand, as similarly small shifts were reported for Cl- binding to the αKG-dependent 
halogenase SyrB2,34 reflecting the comparable positions in the spectrochemical series for 
H2O and Cl- ligands. Addition of OCN– or N3– to the D201G variant red-shifted the MLCT 
transition by roughly 15 nm, indicating that these pseudo halide ligands bound to the Fe(II), 
forming a His2X facial triad within the FIH active site (Fig. 2.2B).   
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Figure 2.2  (A) Activity screens of WT FIH, D201E, D201G and D201A in the presence 
of pseudo halides (2mM). Each reaction contained αKG (100 µM), FeSO4 (25 µM), 
CTAD (100 µM), and ascorbic acid (2 mM). The rate for CTAD hydroxylation is 
denoted. (B) Anaerobic UV-Vis spectra of the MLCT region for the pseudo halides (2 
mM) in complex with (Fe+ αKG)FIH variants (400 µM) constituted with FeSO4 (375 
µM) and αKG (400 µM) in 50mM HEPES pH 7.00. 
 
 
2.3.3 X-ray spectroscopy of (Fe+NOG+Cl)D201G  
Definitive structural data for the His2Cl facial triad was obtained by Fe K-edge X-
ray absorption spectroscopy on the D201G variant of FIH constituted anaerobically with 
FeSO4 (1.0 eq.), N-oxalyl-glycine (NOG, 0.9 eq.), and excess NaCl (100 eq.) in 50 mM 
69 
 
HEPES, pH 7.00. NOG is isostructural to αKG, and has been used in several 
crystallographic studies of FIH to prevent O2 activation.  The X-ray absorption edge energy 
reflects the electron density around the metal center, and can indicate the metal oxidation 
state when compared to similar coordination environments. The edge energy (7123.3 eV) 
fell between that observed for Fe(III)WT-FIH (7125.0 eV)31 and that observed for the 
Fe(II) centers in SyrB2 (7120.9 eV)13 and HIF-prolyl hydroxylase (7121.2 eV)37 suggesting 
that the present FIH sample corresponded to the ferrous state.  
X-ray absorption near-edge structure (XANES) analysis was used to determine the 
coordination number and geometry of the metal center. Metal ions such as Fe(II) that have 
vacancies in the 3d orbitals and exhibit pre-edge features involving 1s→3d electronic 
transitions, the number and intensity of which vary with coordination number and 
geometry. The pre-edge data for FIH reveals partially resolved features arising from 
multiple excited states.23  Three excited states are expected to arise from the 5T2g ground 
state of Oh high-spin Fe(II) centers (4T1g, 4T2g, and 4T1g) and can generally be fit to the data 
between 7111 and 7114 eV. In the case of FIH, only two peaks are required to fit the data, 
similar to the situation for solid state FeI2, where transitions to the lower energy excited 
states are not resolved. These two peaks are observed at 7111.1 and 7113.0 eV and have 
areas of 5.0 x 10-2 eV and 0.9 x 10-2 eV, respectively, giving a total pre-edge peak area of 
5.9 x 10-2 eV, which is somewhat greater than typically observed for Oh high-spin Fe(II) 
(3.1 – 4.4 x 10-2 eV), possibly reflecting a lowering of the symmetry that would allow for 
a small amount of 3d-4p mixing.  The peak intensity ratio (area of lowest energy peak/total 
area) is 0.83, and is similar to that observed for high-spin model Fe(II) complexes (0.72 – 
0.85), as is the energy difference between the resolved peaks (1.9 eV; 1.8 – 2.4 eV in 
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models). The results of the XANES analysis are consistent with a 6-coordinate distorted 
Oh Fe(II) center, as expected for the His2Cl facial triad, a bidentate NOG, and a coordinated 
aquo ligand.   
 
Figure 2.3 Iron K-edge XAS of Fe(II) D201G-FIH (1 mM), NOG (1 mM) and NaCl (100 
mM) in 50 mM HEPES pH 7.0. (A) XANES spectrum. Left insert is an expansion of the 
1s  3d features. Right insert shows the baseline-corrected pre-edge XANES features 
(blue) fit with two peaks (black), with the individual components shown in red and green. 
(B) Unfiltered k-space data and fit. (C) The Fourier-transformed EXAFS spectrum (data, 
blue; fit, black). The fit shown was obtained for 1 N/O @ 2.09(1) Å (σ2 = 0.004(1) Å2) 
+1 Cl @ 2.36(4) Å (σ2 = 0.005(4) Å2) + 1 Imd @ 1.95(4) Å (σ2 = 0.003(3) Å2) + 1 Imd 
@ 2.16 (4) Å (σ2 = 0.003(3) Å2) + 1 NOG @ 2.01(9) and 2.11(9) (σ2 = 0.006(6) Å2); R = 
2.4%. 
 
 
Extended x-ray absorption fine structure (EXAFS) analysis was used to measure 
the distance to Fe-bonded atoms with a precision of ~ ± 0.02 Å.  EXAFS also provides 
information on the atomic number of scattering atoms, readily distinguishing period 2 
(N/O) ligands from period 3 (S/Cl) ligands, as well as a second estimate on the coordination 
number. The EXAFS data were fit using progressively more detailed models to arrive at a 
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best fit.  The data were first fit with a single shell of N donor atoms with coordination 
numbers ranging from 4 - 6 followed by a fit with a single shell of S-donor atoms with 
coordination number between 4 - 6.  Neither single shell fit generated a fit with a % R-
value below 5%.  The data were then fit with a mixed shell of N and S donors, with all 
possible combinations of N and S donors at various distances with coordination number 6. 
This improved the fit, and the best fit (N5S), %R = 6.01 is shown in Supplemental Table 
2.4. Considering the scattering from only the primary ligands in the mixed shell fit did not 
result in a fit with a % R-value of < 5%, scattering from two rigid imidazole rings for 
His199 and His279 was then included. The best EXAFS fits obtained for the D201G data 
are six-coordinate, consistent with the XANES analysis, and feature one S/Cl-donor ligand, 
three N/O-donors and two imidazole rings (%R = 3.0). However, this fit did not accurately 
portray the sample composition as NOG is a bidentate ligand with rigid atoms that were 
likely to contribute to scattering. NOG was subsequently included in the model, reducing 
the %R to 2.4% for the best fit (Table 2.1).  The best fit of the EXAFS corresponded to an 
Fe(His)2(O/N)3Cl center, in agreement with the pseudo-octahedral geometry shown by 
XANES. Notably, it was not possible to obtain an acceptable fit (R < 5%) without including 
a Cl scattering atom in the model (Supplemental Table 2.4). 
Table 2.1 Best fit to EXAFS data for the D201G variant of FIH. 
n Radius Å σ2 (x10-3 Å2) ΔE0 (eV) R factor nvar 
1 N/O 2.09(1) 4(1) -10(2) 0.0236 11 
1 Cl/S 2.36(4) 5(4) 
1 Imd 1.95(4) 3(3) 
1 Imd 2.16(4) 3(3) 
1 NOG 2.01(9) 6(6) 
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 2.11(9)  
 
 
The Fe-Cl distance of the D201G variant (2.36 Å) compares well with Fe-Cl 
distances found in the αKG-dependent halogenases SyrB213 (2.31 Å, EXAFS), and 
WelO516 (2.1 – 2.3 Å, crystallography) indicating that the D201G variant of FIH replicated 
the structure of the halogenase cofactor (Table 2.2). Further, as the O2 activation chemistry 
(Fig. 2.1) and the other metrical details match the halogenase cofactors (Table 2.2), the 
D201G variant is an excellent mimic of the halogenase structures.  
 
Table 2.2 Ligand bond lengths in D201G FIH compared to halogenases. 
 Cl N/O 
SyrB2 Fe(II)a 2.31 2.12 
SyrB2 Fe(II)b 2.47 2.03 – 2.22 
WelO5 Fe(II)c 2.09 – 2.26 2.04 – 2.48 
WelO5 Fe(II) + substrate c 2.32 – 2.34 2.05 – 2.56 
FIH D201G Fed 2.36 1.95 – 2.11 
 
a. Matthews, M. L.; Krest, C. M.; Barr, E. W.; Vaillancourt, F. H.; Walsh, C. T.; Green, 
M. T.; Krebs, C.; Bollinger, J. M., Biochemistry 2009, 48 (20), 4331-4343. 
b. Blasiak, L. C.; Vaillancourt, F. H.; Walsh, C. T.; Drennan, C. L., Nature 2006, 440 
(7082), 368-371.  
c. Mitchell, A. J.; Zhu, Q.; Maggiolo, A. O.; Ananth, N. R.; Hillwig, M. L.; Liu, X. Y.; 
Boal, A. K., Nat Chem Biol 2016, 12 (8), 636-640. 
d. Present work 
2.3.4 Metal binding in D201A/E/G variants 
The presence of an Fe-Cl bond in the D201G variant raised the question of whether 
mutations at this site impair metal binding and if the anionic ligand would increase metal 
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binding affinity. Comparison of crystal structures of D201G (Zn bound), D201A (Fe 
bound) and WT FIH showed that the polar contacts from the D201 were lost in the variant 
proteins, but that the metal retained pseudo-octahedral geometry in the active site by 
binding bicarbonate, implying that the aspartate ligand was not required for metal 
binding.20 Additional crystallographic studies with D201E (Zn and Fe bound structures) 
confirmed this conservative mutation retained polar contacts from the facial triad and the 
ability to bind metal.21 Previous studies conducted by Hangasky, et al. demonstrated the 
binding of αKG to Fe(II) by the D201A/E/G variants using UV-Vis absorption 
spectroscopy to observe the expected Fe2+(t2g)  αKG(π*) MLCT of the (Fe+αKG)FIH 
chromophore.21 While the above indicates that the M+αKG can bind to each of the 
D201A/E/G variants, the binding affinity of these variants has not been reported.  
Intrinsic tryptophan fluorescence quenching was monitored using a PTI fluorimeter 
to determine the equilibrium dissociation constant (Kd) of metal binding to the D201A/E/G 
variants in the presence of a large excess of αKG (Fig. 2.4A). Co(II) was used as an Fe(II) 
mimic in order to conduct the assays aerobically, as was done previously for WT FIH.41 
Samples were excited at 285 nm and emission was monitored at 330 nm as increasing 
amounts of Co(II) were titrated in to the protein solution. We observed that the Kd(Co) for 
WT FIH (Kd = 2.0(2) x 10-6 M) increased by 80-fold in the D201A variant (Table 2.3). This 
difference in Kd(Co) is much greater than the 6-fold increase in Kd seen between the αKG 
dependent oxygenase TfdA and its D116G active site variant.19 The lower metal binding 
affinity for the D201A variant suggests that the Ala substitution sterically impinges on the 
metal center, and may explain the inability of this variant to hydroxylate CTAD.  
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Figure 2.4. Kd(Co) determination based on intrinsic tryptophan fluorescence quenching 
for (A) D201A (green), D201E (blue), D201G (red) and WT FIH (black). (B) The 
D201G sample with (red) 100 mM NaCl in the assay buffer and without (black). Assays 
contained the following: 20 µM FIH, 500 µM αKG, and 10 mM sodium citrate in 50 mM 
HEPES pH 7.0. The titrating solution was composed of 1 mM CoSO4, and 1 mM sodium 
citrate or 10 mM CoSO4, and 10 mM sodium citrate in 50 mM HEPES pH 7.0. 
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Table 2.3 Kd(Co) values. 
  Kd(Co), x 10-6 M 
WT  2.0 ± 0.2 
D201A 157 ± 30 
D201E 5.5 ± 0.8 
D201G  4.5 ± 0.7 
 
 
We observed that the metal binding affinity for the D201E and D201G variants 
were very similar to that of WT FIH, varying by less than three-fold (Table 2.3). This 
suggests that these variants likely retain pseudo-octahedral geometry about the bound metal 
ion. Further, the high metal binding affinity for these variants is consistent with their 
competence to hydroxylate CTAD. Unexpectedly, addition of chloride to the D201G 
variant had no effect on the Kd(Co) (Fig. 2.4B). This Co(II) titration was repeated for 
D201G with both CoSO4 and Co(ClO4)2 (Supplemental Fig. 2.9) to test the possibility that 
the sulfate group was binding in place of the Cl– anion in the chloride-free sample. The 
reproducibility of the Kd(Co) for the D201G variant implies that exogenous ligand binding 
to form a complete His2X facial triad is essential for catalytic activity of the variants, but 
not metal binding.   
 
2.4 Conclusion 
The D201G variant of FIH requires a His2Cl triad to activate O2, as shown by the 
low catalytic activity in the absence of Cl–. This is of crucial importance to the αKG 
dependent oxygenase family of enzymes, as it suggests larger role for a complete His2X 
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facial triad in the chemical steps. Previous studies of this enzyme family have identified 
the requirement of a Cl– anion in the active site to form halogenated product, however the 
role of the His2X facial triad in O2 activation was not explored. The data presented here 
provide evidence that a full His2X triad is an absolute requirement for O2 activation in the 
αKG oxygenases. The XAS metrics for the Fe-Cl bond provide insight into the 
requirements for the His2Cl facial triad structure found in halogenases. This study further 
indicates that an extended anion binding site is not needed to form an Fe-Cl center, as 
suggested from crystallography of  CytC3.12-13  Overall, this work advances knowledge of 
the requirements for anion binding to trigger O2 reactivity, and role of the His2Cl facial 
triad structure in the αKG dependent oxygenases.  
 
2.5 Supplemental Information  
2.5.1 Site directed mutagenesis  
The primers used to mutate the pET28a-WT FIH construct are found below. Each 
mutated plasmid was sequenced (Genewiz, NJ, USA) to ensure only the desired mutation 
was present before being transformed into BL21 (DE3) competent cells for protein 
expression. 
D201A 
forward, 5’-GACACCTGCTCACTATGCTGAGCAGCAGAACTTTT-3’; 
reverse, 5’-AAAAGTTCTGCTGCTCAGCATAGTGAGCAGGTGTC-3’.  
D201G 
forward, 5’-GTGACACCTGCTCACTATGGCGAGCAGCAGAAC-3’;  
reverse, 5’-GTTCTGCTGCTCGCCATAGTGAGCAGGTGTCAC-3’.  
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D201E 
forward, 5’-GACACCTGCTCACTATGAGGAGCAGCAGAACTTTTTT-3’;  
reverse, 5’-AAAAAAGTTCTGCTGCTCCTCATAGTGAGCAGGTGTC-3’. 
2.5.2 Activity assays  
 
Figure 2.5 MALDI-TOF spectra of quenched FIH reaction aliquots showing an increase 
in CTADOH. [CTAD+H] +obs = 4256 m/z ([CTAD+H] +calc = 4254 m/z), [CTADOH+H]+ obs 
= 4272 m/z ([CTADOH+H]+ calc = 4270 m/z) [CTAD+Na]+ obs = 4278 m/z ([CTAD+Na]+ 
calc = 4276 m/z). 
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Figure 2.6 Zoomed-in MALDI spectra. Peaks corresponding to the chlorination of 
CTAD (in a 3:1 ratio of 35Cl and 37Cl isotopes), [CTADCl+H]+calc = 4288 and 4290 m/z, 
are not observed. 4278 m/z = [CTAD+Na]+obs, 4294 m/z = [CTADOH+Na]+ obs, 4298 m/z 
= [CTAD + Acn+H]+ obs. 
 
Figure 2.7 Initial rate of CTAD hydroxylation determined from the relative intensities of 
[CTADOH+H]+ and [CTAD+H]+. 
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2.5.3 UV-Vis spectroscopy 
 
Figure 2.8 Anaerobic UV-Vis spectra of the MLCT region for (Fe+αKG)FIH variants 
(400 µM) constituted with FeSO4 (375 µM) and αKG (400 µM) in 50mM HEPES pH 
7.00. 
2.5.4 X-ray absorption spectroscopy  
Data were collected at the Stanford Synchrotron Radiation Laboratory (SSRL) on 
beam line 9-3. For data collected at SSRL, the samples were cooled to ~10 K using a liquid 
helium cryostat (Oxford Instruments). The ring conditions were 3 GeV and 450-500 mA. 
Beam line optics included a Si(220) double-crystal monochromator. X-ray fluorescence 
data were collected using a 100 element detector (Canberra).  Soller slits with a Z-1 element 
filter were placed between the sample chamber and the detector to minimize scattering. 
Internal energy calibration was performed by collecting spectra simultaneously in 
transmission mode on the corresponding metal foil to determine the first inflection point 
on the edge, which was set to 7111.2 eV for Fe. X-ray absorption near-edge structure 
(XANES) data were collected from -200 to +200 eV relative to the metal K-edge. Extended 
X-ray absorption fine structure (EXAFS) data were collected to 15k above the reference 
edge energy. 
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The SixPack software program1 was used to remove bad channels, average the data, 
and to perform energy calibrations, in addition to data reduction and normalization.2 
Background correction was performed using a Gaussian pre-edge function and a quadratic 
polynomial for the post-edge region followed by normalization of the edge jump. A seven 
section, fourth-order polynomial spline between k = 2 Å-1 and k = 14 Å-1 was used for 
EXAFS baseline correction. The Artemis software program was used for EXAFS analysis 
by utilizing the EXAFS equation with parameters generated using FEFF6. 3-4  The EXAFS 
equation is defined as: 
𝜒𝜒(𝑘𝑘) =  �𝑁𝑁𝑚𝑚𝑓𝑓𝑚𝑚(𝑘𝑘)𝑒𝑒−2𝑘𝑘2𝜎𝜎𝑖𝑖2
𝑘𝑘𝑟𝑟𝑚𝑚
2 sin[ 2𝑘𝑘𝑟𝑟𝑚𝑚 +  𝛿𝛿𝑚𝑚(𝑘𝑘)]
𝑚𝑚
 
where f(k) is the scattering amplitude, δ(k) is the phase-shift, N is the number of 
neighboring atoms, r is the distance to the neighboring atoms, and σ2 is the disorder to the 
nearest neighbor. The data were converted to k-space using the 𝑘𝑘 = [2𝑚𝑚𝑒𝑒(𝐸𝐸−𝐸𝐸0)
ℏ2
]1/2 
relationship, where me is the mass of an electron and ħ is Plank’s constant divided by 2π. 
All data sets were Fourier-transformed using a Kaiser-Bessel window over the range k = 2 
– 14 Å, and fit in r-space over the range r = 1 – 4 Å in order to assess multiple-scattering 
contributions from histidine imidazole rings, and employing an amplitude reduction factor 
(S0) value of 0.9. The reported Fourier-transformed spectra were not phase-corrected. 
Reported data sets were fit with separate sets of Δreff (r – reff) or the change in metal-ligand 
bond distance with respect to the input path distance, and σ2 for the Cl and nitrogen-donors 
including imidazole rings with initial values of 0.0 Å2 and 0.003 Å2, respectively. Each fit 
was initiated with a universal E0 (7125 eV for Fe) and ΔE0 = 0 eV, which was allowed to 
vary for each fit. Histidine ligands were fit as geometrically rigid imidazole rings with 
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varied angles of rotation (α), with α being defined as the rotation around an axis 
perpendicular to the plane of the ring and going through the coordinated nitrogen. The 
distances of the five non-hydrogen atoms in the imidazole ring were fit in terms of a single 
Δreff for various angles (0 – 10°) so that all atoms in the ring move with the Fe-N distance.5-
7 Multiple-scattering parameters for imidazole ligands bound to Fe were generated using 
the FEFF6 software package with the imidazole input obtained from average bond lengths 
and angles gathered from crystallographic data, as previously described.8-9 All multiple 
scattering paths with path lengths outside the fitting window (r = 1 – 4 Å) were discarded. 
Histidine ‘counting’ was performed by adding integer numbers of histidine imidazole 
ligands to fits and assessing the effect on the R-factor and reduced χ 2. N-oxalylglycine 
(NOG) was modeled as a geometrically rigid molecule in an identical manner to the 
histidines. However, NOG was modeled as either the entire structure (Whole) or utilizing 
only the two oxygen atoms that traditionally bind bidentate to iron as well as the two 
backbone carbon atoms attached to them (Ring). The tail of the NOG structure is both 
spatially mobile in correlation with the iron atom as well as distant from the iron center 
and so should contribute little to nothing to the scattering pattern and can be easily omitted. 
To assess the goodness of fit from different fitting models, the fit parameters χ2, 
reduced χ2 (red χ2), and R-factor were minimized. Increasing the number of adjustable 
parameters is generally expected to improve the R-factor; however χ2 may go through a 
minimum, with the increase indicating the model is over-fitting the data. These parameters 
are defined as follows: 
𝜒𝜒2 = 𝑁𝑁idp
𝑁𝑁𝜀𝜀2
�(𝑚𝑚=1
𝑁𝑁
Re[𝜒𝜒�data(𝑅𝑅𝑚𝑚) − 𝜒𝜒�theory(𝑅𝑅𝑚𝑚)]2 + Im[𝜒𝜒�data(𝑅𝑅𝑚𝑚) − 𝜒𝜒�theory(𝑅𝑅𝑚𝑚)]2) 
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And 
𝑟𝑟𝑒𝑒𝑟𝑟𝜒𝜒2 =  𝜒𝜒2
𝑁𝑁idp − 𝑁𝑁var
 
Where Nidp is the number of independent data points defined as 𝑁𝑁idp  =  (2∆𝑟𝑟∆𝑘𝑘)𝜋𝜋 , Δr 
is the fitting range in r-space, Δk is the fitting range in k-space, Nvar is the number of refining 
parameters and represents the degrees of freedom in the fit, 𝑁𝑁𝜀𝜀2 is the number of 
uncertainties to minimize, Re() is the real part of the EXAFS Fourier-transformed data and 
theoretical functions, Im() is the imaginary part of the EXAFS Fourier-transformed data 
and theoretical functions, and 𝜒𝜒�(Ri) is the Fourier-transformed data or theoretical function. 
Additionally, IFEFFIT calculates the R-factor for each fit, which is directly 
proportional to χ2 and a measure of the absolute misfit between the data and theory given 
by: 
𝑅𝑅 =  ∑ {Re[χ�𝑙𝑙𝑚𝑚𝑑𝑑𝑚𝑚(Ri) − χ�𝑑𝑑ℎ𝑒𝑒𝑙𝑙𝑟𝑟𝑒𝑒(Ri)]2 +  Im[χ�𝑙𝑙𝑚𝑚𝑑𝑑𝑚𝑚(Ri) − χ�𝑑𝑑ℎ𝑒𝑒𝑙𝑙𝑟𝑟𝑒𝑒(Ri)]2}ni=0
∑ {Re[χ�data(Ri)]2 + Im[χ�data(Ri)]2}ni=0  
 
Selected fits to the data are shown in Supplemental Table 2.4; the best fit is at the 
bottom of the table. 
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Table 2.4 Selected fits of EXAFS for (Fe+Cl+NOG)D201G using varied ligand 
composition. 
N Radius 
Å 
σ2 
(x10-3 Å2) 
ΔE0 
(eV) 
R 
factor 
nvar 
6N/O 2.13(1) 3(1) -5(1) 0.0818 3 
      
5N/O 2.12(1) 0(1) -5(1) 0.0601 5 
1S/Cl 2.40(3) 5(4)    
      
4N/O 2.12(1) 0(1) -5(2) 0.0597 7 
1Imd 2.08(11) 10(16)    
1Imd 2.25(4) 1(5) 
      
3N/O 2.09(1) 2(1) -9(1) 0.0300 9 
1S/Cl 2.38(3) 4(3)    
1Imd 1.95(3) 2(3)    
1Imd 2.16(3) 3(3)    
   
1N/O 2.09(1) 4(1) -10(2) 0.0236 11 
1S/Cl 2.36(4) 5(4)    
1Imd 1.95(4) 2(3) 
1Imd 2.16(4) 3(3)    
1NOG(ring) 2.01(9) 6(6)    
 2.11(9)  
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2.5.5 Metal titrations 
To control for the possibility that the sulfate group may be binding to the active site 
of the D201G variant without added chloride, resulting in a similar Kd(Co) (5 µM) for the 
chloride-saturated sample, additional assays were conducted using Co(ClO4)2. Changing 
the counter ion of the metal salt did not affect the Kd(Co).  
 
Figure 2.9 Kd(Co) determination based on intrinsic tryptophan fluorescence quenching 
for the D201G sample with (red) and without (black) 100 mM NaCl in the assay buffer. 
Assays contained the following: 20 uM FIH, 500 uM αKG, and 10 mM sodium citrate in 
50 mM HEPES pH 7.0. The titrating solution was composed of 1 mM Co(ClO4)2, and 1 
mM sodium citrate or 10 mM Co(ClO4)2, and 10 mM sodium citrate in 50 mM HEPES 
pH 7.0. Samples were mixed for 7 minutes following addition of metal, then were excited 
at 285 nm. Maximum emission was monitored at 330 nm. 
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CHAPTER 3 
SECOND COORDINATION SPHERE INFLUENCES SUBSTRATE 
SELECTIVITY IN FACTOR INHIBITING HIF (FIH) 
3.1 Introduction 
Bio-orthogonal chemistry has led to a powerful set of tools that enable chemists to 
study biological processes within living cells.1 Two prominent tools are the Staudinger 
ligation2 and the Huisgen 1,3 cycloaddition (“click”) reaction;3,4 both reactions couple an 
organic azide with another functional group. The small size and inherent lack of reactivity 
with enzymes makes azides attractive for biomolecular recognition.1 However, organic 
azides cannot be biosynthesized,1 limiting their applications. Thus, there is a need to hijack 
the molecular machinery of enzymes to produce non-natural peptide modifications, such 
as azidation, in order to facilitate bio-orthogonal efforts.  
The αKG dependent halogenase SyrB2 was engineered to facilitate azidation and 
nitration of substrate through radical rebound chemistry of an exogenous anion, suggesting 
other αKG dependent oxygenases could support this chemistry.5 However, attempts at 
reprogramming the chemistry of other αKG dependent hydroxylases have not been 
successful. In TauD and prolyl-4-hydroxylase, mutations to the facial triad carboxylate to 
permit exogenous anion binding did not support formation of the active (Fe+αKG) 
complex, preventing the enzymes from reacting with O2.6,7 Recently, the αKG dependent 
hydroxylase SadA was reported to halogenate a small molecule substrate with simply an 
Asp→Gly mutation of the facial triad carboxylate residue,8 suggesting non-natural peptide 
modifications of hydroxylases are possible through manipulation of enzyme structure 
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provided that an exogenous anion can bind and the substrate is positioned correctly. While 
the halogenases are thought to follow the same consensus mechanism of the hydroxylases, 
the differences which govern halogenation versus hydroxylation are still being 
elucidated.9–11  
We proposed to engineer FIH to perform radical rebound chemistry with exogenous 
anions, to produce peptides with varied modifications. Recently, our group demonstrated 
that the D201G variant of FIH is only active in the presence of chloride and that the active 
site of this variant contains an Fe-Cl bond, forming a His2Cl facial triad reminiscent of the 
αKG dependent halogenases (Chapter 2), demonstrating 3 out of the 4 criteria for radical 
rebound chemistry. Having the chloride positioned in the active site of the enzyme may 
allow for alternate rebound chemistry to occur if the substrate and anion binding sites are 
arranged to favor anion rebound over •OH rebound (see Chapter 2, Scheme 2.1 for more 
details). Chloride binding to the active site of D201G raises the potential for binding of 
other anions, such as azide.  
Engineering the second coordination sphere within the D201G variant of FIH to 
allow for an exogenous anion to undergo radical rebound could induce novel C-X bond 
formations, which could then be used to prepare peptides for bio-orthogonal conjugations. 
This thesis reports on the anion dependent substrate hydroxylation by FIH variants in initial 
efforts to achieve non-natural peptide modification. Our results from Chapter 2 indicate 
that FIH could be engineered to bind exogenous anions and perform anion-selective 
hydroxylation chemistry, achieving the preliminary steps necessary for alternate rebound 
chemistry.  
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The extensive hydrogen bonding network between the second coordination sphere 
residues and the active site has been reported to play a role in chloride binding in the 
halogenases CtyC3 and SyrB2,12 and aids in coupling O2 activation with substrate 
hydroxylation in FIH.13 We hypothesized that the second coordination sphere residues in 
the αKG dependent oxygenases govern Fe-X orientation relative to substrate through 
hydrogen bonding interactions. In the search for non-natural peptide modifications, various 
ARD sequences were screened. FIH hydroxylates several types of amino acids at the target 
residue within ARD domains whereas Asn is the only known target residue for CTAD.14–
17 Changing the target residue could alter substrate positioning, promoting alternate 
rebound chemistry.8,18 Instead, some variants exhibited substrate selectivity disfavoring the 
Asn residue, suggesting target residue preference could be modified through second sphere 
interactions within FIH. Overall, this study exemplifies the robust hydroxylase nature of 
FIH and high tolerance for chemical diversity within its second coordination sphere.  
3.2 Methods 
 All reagents were purchased from commercial vendors and used as received, with 
the exception of CTAD substrate. CTAD was purchased (EZBiolab, Carmel, IN, USA) as 
a desalted peptide and further purified by reverse phase HPLC methods (described in 
section 3.2.1).  
3.2.1 CTAD purification  
Desalted CTAD peptide representing HIF-1α788-826 with the sequence 
DESGLPQLTSYDAEVNAPIQGSRNLLQGEELLRALDQVN (N803 hydroxylation site 
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underlined) was stored at -20 oC upon arrival. A 2.5 mg/mL solution of desalted peptide in 
20% HPLC Grade Acetonitrile (ACN)/0.1% trifluoroacetic acid (TFA) was prepared and 
filtered with a 0.22 µm syringe filter. Solvents were prepared as follows: Solvent A= 
ddH2O with 0.1% TFA; Solvent B= ACN with 0.1% TFA. A Proto C18 semi prep column 
(Higgins Analytical) was attached to an Agilent HPLC 1100 system. The following Agilent 
ChemStation method was used to isolate pure CTAD from its impurities (current method 
named “CTAD PREP 12.21.16):  
Table 3.1 CTAD purification HPLC method. 
Time (min) % Solvent B Flow rate  (mL/min) 
0.1 25 5 
6 35 5 
23 40 5 
27 95 5 
28 25 5 
30 25 5 
 
To start the method, 1.8 mL of impure CTAD solution was loaded into the manual 
injector using a blunt HPLC injection needle on the end of a 2 mL syringe and the manual 
injector was flipped from “load” to “inject” automatically starting the method. The semi-
pure CTAD peak was manually collected around 9 minutes post injection. Following 
completion of the method, a new injection of impure CTAD solution was made until all 
the impure CTAD was run over the column. Semi-pure CTAD was then flash frozen using 
liquid nitrogen and lyophilized overnight. The semi-pure CTAD was then re-dissolved in 
20% ACN/0.1% TFA and run over the column for a second time using the same method. 
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The pure CTAD peak was manually collected about 10 minutes following injection. Pure 
CTAD was again flash frozen using liquid nitrogen and lyophilized overnight to remove 
ACN. Lyophilized pure CTAD was dissolved in a minimal amount (300 µL) of fresh 50 
mM HEPES buffer pH 7.00 for activity assays. 10 µL of pure CTAD in HEPES was diluted 
in 110 µL of 0.1 M NaOH and the concentration of CTAD was determined using UV-Vis 
spectroscopy at 293 nm (Ɛ= 2,400 M-1cm-1). CTAD was stored at a high concentration at -
20 oC.  
3.2.2 Site directed mutagenesis 
Degenerate primers were designed according to guidelines from Integrated DNA 
Technologies (IDT) (detailed in section 3.5.1). PCR was conducted using the degenerate 
primers and D201G plasmid DNA to develop the library of second coordination sphere 
variants. PCR reactions included Phusion master mix (Fisher), 125 ng/µL forward primer, 
125 ng/µL reverse primer, 100 ng/µL D201G plasmid DNA, 3% DMSO, and sterile H2O. 
PCR cycling conditions were as follows: 
Initial denaturation  98 ºC 1 minute 1 cycle 
 Denature   98 ºC 15 seconds 30 cycles 
 Anneal    62 ºC 30 seconds 30 cycles 
 Extend    72 ºC 3.5 minutes 30 cycles 
 Final extension  72 ºC 10 minutes 1 cycle 
DNA amplification was confirmed using agarose gel electrophoresis and PCR 
products were transformed into XL1-Blue cells. DNA from individual colonies on the 
XL1-Blue plates was isolated using a GeneJet miniprep kit (Fisher) and sequenced. 
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Colonies were picked, miniprepped, and sequenced until all expected mutations possible 
with the degenerate primers were found. Sequenced plasmid DNA stocks were labeled and 
stored at -80 ºC.   
3.2.3 Crude cell lysate screen 
Plasmid DNA for each variant was transformed into BL21-DE3 cells. Individual 2 
mL 2xYT overnight cultures were inoculated with a single colony from the agar plates. 
Overnight cultures were incubated at 37 ºC while shaking at 225 rpm for 12-16 hours. 
Variants were then expressed in BL21-DE3 cells grown in 5 mL cultures of 2xYT media. 
Cultures were inoculated with 100 µL of overnight culture and grown at 37 ºC while 
shaking at 225 rpm until optimal cell density was achieved. Protein expression was induced 
with 0.5 M Isopropyl β-D-1-thiogalactopyranoside (IPTG) at OD600= 0.6-0.8 and incubated 
for 5 hours at 37 ºC while shaking at 225 rpm. Cells were harvested by centrifugation 
(Sorvall Legend RT with swinging buckets) at 3,441 x g for 15 minutes and stored at -20 
ºC. Cell pellets were lysed for activity screens using 1 mL of 1 X lysis buffer (25 mM Tris 
Base, 200 µM EDTA, 1 mg/mL lysozyme, and 1 µg/mL of AEBSF) pH 8.0. Lysates were 
vortexed vigorously, flash frozen using liquid nitrogen, and stored at -80 ºC for one hour. 
Lysates were then thawed at room temperature and centrifuged (Eppendorf, FA-45-18-11 
rotor) at 16,900 x g for 25 minutes to pellet cell membrane components. Supernatant was 
removed and stored at -20 ºC for activity assays.  
Supernatants were thawed on ice in preparation of activity assays. Activity assays 
were conducted with ascorbate (2 mM), αKG (200 µM), FeSO4 (100 µM), CTAD or ARD 
substrate (50 µM) and 10% crude cell lysate in 50 mM HEPES/100 mM NaX pH 7.00. All 
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assay components were mixed to a total volume of 50 µL and incubated at 37 ºC overnight. 
The next morning, 5 µL of each assay was quenched in 20 µL of matrix (3,5-dimethoxy-
4-hydroxycinnamic acid saturated in 75% ACN/0.2% TFA) and analyzed by MALDI-
TOF-MS (Ultraflex, Bruker) monitoring the +1 charge state of the substrate mass and any 
mass additions to the substrate peak. Hydroxylated substrate resulted in a +16 mass shift 
due to loss of a hydrogen followed by •OH rebound from FIH to the peptide substrate. 
Anion rebound modifications were expected to produce a mass shift of +34.5/36.5, +80, 
and +42 for chlorination, bromination, and azidation respectively based on the mass of the 
element added to the mass of the peptide, minus loss of a hydrogen. 
3.2.4 Protein purification 
Selected variants were expressed and purified as previously described (section 
2.2.1). Briefly, His tagged variants were expressed in BL21-DE3 cells and cell pellet was 
harvested. Cell pellet was lysed using sonication and centrifuged (Sorvall RC6, SS-34 
rotor, 14,000 rpm). Supernatant was dialyzed into 10 mM Tris pH 8.0 and run over a Ni-
NTA column to remove contaminating proteins. Restriction grade thrombin was then used 
to cleave the His tag. Cleaved protein was loaded on to the Ni-NTA column again to 
remove the His tag. Cleaved protein was found in the flow through. Flow through was 
treated with 50 mM EDTA overnight at 4 ºC to remove endogenous metals. Protein was 
then isolated from thrombin and EDTA using size exclusion chromatography (Superdex 
75 10/300, GE Life Sciences). Eluted protein was buffer exchanged into 50 mM HEPES 
pH 7.00 and stored at -20 ºC. Protein purity was checked using SDS PAGE and mass 
spectrometry.  
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3.2.5 O2 consumption  
An Oxygraph Plus System (Hansatech) was used to monitor the amount of oxygen 
consumed by the enzyme. This oxygen sensor contains a central reaction vessel surrounded 
by a water jacket, with an oxygen electrode disc at the bottom of the reaction vessel. The 
electrode disc consists of a central platinum cathode and a concentric silver anode. To 
conduct signal across the electrode disc, a KCl bridge is formed between the two electrode 
elements with the aid of a fine paper wick and a layer of PTFE membrane, which is 
selectively permeable to oxygen molecules. A new membrane was prepared and calibrated 
each day with air saturated water and dithionite. 400 µL reactions were equilibrated at 
atmospheric O2 in the reaction vessel at 37 ºC until a stable baseline was achieved. Assays 
were initiated with cold purified enzyme (10 µM) using a Hamilton syringe. The rate of O2 
consumption was monitored over time until the rate of O2 consumption resembled the 
baseline slope. Assays contained 50 µM ascorbate, 100 µM αKG, 50 µM FeSO4, 80 µM 
CTAD and 10 µM FIH in 50 mM HEPES 100 mM NaCl pH 7.00. Typical activity assay 
conditions include 2 mM ascorbate, however ascorbate consumes O2 and resulted in a steep 
baseline slope before purified enzyme was added to the reaction mixture. Therefore, 
controls were done to determine the optimal amount of ascorbate that could be used to 
minimize baseline slope while keeping the Fe2+ reduced. 50 µM ascorbate fit both of these 
conditions as it was equimolar to the amount of FeSO4 (50 µM) and allowed for the amount 
of O2 consumed upon enzyme addition to be distinguished from the baseline signal.  
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3.2.6 Thermal shift assay 
Thermal shift assay experiments were conducted using a BioRad CFX Connect 
Real-Time PCR Detection System instrument. Protein solutions were dispensed in 50 µL 
aliquots into clear 96-well PCR plates and sealed to prevent evaporation. The PCR plates 
were placed in the thermal block of the PCR instrument and heated at a rate of 0.5 °C/s. 
Fluorescence was measured and an image was collected every 0.5 °C. Reference wells 
contained (Fe+αKG) in HEPES buffer without enzyme. Relative fluorescence intensity 
data was obtained from the instrument, plotted for comparison to control samples, and the 
sigmoidal portion of the data was fit using the Boltzman equation in Origin to obtain the 
TM.  
𝑦𝑦 = 𝐴𝐴1 − 𝐴𝐴21 + 𝑒𝑒(𝑥𝑥−𝑥𝑥0)/𝑑𝑑𝑥𝑥 + 𝐴𝐴21 
Samples were composed of 100 µM αKG, 5 µM CoSO4, 5 µM FIH and 5x Sypro 
Orange dye in 50 mM HEPES 100 mM NaCl pH 7.00.  The concentration of enzyme, 
metal, and αKG were previously optimized to obtain a strong fluorescent signal during the 
inhibitor screens described in Appendix B. Samples were denatured using a temperature 
gradient. An increase in fluorescence intensity correlated to an increase in denaturation 
state of the protein. ΔTM was calculated by subtracting the TM of apo FIH from the TM of 
FIH variants. 
                                                 
1 A1= initial temperature  
  A2= final temperature 
   X0= midpoint (TM) 
  dX= time constant  
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3.3 Results and Discussion  
3.3.1 Second sphere mutagenesis    
Target residues were selected for mutation using a rational design approach to 
promote anion rebound over hydroxide rebound. The second sphere interactions of FIH 
were modeled against those of SyrB2 to establish the nearest contacts for the metal center 
orientation relative to substrate. In both enzymes, an extensive hydrogen bonding network 
positions the active site residues, however the residues involved differ significantly 
between the hydroxylase and the halogenase. Sequence alignments of FIH and the αKG 
dependent halogenases (Table 3.2) identified three sites which form polar contacts to the 
primary ligands coordinating the metal center in distinct ways between the two enzyme 
classes. Positions 205, 294, and 296 (bolded in Table 3.2) were chosen as targets for 
manipulating FIH active site configuration to promote alternate rebound chemistry. As 
seen in Figure 3.1, these three residues form hydrogen bonds with the primary sphere 
ligands in both FIH and SyrB2, suggesting these sites are important in positioning. 
 
Figure 3.1 Second coordination sphere interactions with primary ligands in (A) D201G 
FIH (PDB Code: 3D8C,19 Cl- modeled) and (B) SyrB2 (PDB Code: 2FCT20). 
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Table 3.2. Sequence homology of FIH with αKG dependent halogenases. Sites targeted 
for mutation are bolded. 
 199 201 205 279 294 296 
FIH19 H D N H N W 
SyrB220 H A T H A R 
CytC312 H A T H A R 
WelO521 H N S H G F 
CurA22 H G S H V R 
A library of FIH second sphere variants at these three positions in the D201G 
construct was developed using degenerate primers23 in order to broadly sample chemical 
space at each position, while minimizing PCR reactions. Initially, 15 double variants within 
the D201G construct were made containing a mutation at either position 205, 294, or 296. 
An additional library of 58 quadruple variants were also made within the D201G construct 
in which the residues at positions 205, 294 and 296 were varied (Supplemental Table 3.4). 
These variants were then sequenced (Genewiz, South Plainfield, NJ, USA) and over 
expressed in E. coli. A freeze-thaw process was used to lyse the cells. Lysate was then 
centrifuged to remove membrane components as described in section 3.2.2 of this chapter; 
the supernatant, referred to as crude cell lysate, was used to assess endpoint activity of the 
variants, the results of which are elaborated on below. Protein expression was verified 
using SDS PAGE gel electrophoresis of crude cell lysate (Supplemental Fig. 3.9) 
3.3.2 Anion rebound screens  
Bollinger et al established four conditions which facilitate halide rebound 
chemistry: (i) halide anion coordination to Fe(II) cofactor, (ii) O2 activation coupled to 
decarboxylation to form the haloferryl intermediate, (iii) hydrogen atom abstraction and 
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(iv) transfer of halogen atom to substrate radical.5 These conditions were used in Chapter 
2 to evaluate the novel Fe-Cl bond identified in the D201G variant of FIH. However, initial 
activity studies of this single variant did not reveal anion rebound chemistry, prompting 
the site directed mutagenesis study presented in this chapter. Further structural analysis of 
SyrB2 reactivity revealed halogenases position the substrate target residue distal to the oxo 
moiety of the ferryl intermediate, such that halide rebound is facilitated. These 
requirements would need to be met by the D201G second sphere variants in FIH to achieve 
alternate rebound chemistry.  
In order to quickly evaluate the rebound chemistry potential of the D201G variants, 
a crude cell lysate activity screen was developed. Initial screens were conducted in the 
presence of 100 mM NaCl as Cl- was previously shown to bind to the active site of D201G 
(Chapter 2). Variants were incubated with ascorbate, αKG, FeSO4, CTAD in 50 mM 
HEPES/100 mM anion at pH 7.00 and 37 ºC overnight to allow for trace products to 
accumulate. MALDI-TOF-MS was used to detect substrate modifications following 
overnight incubation. Screens without any added anion were conducted in parallel as a 
control. Additional screens with Br- or N3- were conducted to determine if anions of varying 
size could bind to the Fe(II) as Cl- was shown to do and rebound to substrate. As each of 
these modifications results in a unique mass shift, MALDI-TOF-MS was ideal for detecting 
all possible substrate rebound products.  
We hypothesized that varying the second sphere residues would position the anion 
ligand to compete with the hydroxide ligand for rebound chemistry, leading to alternate 
substrate modifications. However, this was not observed. All the variants minimally 
hydroxylated the CTAD substrate with and without added Cl-. The hydroxylated +16 mass 
 101 
shift was seen with all variants, irrespective of anion. Mass shifts of possible alternate 
rebound modifications include chlorination (+34.5/36.5 in a 3:1 ratio), bromination 
(+79/81 in a 1:1 ratio), and azidation (+42). No substrate modifications with these mass 
shifts were seen for any of the variants under the given conditions. The double variant 
halide rebound screens are shown in Figure 3.2.  
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Figure 3.2. Endpoint halide rebound screens in crude cell lysate using the CTAD 
substrate. (A) 205 variants (B) 294 variants and (C) 296 variants. Assays included 
ascorbate (2 mM), αKG (200 µM), FeSO4 (100 µM), CTAD substrate (50 µM) and 10% 
crude cell lysate in 50 mM HEPES/100 mM NaX pH 7.00. 
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 Less than 5% hydroxylated CTAD was detected for all the variants except GNTW 
(residues at positions 201, 205, 294, 296 respectively) which was 15% hydroxylated in the 
presence of Cl-. This was surprising as halogenases prefer small, nonpolar side chains at 
the analogous 294 position, however the Trp→Thr mutation was a conservative change 
within FIH. From this screen, we concluded that all of the second coordination sphere 
double variants impaired CTAD hydroxylation. This low CTAD hydroxylation was likely 
due to impaired Fe/X- binding, with the GNTW mutation having a lesser effect on Fe/X-. 
In addition, the second sphere had a small effect on anion selectivity. Only CTAD 
hydroxylation by GNTW was enhanced by the addition of NaCl to the assay buffer. Some 
variants have a 1-2% increase in hydroxylation activity in the presence of NaBr, however 
the total hydroxylation was less than 5%. Activity screens with added NaN3 had a much 
lower signal to noise ratio than the other NaX additives, therefore the low amount of CTAD 
hydroxylation seen in Figure 3.2 with NaN3 was not deemed significant enough to pursue. 
The increased noise with NaN3 was thought to be due to impaired ionization of the matrix 
quenched samples. An example of a MALDI-TOF-MS spectra is shown below (Fig. 3.3), 
depicting the unmodified CTAD peak ([R+H]+) and the hydroxylated CTAD peak 
([R+OH]+). No other peaks are seen in the spectra with the exception of the [R+Na]+ peak 
which is present in all of the spectra as the pH of the HEPES buffer is adjusted with 1 M 
NaOH. Overall, these screens suggested that these second coordination sphere variants did 
not increase the flexibility of the active site to allow the X- ligand to compete with the 
hydroxide for substrate modification.  
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Figure 3.3 Example MALDI-TOF-MS data from NaX rebound screens with double 
variants. 
 
 Along with hydroxylating Asn803 of CTAD, FIH is known to hydroxylate multiple 
target residues within ARD domains, however the biological significance of this 
hydroxylation is unknown.24,25 Target residues span all facets of diversity including polar, 
neutral, acidic, basic, hydrophobic and hydrophilic residues such as Asn, Asp, His, Ile, 
Leu, and Ser.26,27 The ARD peptide recognition sequence is about half the number of amino 
acids as CTAD; using a shorter substrate may allow for more flexibility in the active site. 
As FIH is highly promiscuous towards these substrates, we hypothesized that the ARD 
substrates may facilitate rebound chemistry over CTAD.  
 Purified (>98%) 19-mer ARD peptides containing each of these target residues at 
position 16, the known site of hydroxylation, were purchased from EZBiolab (Carmel, IN, 
USA). Working stocks of each peptide were prepared in 50 mM HEPES/10% ACN pH 
7.00 and the substrate concentration was verified by BCA assay. Crude cell lysate screens 
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of the D201G second sphere variants at either positions 205, 294, or 296 with Asn, His, 
Leu or Ser ARD substrates were conducted in the presence of 100 mM NaCl as described 
above. Similar to the screen conducted with CTAD substrate, none of the ARD substrates 
displayed a +34.5/36.5 doublet peak indicative of Cl- rebound. Surprisingly, the variants 
hydroxylated the ARD substrates more efficiently than CTAD. 
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Figure 3.4 Endpoint halide rebound screens in crude cell lysate using various ARD target 
residues as substrate. (A) 205 variants (B) 294 variants and (C) 296 variants. Assays 
included ascorbate (2 mM), αKG (200 µM), FeSO4 (100 µM), ARD substrate (50 µM) 
and 10% crude cell lysate in 50 mM HEPES/100 mM NaX pH 7.00. 
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 As seen in Figure 3.4, the Asn target residue is not favored by the D201G second 
sphere variants as it is in WT FIH. His was generally preferred by the variants, especially 
when position 205 was varied. However, there were a few cases where the variants are 
more inclined to hydroxylate Ser or Leu. For example, the GNNY variant containing a 
W296Y mutation strongly preferred the hydrophobic Leu side chain; GNRW and GNNT 
also prefer Leu to a lesser extent than GNNY. Overall second coordination sphere variants 
at positions 205, 294, or 296 in the D201G construct retain some activity towards ARD 
substrates, but lose CTAD reactivity. The observed loss of CTAD reactivity with the 
variants is ideal for those wishing to identify loss of function mutations for FIH, however 
this was not our goal. From this screen, we conclude that the second coordination sphere 
of FIH imparts substrate selectivity; substrate selectivity does not solely rely on the identity 
of the metal center.   
3.3.3 SyrB2 mimic purified variants 
SryB2 catalyzes the O2-dependent chlorination of threonine on syringomycin E 
biosynthesis.28 Crystal structures of SyrB2 revealed the chloride ion replaces the facial 
triad carboxylate to fill the vacant coordination site,20 as reported for the D201G variant of 
FIH (Chapter 2). Other known rebounding anions of SyrB2 include bromination,29 
azidation and nitration,5 making this an ideal enzyme to model our FIH engineering studies. 
As the crude cell lysate screens for alternate rebound chemistry with the D201G second 
sphere variants did not yield the desired result, a more focused study was conducted with 
purified variants. Variants that mimicked the SyrB2 residues at positions 205, 294, and 296 
were expressed and purified as described in section 3.2.4 to investigate the effects of the 
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point mutations on stability and reactivity. Notably, position 205 was mutated to a Ser 
instead of a Thr as seen in the analogous position of SyrB2 because studies of the 
halogenase WelO5 implicated the Ser residue at the position in stabilizing the halogenated 
product by hydrogen bonding to the ferryl intermediate, resulting in complete substrate 
halogenation.21 The S189A mutation in WelO5 yielded an equal amount of hydroxide and 
halide products, highlighting the significance of this residue in rebound chemistry. 
 
Figure 3.5 Anion screens with purified SyrB2-mimic variants and CTAD substrate. 
Single letter amino acid abbreviations represent residues at positions 201, 205, 294, and 
296 respectively. Assay conditions included ascorbate (2 mM), αKG (100 µM), FeSO4 
(50 µM), CTAD substrate (50 µM) and FIH (2 µM) in 50 mM HEPES/100 mM NaX pH 
7.00. 
 
Anion rebound screens were again conducted with the CTAD substrate, this time 
controlling the purity and amount of enzyme used. Similar to the results described in Figure 
3.2, all the SyrB2 mimic variants had little to no hydroxylation activity and no other 
substrate modifications were detected by MALDI-TOF-MS (Fig. 3.5). Consistent with the 
crude cell lysate screen, the purified SyrB2 mimic variants were most active in the presence 
of added chloride.  
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To gain a deeper understanding as to how the stability and reactivity of these 
variants was affected by manipulation of the second coordination sphere interactions, 
additional assays were conducted. First, protein stability was assessed using a thermal shift 
assay in which hydrophobic portions of the protein were labeled with a fluorescent Sypro 
orange dye that monitors protein unfolding.30 As the protein was denatured with increasing 
temperature, hydrophobic portions of the protein were exposed, resulting in an increase in 
fluorescence. From this data, the unfolding temperature (∆TM) was determined and 
compared to that of WT FIH. We hypothesized that the SyrB2 mimic variants would have 
decreased stability than WT FIH due to manipulation of the second sphere interactions and 
that the stability trend would correlate to the hydroxylation screens; i.e. variants with more 
activity would have a (∆TM) closer to that of WT FIH.  
 
Figure 3.6 Thermal stability of SyrB2 mimic variants. Single letter amino acid 
abbreviations represent residues at positions 201, 205, 294, and 296 respectively. 
Samples were composed of 100 µM αKG, 5 µM CoSO4, 5 µM FIH and 5x Sypro Orange 
dye in 50 mM HEPES 100 mM NaCl pH 7.00. 
 
Figure 3.6 shows the thermal melt results for (Co+αKG)WT FIH and the SyrB2 
mimic variants. Co2+ was used in place of Fe2+ to avoid oxidation at ambient O2.  In 
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agreement with our hypothesis, all of the variants substantially destabilized the protein, 
resulting in a lower TM than WT FIH. Analysis of the ∆TM values relative to WT FIH 
revealed that there was not a trend between the ∆TM and the percent CTAD hydroxylation 
seen in Figure 3.5; in fact, the single D201G mutation was the among the most destabilized 
despite having the most hydroxylation activity (Table 3.3). The increased stabilization of 
the GSAR variant, a quadruple variant, relative to the double variants suggests that 
extensive site directed mutagenesis within the second coordination sphere is not 
detrimental to enzyme stability.  
Table 3.3. Thermal stability values for variants. 2 Single letter amino acid abbreviations 
represent residues at positions 201, 205, 294, and 296 respectively. 
 
 TM, ºC  ∆TM, ºC 
from WT FIH 
WT FIH 59.54 ± 0.09  -- 
GNNW 52.77 ± 0.16  -6.77 
GSNW 52.48 ± 0.12  -7.06 
GNAW 54.28 ± 0.10  -5.26 
GNNR 52.98 ± 0.31  -6.56 
GSAR 55.56 ± 0.14  -3.98 
 
Although the SyrB2 mimic variants are less stable than WT FIH, some retain their 
ability to hydroxylate substrate to a low fraction of conversion. In light of these results, 
initial O2 consumption studies of the SyrB2 mimic variants were conducting using a Clark-
type O2 sensor. The amount of O2 consumed by the variants (∆O2) was calculated from the 
difference between the baseline O2 consumption of the reaction mixture represented by the 
black dashed line in Figure 3.7 and each colored line 300 seconds after enzyme initiation.  
                                                 
2 Samples were composed of 100 µM αKG, 5 µM CoSO4, 5 µM FIH and 5x Sypro Orange dye in 50 mM 
HEPES 100 mM NaCl pH 7.00.   
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Figure 3.7 Endpoint O2 consumption of purified SyrB2 mimic variants from baseline 
(black dotted line). Single letter amino acid abbreviations represent residues at positions 
201, 205, 294, and 296 respectively. GSNW (red), GNAW (blue), GNNR (purple), 
GSAR (green) 50 µM ascorbate, 100 µM αKG, 50 µM FeSO4, 80 µM CTAD, 10 µM 
FIH in 50 mM HEPES 100 mM NaCl pH 7.00. 
 
As seen in Figure 3.7, GNNR and GSAR did not consume any measurable O2 
during the given time course upon enzyme addition, suggesting that O2 activation is 
impaired by the W296R mutation, possibly due to unproductive formation of the 
(Fe+aKG)FIH enzyme state. The GNNR double variant was previously expressed and 
purified by Schofield, et al. They also reported that Asn803 CTAD hydroxylation with this 
variant was not detectable, presumably due to the substitution of the hydrophobic Trp 
residue with the polar/charged Arg residue disrupting the interaction with Val802 in the 
CTAD substrate. While this experiment highlighted the essential nature of the W296 
residue, it did not bring us closer to the goal of alternate rebound chemistry as it killed 
reactivity. GSNW consumed a considerable amount of O2 compared to hydroxylated 
substrate, suggesting that reactivity of this variant with O2 is largely uncoupled to substrate 
hydroxylation. Activity of the GNAW variant was more closely coupled than GSNW based 
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on the relative amount of O2 consumed to hydroxylated CTAD. These results provide a 
rationale for the lack of rebound activity seen with the GNNR and GSAR variants as they 
do not consume O2 and suggests positons 205 and 294 are more tolerant of mutations.  
The intriguing ARD hydroxylation results from the crude cell lysate screens (Fig. 
3.4) encouraged us follow up on this altered substrate preference. Overnight endpoint 
activity assays in the presence of ARD substrates with varying target residues were 
conducted with the purified SyrB2 mimic variants. As shown in Figure 3.8, for all the 
purified variants Ser was the least hydroxylated target residue suggesting the hydroxyl 
group is not tolerated well in the active site. All variants favored Asn hydroxylation over 
His and Leu with the exception of GNAW which showed a preference for His/Leu target 
residues in both the crude cell lysate and purified variant activity screens. Also in all cases, 
the amount of hydroxylated ARD was greater than the amount of hydroxylated CTAD in 
the presence of 100 mM NaCl, suggesting an altered substrate preference for the second 
coordination sphere variants.  
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Figure 3.8 Hydroxylation screen with purified SyrB2-mimic variants and ARD 
substrates. Single letter amino acid abbreviations represent residues at positions 201, 205, 
294, and 296 respectively. Assays included 2 mM ascorbate, 100 µM αKG, 50 µM 
FeSO4, 50 µM ARD substrate and 2 µM FIH in 50 mM HEPES 100 mM NaCl pH 7.00. 
 
3.4 Conclusion and Future Directions  
 In the end, this study did not yield the anticipated results. The second coordination 
sphere variants described here did not facilitate alternate rebound chemistry. Presumably, 
mutations to the hydrogen bonding network did not induce enough flexibility to the active 
site of FIH to position the halide ligand closer to the substrate, allowing it to compete with 
the hydroxide ligand for rebound chemistry. Conservative mutations to the second 
coordination sphere residues displayed modest hydroxylation activity, however the amount 
of hydroxylated product was less than that of the single D201G mutation in all cases. 
Curiously, variation to the second sphere altered substrate preference for the N16N ARD 
peptide over the CTAD peptide. Some variants even showed a preference for target 
residues other than Asn. However, there was no apparent trend as to how this target residue 
preference was mediated. More investigation is needed to determine the specifics of how 
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the second coordination sphere residues mediate substrate selectivity. Overall, it was 
concluded that substrate positioning is key for rebound chemistry. FIH is a robust enzyme 
which is specifically hydroxylates substrate. As FIH targets large protein substrates as 
opposed to small molecule substrates, manipulating the structure of the enzyme enough to 
facilitate alternate rebound chemistry may not be possible.  
3.5 Supplemental Information  
3.5.1 Degenerate primer design  
Overhanging degenerate primers were designed using guidelines provided by IDT.  
N205 Degenerate Primers  
5’- GTC CAC TAT GGT GAG CAG CAG RYC TTT TTT GCT CAG-3’ 
 3’-CCA CTC GTC GTC YRG AAA AAA CGA GTC TAT TTT CC-5’ 
R= A/G; Y= C/T 
 
N294 Degenerate Primers 
5’-GG GGG ATT ACC ATC ACT GTG RSR TTC TGG TAT AAG-3’ 
3’-GG TAG TGA CAC YSY AAG ACC ATA TTC CCC CGA G-5’  
R= A/G; S= C/G; Y= C/T 
 
W296 Degenerate Primers  
5’-G ATT ACC ATC ACT GTG AAC TTC AHY TAT AAG GGG GC-3’ 
   3’-GA CAC TTG AAG TDR ATA TTC CCC CGA GGG TGG G-5’ 
H= A/C/T; Y= C/T; D= A/G/T; R= A/G 
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3.5.2 Confirmation of double variant expression in E. coli 
As a control to ensure that protein was being expressed in all of the double variants, 
SDS PAGE gel electrophoresis (Fig. 3.9) was conducted before checking enzyme activity 
using the crude cell lysate screening method. Running the assays to completion (overnight) 
helped control for the differences in expression levels.  
 
Figure 3.9 SDS PAGE analysis of crude cell lysate following expression of variants in E. 
coli. Single letter amino acid abbreviations represent residues at positions 201, 205, 294, 
and 296 respectively. 
 
3.5.2 Quadruple variant library  
After the second coordination sphere double variants were shown to not induce 
alternate rebound chemistry, additional variants with mutations at positions 205, 294, and 
296 were made within the D201G construct to further increase active site flexibility. 
However, only low hydroxylation (< 5%) was seen with these variants. Variants are coded 
by single letter amino acid abbreviations at each position in the following order: 201, 205, 
294, 296. 
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Table 3.4. Second sphere mutagenesis within D201G construct of FIH. Single letter 
amino acid abbreviations represent residues at positions 201, 205, 294, and 296 
respectively. 
Quadruple variants 
GNRN GNTY GART GIRI GSRY GTRS GVRF GVTY 
GNRI GNTN GATW GIRN GSRS GTRY GVRS GIKW 
GNRY GARY GATS GITT GSTF GTTS GVRT  
GNRT GARS GATF GITN GSTI GTTT GVRN  
GNRF GARW GATN GITF GSTN GTTY GVTS  
GNRS GARN GIRY GITY GSTY GTTN GVTT  
GNTT GARF GIRS GITS GTRF GTTI GVTF  
GNTI GARI GIRT GSRI GTRN GVRY GVTN  
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CHAPTER 4 
 
FACIAL TRIAD IS ESSENTIAL FOR COUPLING HYDROXYLATION TO O2 
ACTIVATION IN FIH 
4.1 Introduction 
As a member of the vast alpha-ketoglutarate (αKG) dependent non-heme Fe(II) 
oxygenase family, Factor Inhibiting Hypoxia Inducible Factor (FIH) catalyzes the 
hydroxylation of a variety of peptide substrates upon molecular oxygen (O2) activation. 
Other functions of this enzyme family include halogenation, desaturation, epimerization, 
and most recently endoperoxidation.1,2 These enzymes oxidatively decarboxylate αKG 
producing succinate and CO2, generating a reactive O2-derived species in the process.3 This 
species then oxidizes a third substrate, known as the primary substrate, resulting in post-
translational substrate modification. Maintaining tight control over these two half reactions 
is crucial to proper functioning in this broad class of enzymes.  
In the αKG dependent oxygenases, the process of O2 activation is regulated by a 
“substrate triggering” effect. Substrate triggering dictates that primary substrate (R-
Scheme 4.1) must be bound in a catalytically relevant orientation in order for O2 
binding/activation to occur.4,5 Rapidly following O2 activation is the irreversible formation 
of an Fe(IV)=O intermediate and substrate rebound chemistry. This process results in a 
one-to-one stoichiometry of oxygen consumed to modified substrate. Deviations in this 
stoichiometry suggest an alternate O2 activation pathway for O2 consumption.4 
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Scheme 4.1. Consensus chemical mechanism of the αKG dependent oxygenases. X= 
carboxylate or anion. 
While a variety of catalytic outcomes are possible within this class of enzymes upon 
reacting with O2, nonproductive reactions with oxygen are also seen. “Uncoupled turnover” 
results when an enzyme inactivates following αKG decomposition into CO2 and succinate, 
rendering the substrate unchanged.1 Several groups have reported ascorbate-reversible 
uncoupling of αKG oxygenases as oxidation of the metal led to inactivation.6,7 Other 
alternate pathways implicated in enzyme uncoupling include autohydroxylation and 
reactive oxygen species (ROS) production.3,8 This uncoupled reactivity is thought to serve 
as a proof-reading tool to reject improper substrate positioning or incorrect substrate 
binding.9 While multiple cases of uncoupling have been reported for the αKG dependent 
oxygenases, mechanistic details regarding how and why these enzymes uncouple remain 
unknown.  
The active site of FIH contains the hallmark αKG dependent hydroxylase 
His2(Asp/Glu) facial triad and follows a well-defined consensus mechanism.1,10,11 Initial 
O2 activation studies of the facial triad carboxylate variants in FIH indicated that the D201 
residue is not required for O2 activation and instead aids in coupling O2 activation with 
substrate hydroxylation.12 This observation allowed us to investigate the role of the facial 
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triad carboxylate ligand in coupling O2 reactivity and substrate binding. Previous site-
directed mutagenesis studies conducted with D201 hypothesized that this residue is not 
required for metal binding or hydroxylation activity of FIH.13 However, more recently, it 
was revealed that non-polar mutations at the D201 site bind a halide anion, completing the 
facial triad and permitting hydroxylation activity (Chapter 2). While the kinetics and 
structure of the D201X variants have been reported by our lab and others, questions remain 
over how and why the D201X variants inactivate.12,13 Herein we report a branched 
mechanism of enzyme uncoupling for the D201X variants without substrate triggering and 
describe the fate of the oxidant in the absence of primary substrate, which results in 
autohydroxylation and formation of hydrogen peroxide (H2O2).   
4.2 Methods 
4.2.1 Materials 
The prime substrate for FIH, the C-terminal transactivation domain of HIF-1α (CTAD) 
was purchased (EZBiolab, Carmel, IN, USA) as a desalted 39-residue peptide representing 
HIF-1α788-826 with the sequence 
DESGLPQLTSYDAEVNAPIQGSRNLLQGEELLRALDQVN (N803 hydroxylation site 
underlined). This peptide was unmodified at the peptide termini and contained a C800A 
point mutation to prevent peptide oxidation. The desalted peptide was further purified by 
reverse phase HPLC before use (see Chapter 3, section 3.2.1 for detailed methods).14 All 
other reagents were purchased from commercial vendors and used as received.  
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4.2.2 Protein expression and purification 
Point mutations to the 201 site were made using the QuickChange mutagenesis kit 
(Stratagene) in the pET28a-FIH construct.15 The resulting plasmid DNA was sequenced 
(Genewiz, NJ, USA) to confirm the point mutation. His6-WT FIH and the His6-D201X 
variants were overexpressed in BL21-DE3 E. coli and purified as previously described 
(Chapter 2). Briefly, cell pellets were lysed using sonication, centrifuged, then dialyzed 
into 10 mM Tris pH 8.00 to remove EDTA from the lysis buffer. Centrifugation of the 
supernatant post dialysis further clarified the lysate prior loading on to a Ni-NTA column. 
After loading the lysate, the column was washed with 5 column volumes each of 100% A 
buffer (50 mM Tris pH 8.0, 300 mM NaCl, 15 mM Imidazole) and 15% B buffer (50 mM 
Tris pH 8.0, 300 mM NaCl, 250 mM Imidazole) to remove contaminating proteins before 
eluting the His6-FIH protein with 100% B buffer. Thrombin was then added to the eluent 
to cleave the His6 tag for 36 hours at 4 °C, resulting in >80% cleavage. The cleaved protein 
was loaded on to the Ni-NTA column again to remove the His6 tag and any remaining 
uncleaved protein. This was followed by overnight incubation with 50 mM EDTA to 
remove exogenous metals. Size exclusion chromatography was then used to separate the 
protein from the thrombin and EDTA. Purified protein was aliquotted and stored at 20 °C 
in 50 mM HEPES pH 7.00. Protein purity (>95%) was evaluated using SDS-PAGE.  
4.2.3 O2 consumption assays 
The amount of oxygen consumed by the enzyme was monitored using an Oxygraph 
Plus System (Hansatech). Each day, a new membrane was prepared with subsequent 
electrode calibration. Ascorbate (50 µM), αKG (100 µM), FeSO4 (50 µM), and CTAD (80 
µM) in 50 mM HEPES pH 7.00 (400 µL total) were equilibrated at atmospheric O2 in the 
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reaction vessel at 37ºC until a stable baseline was achieved. The reaction was then initiated 
with cold enzyme using a Hamilton syringe, with a final concentration of 10 µM FIH in 
solution. O2 consumption over time was recorded until the rate of O2 consumption 
resembled the baseline slope.  
4.2.4 Steady-state kinetics varying O2 
Assays were conducted as described for the O2 consumption experiment, with the 
amount of O2 in the system being controlled for. Ratios of N2 and O2 gasses were mixed 
using a flow-meter to provide a wide range of O2 concentrations. Assays were conducted 
at 37 ºC and contained ascorbate (50 µM), αKG (100 µM), FeSO4 (50 µM), CTAD (80 
µM) and FIH (1-5 µM) in 50 mM HEPES pH 7.00. D201G assay buffer contained 100 mM 
NaCl. Upon consumption of O2, either the slope of the O2 trace was monitored to determine 
the initial rate of O2 consumption or a sample of the reaction mixture was taken and 
quenched in matrix (α-Cyano-4-hydroxycinnamic acid dissolved in 75% ACN/ 0.2% TFA) 
At 20 second intervals, 5 µL of assay mixture were quenched in 20 µL of matrix (3,5-
dimethoxy-4-hydroxycinnamic acid saturated in 75% ACN/0.2% TFA).  The ratio of 
hydroxylated to unhydroxylated CTAD substrate was measured using MALDI-TOF-MS 
(Bruker Ultraflextreme MALDI TOF/TOF mass spectrometry system) to determine the 
mole fraction of hydroxylated product at each time point. The initial rates versus O2 
concentration were then plotted in Origin and fit to the Michaelis-Menten equation (below) 
to ascertain the steady-state parameters for each substrate. Equation 1 was used to define 
kcat and KM under the given conditions. Equation 2 defines kcat/KM with greater precision.  
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Equation 11: 𝑦𝑦 = 𝑉𝑉𝑚𝑚𝑚𝑚𝑚𝑚𝑥𝑥
𝐾𝐾𝑀𝑀+𝑥𝑥
 
 
Or 
 
Equation 22: 𝑦𝑦 = �𝑉𝑉 𝐾𝐾� �𝑥𝑥
�1+�𝑥𝑥 𝐾𝐾𝑀𝑀�
��
                                                 1 Vmax= maximal rate of reaction  
  KM= concentration of substrate when reaction velocity is equal to one half the maximal velocity of the 
reaction (Vmax) 
 2 (V/K)= Vmax dived by KM defines kcat/KM, a measure of enzyme efficiency 
  KM= concentration of substrate when reaction velocity is equal to one half the maximal velocity of the 
reaction (Vmax) 
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4.2.5 Autohydroxylation assays 
Autohydroxylation studies were conducted as previously described.15,16 Briefly, 
samples containing αKG (500 µM), FeSO4 (100 µM) and FIH (100 µM) in 50 mM HEPES 
pH 7.00 were prepared anaerobically in a quartz cuvette and sealed. Once out of the glove 
box, slow oxidation was stimulated by removal of the cuvette cap. Absorbance was 
monitored over time upon exposure of the sample to oxygen using an Agilent HP 8453 
diode-array UV-Vis spectrophotometer.  
4.2.6 H2O2 assays 
H2O2 induced oxidation of 2,2’-azino-bis(3-ethylbenzthiazoline-6-sulfonic acid) 
(ABTS)  was coupled with 1 U/mL horseradish peroxidase (HRP) to detect H2O2 
production by FIH.17 The reactions contained αKG (500 µM), FeSO4 (50 µM), CTAD (80 
µM), ABTS (150 µM), and FIH (20 µM) in 50 mM HEPES pH 7.00. H2O2 production was 
monitored by absorbance at 405 nm. Ascorbate was omitted from the reaction mixtures to 
avoid reduction of ABTS+. The amount of ABTS+ produced by the reactions was calculated 
using Beer’s Law (ƐABTS+=36,100 M-1cm-1)18 and fit (Origin) to a single exponential 
equation.   
H2O2 + 2 ABTS → 2 ABTS∙+ 
2.2.7 EPR 
Spectra of the vanadyl-substituted WT FIH and the D201X variants were collected on 
a Bruker Elexsys-500 EPR spectrometer using Q-Band (QT403 cavity). Samples were 
positioned under vacuum in a liquid-nitrogen cryostat. Samples were composed of 1 mM 
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FIH, 0.9 mM VOSO4 in 10 mM H2SO4, 0.9 mM succinate in water, and 0.9 mM CTAD 
(when noted) in 50 mM HEPES pH 7.00. Metal was added in 0.5 uL increments to prevent 
precipitation. Samples were loaded into EPR tubes and flash frozen with LN2 for analysis. 
Spectra were collected at 90 K with the following settings: 34 MHz frequency, 0.61 mW 
power, 2.5 G modulation amplitude, and 40.96 ms time constant and conversion time. Data 
was simulated using XSophe software (Bruker). Error was determined by visual 
differences in the simulated spectra upon incrementally increasing/decreasing each 
simulation parameter. 
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4.3 Results and Discussion  
4.3.1. Catalytic activity of D201X variants  
Proper O2 activation is required for coupled catalytic activity of αKG dependent 
oxygenases. It is well known for this class of enzymes that the binding of primary substrate 
“triggers” the release of an aquo ligand from the Fe(II) cofactor, providing a vacant 
coordination site for O2 to bind (Scheme 4.1).19 The strength of the Fe-OH2 bond mediates 
this substrate triggering mechanism and subsequent O2 activation. Upon O2 activation, 
αKG is oxidatively decarboxylated to produce succinate and CO2. Uncoupled chemistry 
results when the half reaction of decarboxylation occurs faster than that of product 
formation and has been noted for several αKG dependent oxygenases.8,11,15,16,20,21 
Tight coupling between CTAD binding and subsequent O2 activation is required for 
effective hypoxia sensing by FIH as evidenced by changes in the coordination geometry of 
the Fe(II) cofactor.14 In addition, this O2 activation step is rate limiting, supporting FIH’s 
role as an O2 sensor.22 This was verified by an inverse solvent isotope effect (SIE) 
indicating that there was a pre-equilibrium aquo release followed by an irreversible step in 
the consensus mechanism.14 Previous studies of the D201X variants identified uncoupling 
between succinate formation and CTADOH.12 In order to gain insight into the substrate 
triggering effect and the resulting uncoupled O2 activation chemistry in the D201X 
variants, steady-state kinetics assays were conducted varying O2 and monitoring O2 
consumption and CTADOH in tandem.  
The kinetic studies varying O2 using a Clark-type O2 sensor (Fig. 4.1) showed 
pronounced uncoupling between the two half reactions of the D201X variants, whereas the 
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rates of O2 consumption and CTADOH were equal for WT FIH. The exceedingly low 
reactivity of D201A made it difficult to distinguish O2 consumption from the instrument 
noise. kcat of CTADOH production for both the D201E and D201G variants was much 
slower than kcat of O2 consumption (Supplemental Table 4.4), supporting uncoupled 
catalytic activity. As kcat measures turnover when CTAD and other substrates are 
saturating, a better measure of branching is kcat/KM(O2) (Table 4.1). If O2 consumption were 
tightly coupled to CTADOH, kcat/KM(O2) for CTADOH formation divided by the kcat/KM(O2) 
for O2 consumption would equal 1. Based on the kcat/KM(O2) values reported in Table 4.1, 
this is only the case for WT FIH. The ratios of kcat/KM(O2) for D201E (0.05) and D201G 
(0.03) were nowhere near unity, confirming that O2 activation is largely uncoupled. The 
20-35 fold changes between the kcat/KM(O2) seen with D201G and D201E for O2 
consumption versus CTADOH suggested there was an alternate pathway for the fate of O2. 
This data indicate that the reaction pathway is branched, and that O2 can be consumed 
without substrate present.  
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Figure 4.1 Steady-state kinetics varying O2 using an oxygen sensor monitoring O2 
consumption (filled shapes) versus CTADOH (empty shapes). Assays were conducted at 
37 ºC and contained ascorbate (50 µM), αKG (100 µM), FeSO4 (50 µM), CTAD (80 µM) 
and FIH (1-5 µM) in 50 mM HEPES pH 7.00. D201G assay buffer contained 100 mM 
NaCl. 
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Table 4.1 kcat/KM(O2) values for O2 consumption and CTADOH formation. 
 kcat/KM(O2) app 
(μM-1 min-1) 
d[O2]/dt          d[CTADOH]/dt 
WT FIH 0.097 ± 0.008 0.12 ± 0.02 
D201G 0.08 ± 0.03 0.004 ± 0.003 
D201E 0.07 ± 0.01 0.002 ± 0.001 
 
To further explore the mechanistic branching in the D201X variants, O2 consumption 
assays were conducted in the presence and absence of CTAD, and the fate of activated O2 
was measured. αKG dependent oxygenases typically react sluggishly with O2 until 
triggered by substrate binding. For example, the halogenase SyrB2 reacts with O2 ~5000 
times faster upon binding of primary substrate.5 A  more closely related enzyme, PHD2, 
has been reported to react 30 times faster with O2 in the presence of primary substrate.23 
Due to known structural differences in the substrate-binding intermediate of the facial triad 
variants (II-Scheme 4.1) and the increased rate of autohydroxylation compared to WT FIH, 
we hypothesized that the D201X variants may be primed to react with O2 before CTAD 
binds.12  
O2 consumption was monitored using a Clark-type electrode upon addition of enzyme 
to the reaction mixture. As seen in Supplemental Figure 4.6, WT FIH, D201E and D201G 
all consumed O2 when initiated with enzyme. Without CTAD, D201E rapidly consumed 
O2 (Fig. 4.2A), whereas D201G and WT FIH slowly consume O2 at relatively the same rate 
(Table 4.2). D201A only consumed 2-5 µM O2 regardless of primary substrate indicating 
that removing the facial triad ligand at this site weakens O2 activation, supporting the lack 
of hydroxylation activity seen with this variant. In the absence of CTAD, D201G and WT 
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FIH consumed 5 µM and 8 µM O2 respectively, several fold less than in the presence of 
CTAD, which suggested these variants were substrate trigged. The similar reactivity of 
D201E (~20 µM O2 consumed) with or without CTAD supported the hypothesis that 
D201E can react with O2 without substrate triggering.  
 
Figure 4.2 (A) O2 consumption in the absence of CTAD substrate for all D201X variants 
and WT FIH. (B) Steady state kinetics varying O2 for D201E in the absence of CTAD 
using an oxygen sensor monitoring O2 consumption. Assays were conducted at 37 ºC and 
contained ascorbate (50 µM), αKG (100 µM), FeSO4 (50 µM), CTAD (80 µM) and FIH 
(1-5 µM) in 50 mM HEPES pH 7.00. D201G assay buffer contained 100 mM NaCl. 
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Additional assays were conducted varying O2 while monitoring O2 consumption to 
define the kinetics of O2 consumption in the absence of CTAD for D201E (Fig. 4.2B). 
Interestingly, kcat(O2) without CTAD present (3.0 min-1) is about equal to kcat(O2) with CTAD 
(3.6 min-1) (Supplemental Information, Table 4.4). The similarities in kcat suggest that 
D201E is primed to react with O2 before it is presented with primary substrate, resulting in 
little to no CTADOH. This reactivity is supported by structural evidence reported in 
Solomon et al., in which we described that D201E is mostly five coordinate Fe(II) before 
it encounters CTAD, suggesting there is an open coordination site for O2 to bind whereas 
WT FIH remains six coordinate until CTAD is present.24 This change in coordination 
environment resulting in uncoupled turnover has also been reported for TauD.3  
 
Table 4.2 Kinetic values describing substrate triggering. 
 kcat(CTAD) app 
(min-1) 
d[CTADOH]/dt 
kcat(CTAD) app 
(min-1) 
d[O2]/dt 
Productive 
triggering ratio 
O2 uptake  
-CTAD 
(min-1) 
Unproductive 
triggering ratio 
WT  28 ± 3 33 ± 4 0.85 -0.18 ± 0.002 156 
D201A -- -- -- -0.12 ± 0.002 -- 
D201E 0.08 ± 0.63 3.6 ± 0.2 0.02 -0.59 ± 0.002 0.14 
D201G  0.58 ± 0.02 6.1 ± 0.7 0.10 -0.26 ± 0.001 2.2 
 
Table 4.2 summarizes the substrate triggering data presented here. The triggering ratio 
provides insight into the efficiency of product formation. For substrate triggered enzymes, 
the productive triggering ratio was expected to be 1. A productive triggering ratio of less 
than 1 suggests the enzyme can react with O2 without primary substrate. As seen in Table 
4.2, the productive triggering ratio is about 1 for WT FIH and almost 10-fold lower for 
D201E and D201G. The unproductive triggering ratio is extremely high for substrate 
triggered O2 reactions, such as WT FIH which has a triggering ratio of 156, and low (0.14 
and 2.2) for constitutively triggered reactions, seen with the D201X variants.  
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Substrate triggered activation of the Fe(II) cofactor for reaction with O2 is a hallmark 
trait of the αKG dependent oxygenases1,3,25 and is thought to act as a defense mechanism 
against deleterious auto-oxidation reactions and improper substrate binding.4,5 Reported 
reactions for this class of enzymes with O2 in the absence of substrate were sluggish, for 
example TauD reacted 1,000 times faster with O2 in the presence of substrate.26 However, 
the results presented here suggest this is not always the case as D201E reacts with O2 as 
well with substrate as it does without, leading to the notion that this variant is constitutively 
triggered. Previous studies suggest untriggered enzymes may proceed through a different 
mechanism as there is no evidence of accumulated Fe(IV)=O intermediate under these 
conditions, therefore we sought to track the fate of O2 in this untriggered pathway.5,26 
4.3.2 Triggering efficiency 
The O2 reactivity studies described above indicated that the D201X variants react with 
O2 without substrate present, leading to uncoupled turnover. In order to track the fate of O2 
in this untriggered mechanism, autohydroxylation and ROS production studies were 
conducted. Autohydroxylation has been reported for other αKG dependent oxygenases 
including TfdA and Jmjd6, as well as WT FIH.14,15,20,27 Previous studies revealed that the 
D201X variants autohydroxylated faster than WT FIH, however rates of autohydroxylation 
were not stated.12 Autohydroxylation is evidence by the accumulation of a pink 
chromophore (λmax= 515 nm, Ɛ515= 2500 M-1cm-1) in D201A and D201G and a purple 
Fe(III)-O-Trp296 chromophore for D201E and WT FIH (λmax= 583 nm, Ɛ583= 3000 M-1cm-
1).12 Herein we report on the initial rate of TrpOH and quantification of autohydroxylated 
product formation in the (Fe+αKG)FIH samples upon exposure to air. As seen in Figure 
4.3, D201A produced the most TrpOH product at the fastest rate, compared the WT FIH and 
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the other D201X variants. D201A autohydroxylated about 50% of the available enzyme 
whereas D201E, D201G, and WT FIH autohydroxylated 10-20%. The initial rates of TrpOH 
product formation were reported (Table 4.3). Results suggest the concentration of TrpOH is 
high when the variants have poor triggering.  
 
Figure 4.3 Formation of autohydroxylated product, evidenced by the appearance of a 
chromophore at 583 nm for WT and D201E and at 515 nm for D201G and D201A. 
D201E (triangle), D201A (diamond), WT (square), and D201G (circle). 
Autohydroxylation assays were conducted using αKG (500 µM), FeSO4 (100 µM) and 
FIH (100 µM) in 50 mM HEPES pH 7.00. 100 mM NaCl was added to the assay buffer 
for D201G. 
4.3.3 ROS production 
In addition, some uncoupled αKG dependent oxygenases have been reported to 
produce ROS as a byproduct.17,28 Possible ROS include superoxide (O2-), hydrogen 
peroxide (H2O2), and hydroxyl radicals (OH∙) based on the number of electrons transferred 
to O2.4,29 To probe if ROS were formed by the D201X variants as a product of untriggered 
reactions with O2, a UV-Vis spectroscopy based assay was conducted. A peroxidase/ABTS 
assay was utilized to detect H2O2 formation by monitoring the accumulation of ABTS+ at 
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405 nm in the absence of CTAD (Fig. 4.4).18 The 1:2 stoichiometry of H2O2 to ABTS+ 
allowed for the concentration of H2O2 to be easily determined. Without CTAD, very low 
amounts of H2O2 were produced. D201E quickly reacted and was inactivated, whereas WT 
FIH, D201G and D201A showed a linear increase in product formation over time. The 
autohydroxylation and peroxidase assays in the absence of CTAD provided insight into the 
fate of O2 without substrate triggering, however there was still unaccounted for O2 
following substrate triggering.  
 
Figure 4.4 H2O2 formation detected by oxidation of ABTS in the absence of CTAD. 
D201E (triangle), D201A (diamond), WT (square), and D201G (circle). H2O2 assays 
contained αKG (500 µM), FeSO4 (50 µM), CTAD (80 µM), ABTS (150 µM), and FIH 
(20 µM) in 50 mM HEPES pH 7.00. 100 mM NaCl was added to the D201G assay 
buffer. 
Table 4.3 Rate of product formation in the absence of CTAD. 
 3 TrpOH (kobs)  
min-1 
4 H2O2 (vo/[E]) 
min-1 
WT 0.008  ± 0.001 0.002 ± 0.30 
D201A 0.056  ± 0.002 0.008 ± 0.03 
D201E 0.029  ± 0.003 0.015  
D201G 0.027  ± 0.001 0.003 ± 0.12 
                                                 
3 TrpOH data was fit to a single exponential equation.  
4 H2O2 data was fit to a linear equation. The slope of the data was divided by the enzyme concentration (20 
µM) to obtain the initial rate.  
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Based on the O2 kinetics and spectroscopic data presented here, we propose the 
following branched chemical mechanism of untriggered reactivity with O2 for the D201X 
variants in the absence of CTAD. As shown in Scheme 4.2, these variants proceed through 
the same states as WT FIH through the formation of the Fe(IV)=O intermediate. From this 
state, there were two potential pathways: hydrogen atom transfer to form a Trp296 radical, 
resulting in autohydroxylation or hydrolysis to form H2O2. As a result of the data presented 
here, we propose that a combination of kinetic and structural factors regulate the fate of O2 
from the Fe(IV)=O intermediate.  
 
Scheme 4.2 Proposed branched mechanism of untriggered O2 reactivity in αKG 
dependent oxygenases in the absence of primary substrate (R). 
4.3.4 Ferryl geometry at branch point   
In order to test our hypothesis that untriggered reactions with O2 deviate from the 
consensus chemical mechanism following formation of the Fe(IV)=O intermediate, EPR 
studies were conducted. Recently, vanadyl was shown to be a suitable Fe(IV)=O structural 
mimic to facilitate EPR and crystallographic studies of this crucial intermediate state in 
TauD.30 We adopted this technique to gain insight into the structure of the metal center of 
the D201X variants and WT FIH. Samples consisting of (VO+succinate)FIH with and 
without CTAD were prepared, loaded into quartz capillary tubes and flash frozen. All 
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samples were run at liquid nitrogen temperatures to ensure powder pattern spectra free of 
molecular tumbling.  
Vanadyl EPR spectra typically exhibit axial (Az>Ax=Ay) or near-axial symmetry due 
to the dominance of the vanadium-oxygen interaction in defining the d-orbital splitting.31 
Q-Band EPR simulations of the experimental data shown in Figure 4.5 revealed all D201X 
variants and WT FIH displayed axial symmetry with and without CTAD, which was 
expected for the (VO+succinate)FIH sample composition. Additional analysis of the 
hyperfine splitting revealed a geometric shift in the Fe(IV)=O intermediate upon addition 
of CTAD to WT FIH and D201G as evidenced by a 4-5 MHz change in A┴ (Table 4.4). 
Interestingly, A┴  increased in the presence of CTAD for WT FIH and decrease for D201G. 
These geometric differences may explain the coupled versus uncoupled nature of WT and 
D201G respectively following CTAD binding. The D201E and D201A variants did not 
exhibit any geometric shift upon addition of CTAD, suggesting these variants are poised 
to react with O2 without substrate triggering.  
Taking a closer look at the WT FIH EPR spectra (Figure 4.5), we see that the spectra 
without CTAD yielded simulation parameters of g = [1.943, 1.979, 1.979] ± 0.001 and A 
= [515, 195, 180] ± 3 MHz. Upon addition of CTAD, A┴ (derived from the average of Ax 
and Ay) was increased, yielding simulation parameters of A= [525, 195, 190] ± 3 MHz. 
CTAD addition also increased Az by 10 MHz suggesting weakening of the V=O bond. The 
small shifts in g values +/- CTAD are still being investigated at the time of this writing. 
The A║ hyperfine simulation value provides insight into the identity of the ligands in the 
equatorial positions of the vanadyl. For WT FIH, the observed A║= 512 MHz (170 x 10-4 
cm-1) correlates to the expected value of 170.9 x 10-4 cm-1 for two carboxylate, one 
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perpendicular, and one parallel nitrogen ligand.31 While A║ values may deviate from the 
theoretical value due to changes in symmetry, it provides a reasonable reference to 
establish the ligand coordination environment of the Fe(IV)=O intermediate. This data 
suggested that these variants uncouple after the formation of the Fe(IV)=O intermediate as 
all the variants formed the Fe(IV)=O based on A║ values for the V=O mimic.  
 
Figure 4.5 Vanadyl Q-Band EPR of WT FIH and D201X variants in the presence of 
succinate, with or without CTAD. WT FIH (black), D201A (green), D201E (blue), and 
D201G (red). Samples were composed of 1 mM FIH, 0.9 mM VOSO4, 0.9 mM succinate, 
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and 0.9 mM CTAD (when noted) in 50 mM HEPES pH 7.00.  The D201G sample was 
prepared in 50 mM HEPES/100 mM NaCl buffer pH 7.00. 
Table 4.4 (VO+succ)FIH Q-Band EPR Simulation Parameters. 
 5A┴  
(MHz) 
A║ (MHz) 6g┴ g║ 
WT FIH 188 515 1.979 1.943 
WT 
CTAD 
193 525 1.980 1.943 
D201A 181 504 1.979 1.943 
D201A 
CTAD 
181 504 1.979 1.943 
D201E 181 509 1.978 1.943 
D201E 
CTAD 
181 509 1.979 1.943 
D201G 189 515 1.978 1.943 
D201G 
CTAD 
185 510 1.979 1.943 
 
The change in A┴ for the D201X variants that productively hydroxylate substrate 
indicate that the metal centers of WT FIH and chloride-saturated D201G are triggered by 
substrate, leading to O2 activation. In contrast, the geometry of the metal centers in 
D201E and D201A were insensitive to CTAD and therefore were constitutively triggered. 
The lack of sensitivity of D201E and D201A supported their increased rates of 
autohydroxylation.  
                                                 5 Hyperfine uncertainty values: A ± 3 MHz 6 g values uncertainty: g ± 0.002 
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4.4 Conclusion 
This study provides further insight into the kinetics of uncoupling for the D201X 
variants of FIH, offering a basis for reactivity of constitutively triggered enzymes in the 
αKG dependent oxygenase family of enzymes. It was previously established that variants 
at the 201 site could hydroxylate peptide substrate, given the facial triad remained intact 
with either a carboxylate or an anion to coordinate the metal (Chapter 2). Kinetic studies 
varying O2 revealed that the variants reacted with O2 much faster than they produced 
CTADOH, suggesting a branched catalytic mechanism. The facial triad variants retained the 
ability to activate O2 but lost the ability to trigger upon substrate binding. The formation 
of TrpOH and H2O2 furnished a pathway for this unreacted oxygen. This is the first reported 
example of ROS formation in FIH. This work directly implicates the native aspartate 
residue in substrate triggering. EPR provided structural data to demonstrate that the metal 
geometry changed in the presence of CTAD, consistent with changes in coordination 
reported by Solomon et al.24 Based on the evidence provided here, we conclude that the 
facial triad is essential for coupling hydroxylation to O2 activation in FIH.   
4.5 Supplemental Information 
4.5.1 O2 consumption 
 To confirm the D201X variants consumed O2 in the presence of CTAD, 
additional assays were conducted. As shown in Fig 4.6, WT, D201G, and D201E all 
rapidly consume O2 with CTAD present. D201A slowly reacts with O2.  
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Figure 4.6. O2 consumption of the D201X variants and WT FIH with CTAD present. 
The different enzyme variants are represented as follows: WT FIH (black), D201A 
(green), D201E (blue), D201G (red). Assays were conducted at 37 ºC and contained 
ascorbate (50 µM), αKG (100 µM), FeSO4 (50 µM), CTAD (80 µM- when noted) and 
FIH (10 µM) in 50 mM HEPES pH 7.00. D201G assay buffer contained 100 mM NaCl. 
4.5.2 Steady-state kinetics 
Table 4.5 summarizes the steady-state kinetic data for the D201X variants and 
WT FIH, which was presented in various parts of the results and discussion section of 
this chapter.  
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Table 4.5 Steady-state kinetics varying O2.7 
 kcat app (min-1) 
d[O2]/dt  d[CTADOH]/dt 
kcat/KM(O2) app (μM-1 min-1) 
 d[O2]/dt         d[CTADOH]/dt 
KM(O2) app (μM) 
   d[O2]/dt    d[CTADOH]/dt 
WT FIH 33 ± 4 28 ± 3 0.097 ± 0.008 0.122 ± 0.02 343 ± 63 230 ± 64 
D201G 6.1 ± 0.7 0.58 ± 0.63 0.08 ± 0.03 0.004 ± 0.003 76 ± 33 141 ± 234 
D201E 3.6 ± 0.2 0.08 ± 0.02 0.073 ± 0.01 0.002 ± 0.001 49 ± 9 45 ± 65 
D201E  
(without CTAD) 
3.0 ± 0.6 -- 0.014 ± 0.006 -- 210 ± 95 -- 
 
4.5.3 ROS production 
 Additional H2O2 assays were conducted in the presence of CTAD. Figure 4.7 
shows the formation of H2O2 under the given conditions, suggesting that H2O2 formation 
was an alternate pathway for O2 consumption both in the presence and absence of CTAD.  
                                                 
7 Assays were conducted at 37 ºC and contained ascorbate (50 µM), αKG (100 µM), FeSO4 (50 µM), 
CTAD (80 µM) and FIH (1-5 µM) in 50 mM HEPES pH 7.00. D201G assay buffer contained 100 mM 
NaCl. 
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Figure 4.7 H2O2 formation detected by oxidation of ABTS in the presence of CTAD. 
D201E (triangle), D201A (diamond), WT (square), and D201G (circle). H2O2 assays 
contained αKG (500 µM), FeSO4 (50 µM), CTAD (80 µM), ABTS (150 µM), and FIH 
(20 µM) in 50 mM HEPES pH 7.00. 100 mM NaCl was added to the D201G assay 
buffer. 
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APPENDIX A 
 
MODULATING HIF-1α TRANSCRIPTIONAL RESPONSE THROUGH 
ENZYME DELIVERY 
A.1 Introduction 
Due to the plethora of genes regulated by Hypoxia Inducible Factor (HIF)-1, control 
over this transcription factor is of high therapeutic interest. In this research, we aimed to 
manipulate the catalytic activity of the HIF hydroxylases to control the hypoxic response 
through enzyme delivery. Overexpressed HIF-1α levels are found in numerous disease 
states such as tumor growth and hypertension, highlighting the need for delivery of active 
enzyme to downregulate genes involved in these processes.1 We hypothesized that in vivo 
HIF-1α levels could be controlled through targeted delivery of FIH using nanomaterials. 
Purified protein was delivered to normoxic HeLa cells. Delivery efficiency was monitored 
through gene expression analysis both at the mRNA and protein levels as outlined in 
Scheme A.1. Development of an efficient delivery system provides a broad range of control 
over genes regulated by HIF-1α. 
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Scheme A.1 Experimental workflow for FIH delivery project.  
A.2 Methods 
A.2.1 Delivery of FITC-FIH polymer emulsion  
FIH was labeled using fluorescein isothiocyanate (FITC) to quickly confirm 
enzyme delivery into cells using a polymer stabilized nanoparticle delivery system.(xx ref) 
A 1 mg stock of His tagged FIH in 50 mM HEPES pH 7.00 was thawed on ice. 150 µg of 
solid FITC were dissolved in 50 µL DMSO for protein labeling. A 6:1 ratio of FIH:FITC 
was then prepared in 100 mM NaHCO3 pH 8.5 and incubated overnight at 4 ºC. The 
FIH:FITC solution was loaded on to a prepacked gravity PD-10 desalting column (GE 
Healthcare) to remove unbound FITC. Following FITC labeling of FIH, a 1:1 ratio of 
FITC-FIH and polymer emulsion was prepared. The emulsion was formed by dissolving 
the polymer in a mixture of linoleic acid and decanoic acid. 50 µL of the FITC-FIH-
polymer emulsion was diluted in 500 µL serum free DMEM (GenClone) containing 1% 
pen/strep antibiotic; this mixture was added to HeLa cells plated at 60,000 cells per well 
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and incubated for 1 hour at 37 ºC and 5% CO2. Following incubation, the DMEM media 
was rinsed off and replaced with 1X PBS. Cells were visualized using fluorescent 
microscopy (Nikon A1 Spectral Confocal) to confirm enzyme delivery.  
A.2.2 RT-qPCR primer design and validation 
Housekeeping and target gene primers were designed using Primer Blast software 
and ordered from IDT (25 nmol DNA oligio standard desalting). TM and length of 
housekeeping primer (beta actin) were designed to be as close to those of the target gene 
primers as possible. 10 µM working stocks of primers were prepared in nuclease free H2O 
and validated. Assays containing 2X SYBR Green Master Mix and 0.4 µM primer were 
prepared, varying concentrations of cDNA (1:1, 1:5, 1:25, 1:125) to determine optimal 
annealing temperature and measureable CT range for the template DNA. An annealing 
temperature gradient was run on the BioRad CFX Connect Real-Time PCR Detection 
System instrument followed by a thermal melt program to verify TM of each primer in the 
presence of template DNA. Products were then run on an agarose gel to identify possible 
primer-dimers. A standard curve of CTs was constructed from the serial dilutions of 
template DNA. The optimized annealing temperatures were used to conduct the following 
RT-qPCR experiments.  
A.2.3 RT-qPCR 
HeLa cells were treated for 24 hours at 37 ºC and 5% CO2 with either no CoCl2, 
100 µM CoCl2 or 250 µM CoCl2, then were trypsinized and pelleted. Cells were lysed with 
sonication (2 seconds on/1 minute off for three cycles at 50 amplitude) followed by mRNA 
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isolation using a Pure Link mRNA Isolation Kit (Life Technologies). The mRNA was then 
converted to cDNA using an iScript cDNA Synthesis Kit (BioRad). The concentration of 
cDNA (A260) was verified using a nanodrop. Samples were prepared for RT-qPCR in 96-
well PCR plates and sealed to prevent evaporation. Samples contained 2X SYBR Green 
Master Mix (ThermoFisher), 0.4 µM forward primer, 0.4 µM reverse primer, 500 ng 
template cDNA, and nuclease free H2O. Primers were designed and validated as described 
above. Plates were run on a BioRad CFX Connect Real-Time PCR Detection System 
instrument with the following program:  
 Initial Denaturation 95 ºC   10 min  1 cycle 
 
 Denaturation  95 ºC  15 s   
        40 cycles 
 Annealing/Extension 60 ºC*  1 min   
 
*annealing/extension temperature was optimized for each set of primers 
Expression of target genes was normalized to expression of beta actin housekeeping gene 
and quantitated using the comparative CT method (2-ΔΔCT ).2,3  
A.2.4 Western Blotting 
Western blotting procedures required substantial optimization to visualized HIF-1α 
protein levels in CoCl2 treated mammalian cells. HeLa cells were treated for 24 hours at 
37 ºC and 5% CO2 with either no CoCl2, 100 µM CoCl2 or 250 µM CoCl2. HeLa cells were 
then extracted from the cell culture plate using RIPA buffer (Fisher) containing 10 µL/mL 
protease cocktail inhibitor (Sigma #P8340). Cells were scraped into a sterile falcon tube 
and incubated on ice for 15 minutes. Next, cells were lysed with sonication (2 second on/1 
minute off for three cycles at 50 amplitude), incubated on ice for 15 minutes, and 
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centrifuged for 5 minutes at 12,500 rpm (Eppendorf, FA-45-18-11 rotor) at 4 ºC. The 
supernatant containing nuclear extract was then harvested and the concentration of total 
protein concentration was verified using a bicinchoninic acid (BCA) assay. Protein was 
aliquotted and stored at -80 ºC for future use.  
10% acrylamide SDS PAGE gels were prepared for protein separation. 50 µg of 
denatured nuclear protein were loaded in each well. 15 µL of a prestained protein marker 
(Fisher) was also loaded on to the gel as a molecular weight control. The SDS PAGE gel 
was run at 120 V until the dye front reached the bottom of the gel. Separated proteins were 
then transferred on to a nitrocellulose membrane at 100 v for 1 hour and 45 minutes at 4 
ºC. The membrane was then blocked in 5% dry milk in TBST for 1 hour while shaking at 
room temperature. Blocking buffer was removed and replaced with HIF-1α primary 
antibody (Cell Signaling) solution (1:1,000 5% BSA in TBST). The membrane was then 
incubated in primary antibody solution overnight at 4 ºC while shaking. Following primary 
antibody incubation, the membrane was rinsed three times with TBST to remove primary 
antibody solution. The membrane was then incubated in secondary antibody (Novus anti 
rabbit) solution (1:20,000 5% BSA in TBST) for 1 hour while shaking at room temperature. 
The membrane was again rinsed three times with TBST prior to adding Pierce ECL 
Western Blotting Substrate (Fisher). This chemiluminescent substrate was incubated on the 
membrane for 1 minute at room temperature, then visualized with UV light on BioRad 
ChemiDoc system.  
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A.2.5 Proliferation assays 
Cell proliferation was monitored using a Cell Titer 96 Aqueous One solution 
(Promega) assay. Cells were plated at various densities in a 96 well plate containing 100 
µL of media containing no CoCl2, 50 µM CoCl2, 100 µM CoCl2, 250 µM CoCl2, 500 µM 
CoCl2, or 1 mM CoCl2 and incubated for 24 hours at 37 ºC and 5% CO2. Following 
incubation, 20 µL of Promega Cell Titer 96 reagent was added directly to the cell media. 
The 96 well plate was then incubated for 1 hour at 37 ºC and 5% CO2. Absorbance at 490 
nm was recorded for each well to assess cell viability during hypoxic treatment.  
A.2.6 FIH-polymer emulsion delivery optimization 
HeLa cells were plated at a density of 3 x 105 cells per well and left to adhere 
overnight. A solution of unlabeled His-FIH-polymer emulsion was prepared in 1X PBS 
containing 2.4 µM His-FIH, 36 µM polymer, and 10% linoleic/decanoic acid emulsion. 
This His-FIH-polymer emulsion was added to DMEM media containing 10% FBS and 1% 
pen/strep. The DMEM-His-FIH-polymer emulsion solution was added to the HeLa cells 
and incubated for 24 hours at 37 ºC and 5% CO2. Following incubation, cells were 
trypsinized and lysed for RT-qPCR and western blot analysis as described above.  
A.3 Results and Discussion  
A.3.1 FITC-FIH polymer emulsion controls  
 In collaboration with the Rotello group at UMass Amherst, a polymer-stabilized 
nanocapsule delivery system (Scheme A.2) was optimized for delivery of His tagged FIH 
into mammalian cells.  
 154 
 
Scheme A.2 Protein-polymer nanocapsule system design.  
 
 
To determine if this polymer emulsion system would be amenable for FIH delivery, 
initial controls were conducted with FITC labeled FIH. FIH was labeled with FITC and 
incubated with the polymer to form the nanocapsule emulsion, which was then added to 
the HeLa cell growth medium. As HeLa cells are well characterized and known for their 
robust nature, initial delivery attempts were conducted with this cell line. As seen in Figure 
A.1, preliminary data suggested this polymer stabilized nanocapsule system delivered FIH 
into the cells. Delivered FIH appeared in green in Figure A.1D whereas there was no green 
signal in the cells without FITC labeled FIH (Fig. A.1C) as expected. The brightfield 
images (Fig. A.1A-B) suggested the cells were still healthy and adherent following 
incubation with the polymer emulsion. The areas of punctate FITC signal seen in Figure 
A.1D suggest there was some protein aggregation upon delivery.  
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Figure A.1 FIH delivery in normoxic HeLa cells. Confocal microscopy images collected 
by the Rotello group. (A) Bright field image of HeLa cells without delivery. (B) Bright 
field image of HeLa cells with delivered FITC labeled FIH in polymer stabilized 
nanocapsules. (C) Fluorescence image of HeLa cells without delivery. (D) Fluorescence 
image of HeLa cells with delivered FITC labeled FIH in polymer stabilized 
nanocapsules. 
 
FITC-labeled FIH was distributed throughout the cell upon delivery. FITC provided a 
simple and efficient readout to confirm enzyme delivery into the cells using the polymer 
stabilized nanocapsule system. However, FITC labeling killed the catalytic activity of FIH, 
therefore a new fluorescent method of detection was sought to visualize enzyme delivery 
and retain activity. 
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Figure A.2 Activity of FIH in the presence of the polymer emulsion. Initial rate assays 
were conducted at 2 mM ascorbate, 200 µM aKG, 50 µM FeSO4, 80 µM CTAD, 10 µM 
polymer, and 0.7 µM FIH in 50 mM HEPES pH 7.00 at 37 oC. Time points were 
quenched every 15 seconds for 2 minutes and analyzed using MALDI-TOF MS to 
measure the rate of hydroxylation.  
 
 
Upon discovering that FITC-labeled His-FIH was inactive, additional activity 
assays were conducted in the presence of polymer. His-FIH maintains catalytic activity 
when incubated with the polymer on the bench top (Fig. A.2) which provided justification 
to test the activity of His-FIH following delivery into HeLa cells. His-FIH was used for 
delivery because it has a shorter purification, yields more protein than cleaved 
purifications, and provides a fluorescent readout for delivery using a His antibody instead 
of FITC.  
A.3.2 Optimization of hypoxic cell treatment and delivery conditions 
 Once it was established that FIH could be delivered into mammalian cells using the 
Rotello polymer stabilized nanocapsule system, controls were conducted to mimic hypoxia 
in cells. Delivery of FIH to hypoxic cells was of interest as FIH is normally inhibited at 
low pO2. Activating FIH in hypoxia through enzyme delivery could regulate HIF-1α levels, 
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which are normally overexpressed in hypoxia. As an oxygen-regulated cell culture 
incubator was not readily available for use, hypoxia was mimicked using CoCl2. CoCl2 is 
a well-known to replace iron in the active site of the HIF hydroxylases, rendering them 
active as seen in hypoxia.4  
Controls were conducted to optimize the amount CoCl2 and length of CoCl2 
treatment required to induce hypoxic conditions in mammalian cells. Establishing methods 
for efficient detection of HIF-1α mRNA and protein levels following inhibition of the HIF 
hydroxylases by CoCl2 was necessary before assessing the effect of delivered FIH. Initial 
RT-qPCR controls were conducted by incubating HeLa cells with either 100 µM of 250 
µM CoCl2 for 24 hours. Cells were lysed and prepared for RT-qPCR as described in the 
methods section (A.2.3).  
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Figure A.3 Quantitative RT-PCR following mRNA isolation from HeLa cells. 
Expression of target genes was normalized to expression of beta actin and quantitated 
using the comparative CT method (2-ΔΔ CT ). mRNA levels of HIF-1α and related genes 
are reported following 24 hour incubation with CoCl2. 
 
Incubation with CoCl2 had minimal effect on gene expression of HIF-1α and related 
genes in HeLa cells. The most significant result was an almost 2-fold increase in the mRNA 
levels of GAPDH following 100 µM CoCl2 treatment. Similar fold changes were expected 
for HIF-1α and VEGFA, however lesser increases in mRNA were seen. The increase in 
FIH mRNA levels with increasing CoCl2 was surprising as hypoxia renders FIH 
transcriptionally silent,5 but it should not affect mRNA levels. These controls provided a 
baseline for comparison of mRNA levels following FIH delivery to CoCl2 treatment cells.  
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After optimizing initial controls of mRNA quantitation following CoCl2 treatment, 
western blot assays were conducted to assess the effect of CoCl2 treatment on protein 
levels. CoCl2 concentrations, incubation time, and number of cells plated were varied to 
visualize protein levels using western blot. Several attempts at western blot on CoCl2 
treated protein extracts failed to detect an accumulation of HIF-1α as would be expected in 
hypoxia. Modifying antibody dilutions and blocking conditions did not improve results.  
 
 
Figure A.4 Western blot optimization to detect HIF-1α protein levels in CoCl2 treated 
HeLa cells and untreated MCF-7 cells. 
 
As a control for increased HIF-1α protein, an aliquot of MCF-7 (a breast cancer 
cell line) nuclear lysate was obtained from the Hardy lab. MCF-7 HIF-1α protein levels 
were visualized using western blot (Fig. A.4), however HIF-1α remained elusive in CoCl2 
treated HeLa cells. This blot confirmed that our antibody recognized the correct target and 
suggested an increase in HIF1α protein levels following CoCl2 levels might be more 
apparent in MCF-7 cells.  
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Figure A.5 Proliferation assays to assess cell viability following 24 hour treatment with 
100 µM CoCl2. 
 
Following the observation that HIF-1α protein levels were more easily detected by 
western blot in MCF-7 cells, proliferation assays were conducted with both HeLa and 
MCF-7 cells treated with 100 µM CoCl2. Results confirmed that cell viability was not 
affected by mimicking hypoxia at various cell densities (Fig. A.5). 
A.4 Conclusion and Future Directions  
 From the data presented here, we conclude FIH was delivered successfully into 
HeLa cells using the polymer-stabilized nanoparticle emulsion system developed by the 
Rotello lab at UMass Amherst. Attempts at mimicking hypoxia in CoCl2 treated 
mammalian cells proved inconsistent, both in HeLa and MCF-7 cells. Additional data from 
optimization experiments in both cell lines can be found in notebooks VCIV and VCVI.  
Delivery attempts of His-FIH-polymer emulsions were halted until baseline 
hypoxic levels of mRNA and protein for HIF-1α and related genes could be reproducibility 
established. Cell culture and hypoxia controls were taken over by another graduate student 
with more mammalian cell culture experience.  
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Once hypoxia can be maintained reliably in mammalian cells, delivery attempts can 
be continued to investigate the effect of addition of active FIH on HIF-1α both in hypoxia 
and normoxia. Upon establishing the effect of delivered FIH on HIF-1α mRNA and protein 
levels, the activity of the delivered FIH must be confirmed. Additionally, siRNA 
knockdowns of the HIF hydroxylase genes in the cell line of interest should be conducted 
in order to ensure that the changes in gene expression/protein levels following delivery are 
indeed due to the delivered protein and not endogenous protein.  
A.5 Supplemental Information 
A.5.1 RT-qPCR primers  
 
HIF-1α forward 
 5’-TGGTGGTTACTCAGCACTTTTAG-3’ 
 
HIF-1α reverse 
 5’- AATCTCCGTCCCTCAACCTCT-3’ 
 
GAPDH forward 
 5’- ACCCTGGCTCCATGAACATTT-3’ 
 
GAPDH reverse 
 5’- TGGTCAACCCTTCCACG-3’ 
 
VEGFA forward 
 5’-GAGCCCAGAGTGGCGA-3’ 
 
VEGFA reverse 
 5’-GATGATTCTGCCCTCCTCC-3’ 
 
FIH forward 
 5’-CTTATTGAGAATGAGGAGCCTGT-3’ 
 
FIH reverse 
 5’-TCTTGCAGGTATTCAAGGTCC-3’ 
  
Beta Actin forward 
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 5’- CCTCGCCTTTGCCGAT-3’ 
 
Beta Actin reverse 
 5’-GCGGCGATATCATCATCCA-3’ 
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APPENDIX B 
COMPOUND SCREENING TO IDENTIFY SELECTIVE INHIBITORS OF HIF 
HYDROXYLASES 
B.1 Introduction 
 The HIF hydroxylases are often the subject of inhibition studies as they regulate 
key physiological processes. Of this class of enzymes, our lab specifically focuses on 
Factor Inhibiting HIF (FIH) and Prolyl Hydroxylase Domain 2 (PHD2). Inhibitors of FIH 
and PHD2 are attractive targets to mediate conditions which result from upregulation of 
HIF-1α, such as in wound healing and tissue repair by reducing cellular apoptosis, 
promoting release of growth and angiogenic factors, and intensifying the formation of 
extracellular matrix.1–3 The high degree of similarity between the active sites of FIH and 
PHD2 presents a challenge of inhibitor selectivity as both enzymes coordinate a Fe(II) 
metal center with a His2Asp facial triad.
4 However, selective inhibition has been 
demonstrated with other metalloenzyme families such as lipoxygenases5 and 
matrixmetalloproteinases,6 suggesting that differences in active site size and shape can 
impart selectivity.  
Previous inhibition studies have identified some classes of compounds known to 
inhibit PHD2 such as pyrones, pyridinones, and catechols.7 The goal of this project was to 
expand knowledge of structural requirements for FIH and PHD2 inhibition by screening 
small libraries of compounds to identify structurally diverse inhibitors. The types of 
molecules and/or functional groups that inhibit activity of the HIF hydroxylases were 
evaluated. This was accomplished through small compound library screens, defining the 
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extent of inhibition for those compounds, and determining their mechanism of action. This 
work contributed new knowledge to understanding the types of molecules and interactions 
required for HIF hydroxylase inhibition.  
B.2 Methods 
 All reagents were purchased from commercial vendors and used as received, with 
the exception of recombinant enzyme and inhibitor compounds.  
B.2.1 PHD2 protein purification 
Recombinant human PHD2 was expressed and purified in truncated form 
containing only the catalytic domain (residues 177-426). PHD2 was overexpressed with an 
N-terminal GST fusion tag in E. coli BL21(DE3) cells using a pGEX-4T-1 vector 
(Stratagene). The GST-PHD2 construct was purified using affinity chromatography (GE 
Bioscience GSTrap), followed by thrombin cleavage to remove the GST tag. Thrombin 
was removed with a HiTrap Benzamidine column (GE Healthcare). Protein was incubated 
with 50 mM EDTA to remove exogenous metals then buffer exchanged into 50 mM 
HEPES/150 mM NaCl pH 7.00 for storage. Protein purity was evaluated using SDS-PAGE 
and mass spectrometry.  
B.2.2 Compound solubility  
Inhibitor compounds were synthesized by the Xiao lab at UMass Amherst and 
received in solid form. 50 mM stock solutions of each compound were prepared in 100% 
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DMSO and stored at -20 ºC. Compounds were diluted to 5 mM working stocks using 50 
mM CAPS pH 12.05.  
B.2.3 Initial rate assays 
Each assay was conducted using 1 mM ascorbate, 7.5 µM αKG, 20 µM 
(NH4)2Fe(SO4)2, 20 µM CODD, 100 µM inhibitor compound, and 1 µM PHD2 in 50 mM 
HEPES pH 7.00 at 37°C with 50 uL total reaction volume. All reagents except substrate 
were mixed and incubated at room temperature for 2.5 minutes followed by a 30 second 
incubation at 37°C. The reaction was then initiated with CODD and conducted at 37°C. 5 
uL aliquots were quenched in 20 uL of MALDI matrix (4-α-cyanohydroxycinnamic acid 
in 66% acetonitrile and 0.2% trifluoroacetic acid). Quenching occurred at 30 second, 1 
minute, 1.5 minute, and 2 minute time points. PHD2 hydroxylation of the CODD substrate 
was monitored by comparing the relative intensities of the CODD peak (2134 m/z) to the 
hydroxylated CODD peak (2150 m/z) using a Bruker Microflex MALDI TOF.   
B.2.4 IC50 assays 
Time-dependent initial rate assays varying the concentration of inhibitor 
established the IC50 for each compound. Assays contained 1 mM ascorbate, 7.5 or 50 µM 
αKG, 20 µM (NH4)2Fe(SO4)2, 20 µM CODD, and 1 µM PHD2 in 50 mM HEPES pH 7.00 
at 37°C with 50 uL total reaction volume. Assays were conducted in the same manner as 
the initial rate studies described above. The initial rate of enzyme activity at each inhibitor 
concentration was plotted in Origin and fit to a dose response function.  
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B.2.5 Thermal shift assays 
Thermal shift assay experiments were conducted using a BioRad CFX Connect 
Real-Time PCR Detection System instrument. Protein-inhibitor solutions were dispensed 
in 50 µL aliquots into clear 96-well PCR plates and sealed to prevent evaporation. The 
PCR plates were placed in the thermal block of the PCR instrument and heated at a rate of 
1 °C/20 s. Fluorescence was measured and an image was collected every 0.5 °C. Reference 
wells contained protein without inhibitor. Relative fluorescence intensity data was obtained 
from the instrument, plotted for comparison to control samples, and the sigmoidal portion 
of the data was fit using the Boltzman equation to obtain the TM.  
𝑦 =  𝐴1 − 𝐴2﷩1 +  𝑒﷩(𝑥 − 𝑥0)/𝑑𝑥﷩﷩ + 𝐴21 
All ΔTM values are in reference to apo PHD2. Assays were conducted using 5 µM WT 
PHD2, 5 μM MnSO4, 100 μM ligand, and 5 x Sypro Orange dye in 50 mM HEPES pH 
7.00. ΔTM was calculated by subtracting the TM of apo PHD2 from the TM of PHD2+ligand 
samples.  
B.3 Example Screening Study 
 To efficiently assess the potency of inhibitor compound libraries, a screening 
procedure was developed and is described below: 
1. Initial rate determination of enzyme activity in the presence of 100 µM 
inhibitor compound.  
                                                 
1 A1= initial temperature  
  A2= final temperature 
   X0= midpoint (TM) 
  dX= time constant 
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2. IC50 assays on inhibitor compounds with greater than 50% initial rate 
inhibition in step 1.  
3. Thermal shift assay to evaluate impact of compound on enzyme stability.  
4. Competition assays to determine mechanism of action for inhibitor compound.  
 
 
Scheme B.1 Nobiletin-derivative compound structures. 
A selection of nine nobiletin-derivative compounds were synthesized by the Xiao 
lab at UMass Amherst (Scheme B.1). Nobiletin is a type of o-methylated flavonoid isolated 
from the tiansheng plant with documented anti-tumor activity through inhibition of 
angiogeneic mediators such as HIF-1α, VEGF, and NF-κB.8 These compounds were 
attractive as potential inhibitors of the HIF hydroxylases as they could compete with αKG 
for binding to the active site metal. Compounds were dissolved in 100% DMSO to a 
concentration of 50 mM for solubility, then diluted to 5 mM working stocks in 50 mM 
CAPS pH 12.05 for initial activity screens as described above. As seen in Figure B.1, 
compounds 5, 7, and 9 had the greatest impact on enzyme activity, inhibiting the initial rate 
of PHD2 hydroxylation of CODD by more than 50%. Structural analysis of these 
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compounds suggested that the ortho and meta hydroxyl groups on the benzene ring of 
compounds 5 and 9 conferred selectivity over the other compounds.  
 
 
Figure B.1 Initial rate of PHD2 hydroxylation of CODD in the presence of Xiao lab 
compounds. Assays were conducted with 1 mM ascorbate, 7.5 µM αKG, 20 µM 
(NH4)2Fe(SO4)2, 100 µM compound, 1 µM PHD2, and 20 µM CODD in 50 mM HEPES 
pH 7.00.* denotes most potent inhibitors.  
 
The Thermal Shift Assay is a label-free technique which monitors interactions 
between a target molecule and its binding ligands.9 Ligand-binding affinity was assessed 
from the shift in the unfolding temperature (Δ TM) obtained in the presence of ligands 
relative to that obtained in the unbound form of the molecule. In this assay, the 
thermocycler function on an RT-PCR instrument was used to vary the melting temperature 
while Sypro Orange dye provided the fluorescent signal. Destabilization of the target by 
the ligand results in a lower melting temperature, whereas an increase in melting 
temperature in the presence of ligand suggests stabilization. As seen in Figure B.2, all of 
the compounds stabilized the (Mn)PHD2 enzyme form, inferring that the compounds were 
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mimicking αKG binding. N-oxalylglycine (NOG) acted as a positive control and provided 
a reference Δ TM for a known strong inhibitor of PHD2.10  
 
Figure B.2 Thermal shift assay to determine stability of PHD2 in the presence of the 
Xiao lab compounds. Assays were conducted using 5 µM WT PHD2, 5 μM MnSO4,100 
μM ligand, and 5 x Sypro Orange dye in 50 mM HEPES pH 7.00. * denotes most potent 
inhibitors from initial rate screen (Fig. B1).  
 
 
 
 
 
 
 
Table B.1 TM results from Xiao lab compound screen. 
Sample TM (°C) ΔTM (°C) from 
PHD2+Mn 
Apo PHD2 44.1 ± 0.05 -- 
 171 
(Mn)PHD2 45.1 ± 0.04 -- 
(Mn+NOG)PHD2 56.1 ± 0.12 11 
(Mn+C1)PHD2 47.7 ± 0.07 2.6 
(Mn+C2)PHD2 47.6 ± 0.07 2.5 
(Mn+C3)PHD2 48.2 ± 0.06 3.1 
(Mn+C4)PHD2 47.9 ± 0.06 2.8 
(Mn+C5)PHD2 47.1 ± 0.09 2 
(Mn+C6)PHD2 47.9 ± 0.06 2.8 
(Mn+C7)PHD2 48.0 ± 0.06 2.9 
(Mn+C8)PHD2 48.4 ± 0.04 3.3 
(Mn+C9)PHD2 48.2 ± 0.05 3.1 
 
Unfortunately, none of the compounds stabilized PHD2 to the extent of NOG 
(Table B.1). The Δ TM of 11 °C for NOG was 4-5 fold greater than that of all the nobiletin 
derivatives, suggesting these compounds would have high IC50’s against PHD2. To test 
this theory, IC50 studies were carried out with compounds 5 and 9 as they had the largest 
impact on the initial rate of PHD2 activity in Figure B2. Figure B.3 reveals the moderate 
IC50’s for these compounds under low and saturating αKG conditions to test for 
competition with αKG binding.  
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Figure B.3 IC50 studies monitoring the initial rate of CODD hydroxylation by PHD2 
varying the concentration of compounds 5 (A) and 9 (B) at low (black) and high (red) 
concentrations of αKG. Assays were conducted in the presence of 1 mM ascorbate, 
7.5/50 µM αKG, 20 µM (NH4)2Fe(SO4)2, 100 µM compound, 1 µM PHD2, and 20 µM 
CODD in 50 mM HEPES pH 7.0 
B.4 Conclusion and Future Directions  
 Based on the lackluster binding and activity results presented here, studies of the 
nobiletin derivative compounds were halted. Activity screens with FIH produced similar 
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results. In a continued effort to identify structural requirements for selective inhibition of 
the HIF hydroxylases, additional compounds were screened through various 
collaborations. A ~40 compound library from the Olsen lab at Midwestern University also 
failed to inhibit the HIF hydroxylases to a significant extent. Structures of the Olsen lab 
compounds are described below (Scheme B.2). An ideal inhibitor would selectively inhibit 
either FIH or PHD2 (but not both) with an IC50 of < 1 µM by competing with aKG for 
active site binding. Another method of action for HIF hydroxylases is Fe(II) chelation, 
however this could have detrimental effects on other pathways in vivo. In order to increase 
chances of successful identification of selective inhibitors, larger libraries of αKG mimic 
compounds should be screened.  
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B.5 Supplemental Information  
 
Scheme B.2 Structures of compounds from Olsen lab. 
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